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1. Introduction 
1.1 The Drug Discovery Process 
Drug discovery is an extremely laborious and expensive process, requires an average of 13 years of 
research and an investment of US$1.8 billion to bring a single drug from the bench to a patient's 
bedside
1
; this is not in the least surprising, when one considers the complexity of biological 
systems, most of which is only now beginning to be understood. Despite increase in investment in 
drug discovery, the output is considerably low due to high rate of drug failure in clinical trials
2
. 
Consequently, in order to reduce the cost and time of a drug to reach market, new technologies were 
ventured. The genomics and the post-genomics eras, with the parallel advances in high-throughput 
experimental methods and screening techniques to analyze whole genomes and proteomes, are 
witnessing an explosion in the types and amount of information available, not only with respect to 
the genome sequences and protein structures but also with respect to gene-expression, regulation 
and protein–protein interactions. The availability of such information in publicly accessible 
databases and the advances in both computing power as well as in computational methods for data 
mining and modeling, have led to the emergence of several in silico approaches to systematically 
address several questions in biology, with an obvious impact on drug discovery
3,4
. Today, drug 
discovery usually follows the general scheme presented in Figure 1.1. In short, the goal is to 
identify a compound that can modulate the effect of a molecular target that regulates a biological 
process related to a disease. Once a target has been identified and shown to be relevant in a disease 
model, high throughput screening, or its theoretical counterpart, virtual screening, is usually 
employed to generate a set of hit compounds.  Following this, some of the promising molecules that 
show good physico-chemical properties are subject to further chemical exploration. The synthesized 
compounds in these lead series are evaluated and a structure–activity relationship (SAR) is derived, 
as well as the pharmacokinetic and pharmacodynamic profiles of the most promising compounds. 
The final phase in preclinical research is the transformation of a lead structure into a candidate drug, 
which is then considered for testing in clinical trials.   
1.2 Molecular Modeling and rational drug design in drug discovery 
Historically, serendipity and trial and error have played a major role in the discovery of drugs. The 
source of active substances has often been medical plants and herbs. With the advent of synthetic 
organic chemistry and modern pharmacology a more systematic search for new pharmaceutically 
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active compounds began, and these were often evaluated using animal experiments. The chemical 
modification of lead compounds, on a trial-and-error basis, typically led to compounds with 
improved potency, selectivity and bioavailability and reduced toxicity. However, this approach is 
costly and labor- and time-intensive and researchers in the pharmaceutical industry are constantly 
developing methods with a view to increase the efficiency of the drug discovery process. Two 
directions have evolved from these efforts. The „random‟ approach involves the development of 
HTS assays and the testing of a large number of compounds, and combinatorial chemistry is used to 
satisfy the need for extensive compound libraries. The „rational‟, approach relies on the knowledge 
of the structure of the target protein or knowledge about available potential compounds. Rational 
design approach involves the prediction of hypothetical ligands for the target protein from 
molecular modeling and the subsequent chemical synthesis and biological testing of specific 
compounds. Many rational design approaches have been suggested to increase the cost-
effectiveness of discovery programs. Such approaches include ligand based approaches such as 
pharmacophore modeling, determination of quantitative structure-activity relationships (QSAR), 
which use accumulated information for ligands of previously executed discovery programs, and 
receptor based approaches such as docking, which use available information about target protein 
structure. One of most commonly used rational design approach is the so-called virtual or in silico 
screening; this methodology involves the computational filtering of a large body of molecules (e.g., 
those comprising a corporate database or a database of commercially available molecules) to 
identify those that have a high probability of activity in the biological test system of interest. Thus a 
virtual screening method takes as input all those molecules that might be acquired (or synthesized) 
and tested, and then outputs those few that should be tested. Although there are numerous methods 
for performing a virtual screening, they can be roughly classified into two main types: ligand-based 
approaches which do not utilize the structure of the biological target in screening, and structure-
based approaches, which utilize the structure of the biological target, usually obtained by NMR or 
X-ray methods, and a variety of molecular docking algorithms and scoring functions. Hybrid 
approaches which combine aspects from ligand-based and structure-based methods are also 
frequently employed in virtual screening studies. 
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Figure 1.1 Drug Discovery Pipeline.  
1.2.1 Ligand based approaches 
Ligand-based approaches typically utilize knowledge of a set of compounds with known activity 
against the biological target. These approaches are frequently employed in the absence of structural 
information on the target in question. The key concept in ligand based approaches is that 
compounds that are structurally similar or have similar structural components to the known active 
compounds are more likely to have activity themselves. A variety of ligand-based screening 
methods have been developed, such as substructure and similarity searching, pharmacophore 
searching, clustering methods, and QSAR methods. Among these, the pharmacophore screening is 
certainly one of the most used methods.  
Pharmacophore modeling allows determining the spatial arrangement of chemical features that 
confer drug activity toward a target receptor. Having established the chemical space occupied by 
active ligands, pharmacophore modeling software allows researchers to create 3D structure-activity 
relationships, screen databases, and generate hits without the benefit of a receptor structure. 
Compared to other ligand-based methods provides several advantages: i) can take into account 3D 
conformational variations and functional group properties such as polarity, hydrogen bond 
potential, aromaticity, and hydrophobicity; ii) can identify lead compounds that are structurally 
dissimilar to those already known, a process known as „scaffold-hopping‟ or „lead-hopping‟; iii) can 
also incorporate known structural information of the biological target‟s active site, if any is known, 
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in the form of exclusion spheres or a molecular surface, both of which create barriers the 
compounds being searched are not permitted to encroach. 
1.2.2 Structure based approach 
In structure-based drug design (SBDD), the knowledge of the three-dimensional structure of a target 
is exploited to design small molecules able to tightly bind the active site and modulate the 
biological function in a desired way; the same tools could be used to assess the selectivity of the 
potential ligands towards different targets, making it easier to develop drugs with fewer side effects. 
This could reduce the time and resources needed to identify new interesting lead compounds. The 
structure-based methods, such as docking, have been successfully used to identify new hits from 
large libraries of chemical compounds and to predict their binding modes and affinities, and 
currently represent one of the primary methodologies used to discover new “hit” compounds. 
Molecular docking involves two main processes: pose prediction and scoring. In pose prediction a 
search algorithm determines an optimal conformation and orientation for a given compound in the 
receptor, or active site. This is followed by scoring to determine whether the pose will be accepted 
or rejected. Therefore, docking techniques enable both to predict the binding mode of a ligand and 
to roughly estimate its binding affinity for the biological target. Several scoring functions have been 
developed to approximate the interaction energy between proteins and related ligands, and all of 
these are simple linear mathematical models that estimate chemical properties (such as shape, 
charge distribution, hydrophobic/hydrophilic potentials and so on) of the molecules. 
1.3 Cancer and Aging in drug discovery 
The ultimate goal of biomedical research is to translate laboratory discoveries or clinical 
observations into new therapies to ameliorate disease and extend life expectancy and quality, 
namely the average total number of years of remaining meaningful life at a given age
5
. Ageing is a 
complex and multifactorial process characterized by the many forms of damage accumulation at the 
molecular, cellular, and tissue level that progress with advancing age, decreasing the body‟s normal 
response and function. No single theory currently exists that can explain all of the hallmarks of 
ageing, suggesting that ageing is a multi-step and multi-event process
6
. At first glance, cancer and 
ageing have an inverse relationship because cancer cells are capable of uncontrolled growth and 
division, whereas ageing cells have a diminished proliferative capacity. Indeed, it has been well-
established that older adults have a higher risk for cancer, as well as a higher risk of the onset of 
others chronic inflammation-associated diseases such as diabetes, stroke, and neurodegenerative 
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disease. Ageing is involved in a number of events responsible for carcinogenesis and cancer 
development at the molecular, cellular, and tissue levels. Actually, ageing and cancer have common 
origins due to internal and environmental stress and share some common hallmarks such as 
genomic instability, epigenetic alteration, aberrant telomeres, inflammation and immune injury, 
reprogrammed metabolism, and impaired degradation of intracellular biomolecules and organelles
7
. 
The pharmaceutical industry is always searching for new biological targets to generate novel 
therapies; aging could represent a “blockbuster” market because the target patient group includes 
potentially every person, and humans are very willing to pay for chronic medical therapy in order to 
delay the aging process. Thus, there are many convincing reasons why aging and aging-related 
diseases should be a major focus for drug discovery
8
. At the same time, oncology has become the 
largest therapeutic area in the pharmaceutical industry in terms of the number of projects, clinical 
trials and research and development (R&D) spending
9
, but despite the enormous resources being 
invested in prevention and treatment, cancer remains one of the leading causes of mortality 
worldwide. 
1.4 Selected Targets and their Involvement in Human Pathologies 
Among all possible protein targets involved in aging-related diseases and cancer, we focused our 
attention on proteasome (and its variant immunoproteasome), sirtuins and interleukin 6. These three 
targets are completely unrelated and play different roles in human cells, but the modulation of its 
activity (activation or inhibition) using small molecules could have beneficial effects on one or 
more aging-related diseases and cancer. 
Proteasome is the central catalytic unit of the ubiquitin proteasome system (UPS), which is used to 
degrade the main part of intracellular proteins. 20S standard proteasome (s-proteasome) is a 
cylinder-shaped complex that is composed of four stacked rings, each consisting of seven protein 
subunits; while associated with several regulator complexes, performs two crucial functions for cell 
metabolism: first of all, by degrading obsolete, misfolded or aberrant proteins proteasomes perform 
housekeeping function and maintain the cellular homeostasis; secondly, through the time-specific 
cleavage of short-life proteins, like transcription factors or transcription factor‟s inhibitors, are able 
to switch on/off many cellular pathways. Hence, the proteasome as central core of the UPS, is a sort 
of mandatory terminator of proteins and its inactivation leads to cellular death by apoptosis or 
necrosis. The immunoproteasome (i-proteasome) originates from the substitution of some 
constitutive catalytic subunits stimulated by pro-inflammatory citokines such as INF-γ e TNF-α, 
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and it is highly expressed in normal conditions only by specific cells types of the human body, such 
as those involved in immune-related function. Inhibiting or enhancing activity of proteasome or 
immunoproteasome could represent a promising strategy to counteract neurodegenerative diseases 
as well as cancer pathologies. 
Sirtuins are a family of NAD
+
-dependent enzymes that was proposed to control organismal life span 
about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these 
enzymes in numerous physiological processes and disease conditions, including metabolism, 
nutritional behavior, circadian rhythm, but also inflammation and cancer. In mammals, seven 
sirtuins have been identified (SIRT1-7), of which two are predominantly nuclear, SIRT6 and 
SIRT7, two are nuclear and cytosolic, SIRT1 and SIRT2, and three are mitochondrial, SIRT3-5. 
Sirtuin activators could slow the process of cellular senescence, and therefore could be useful in 
treatment of metabolic and neurodegenerative diseases, while sirtuin inhibitors could be appealing 
for the development of new anticancer and anti-inflammatory therapies. 
Interleukin-6 (IL-6) is a pleiotropic cytokine with significant functions in the regulation of the 
immune system, and plays a pivotal role in host defense against pathogens and acute stress. 
However, increased or deregulated expression of IL-6 significantly contributes to the pathogenesis 
of various human diseases. The pathological roles of the IL-6 pathway in inflammation, 
autoimmunity, and cancer were revealed by numerous preclinical and clinical studies. Therapeutic 
strategies targeting the IL-6 pathway are in development for cancers, inflammatory and 
autoimmune diseases.  
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2. Aim of the Thesis 
The overall aim of the work presented in this thesis was the rational design of new compounds able 
to modulate activity of relevant targets involved in cancer and aging-related pathologies, namely 
proteasome and immunoproteasome, sirtuins and interleukin 6. 
The objective of the thesis was accomplished through a multidisciplinary approach that involved 
different steps: 
Step 1: Hit identification  
State-of-the-art molecular modeling techniques, mainly virtual screening methods, was applied to 
selected targets to identify a limited number of small molecules able to modulate their biological 
activity 
Step 2: In Vitro Testing 
Compounds identified during Step 1 were submitted to biological testing in vitro to measure 
biological activity and identify the structure-activity relationships (SAR) that allow understanding 
the minimum requirements for activation or inhibition of biological targets.  
Step 3: Lead Optimization 
The more promising chemical scaffolds and the SAR data coming from Step 2 were used to design 
specific structural modifications, obtained trough chemical synthesis, by introducing and modifying 
functional groups able to improve biological activity and, at the same time, to affect 
pharmacokinetic and pharmacodynamic profiles, such as selectivity towards similar targets or 
bioavailability. 
Step 4: Biological Profiling 
Lead compound obtained from Step 3 were submitted to complete biological profiling to verify the 
agreement between measured activation or inhibition of each compounds and its functional activity 
in selected tissues. 
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3. Proteasome and Immunoproteasome Inhibitors 
3.1 Proteasomes: mandatory terminators. 
Proteasome is the central catalytic unit of the ubiquitin proteasome system (UPS), which is used to 
degrade the main part of intracellular proteins. 20S standard proteasome (s-proteasome) is a 
cylinder-shaped complex that is composed of four stacked rings, each consisting of seven protein 
subunits. Each of the two inner rings contain β subunits (β1 - β7), three of which (β1, β2, β5) harbor 
the proteolytic active sites catalyzing, by their N-terminal threonine residues, a caspase-like (C-
like), trypsin-like (T-like) and chymotrypsin-like (CT-like) activity,  respectively. The α-subunits 
(α1 - α7), which compose the two outer rings, have other functions such as gating the central 
chamber (thereby enabling the entry of substrates into the inner proteolytic cavity) and the binding 
of regulator complexes like the PA700, PA28 and PA200
10,11
. The association of these regulator 
complexes leads to formation of multiple forms of proteasomes like 26S (PA700-20S) and 30S 
(PA700-20S PA700), PA28-20S and PA28-20S-PA28 complexes as well as hybrid proteasomes 
(PA28-20S-PA700). 26S/30S proteasomes recognize target proteins by the presence of 
polyubiquitin chains which are then released and the target proteins are unfolded and cleaved in a 
ATP-dependent manner
12–14
. The covalent attachment of ubiquitin to acceptor lysines in a substrate 
is a multi-step process that begins with activation of ubiquitin by E1 enzyme, which transports 
ubiquitin to an ubiquitin-conjugating enzyme (E2). The latter transfers ubiquitin to substrate either 
by itself or in cooperation with an ubiquitin ligase (E3). Afterwards, additional ubiquitins can be 
added to the first, by linkage to one of its lysines, giving rise to the polyubiquitin chain. After 
proteasome targeting, ubiquitin is recycled by deubiquitylating enzymes (DUBs), some of which 
also function to oppose the action of E3s
15
.  It is worthy to note that the binding of 
polyubiquitylated proteins to the 19S regulator of mammalian and yeast 26S proteasomes enhances 
the peptidase activities of 20S proteasome about two-fold in a process requiring ATP hydrolysis
16
. 
UPS performs two crucial functions for cell metabolism: first of all, by degrading obsolete, 
misfolded or aberrant proteins proteasomes perform housekeeping function and maintain the 
cellular homeostasis; secondly, through the time-specific cleavage of short-life proteins, like 
transcription factors or transcription factor‟s inhibitors (e.g. UPS cleaves IκB-α leading to the 
entrance of NF-κB in the nucleus) proteasomes are able to switch on/off many cellular pathways. 
Hence, the proteasome as central core of the UPS, is a sort of mandatory terminator of proteins and 
its inactivation leads to cellular death by apoptosis or necrosis
17–19
. 
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Proteasome not only cleaves proteins but also can ligate two of the produced fragments, thereby 
generating peptides with a sequence that differs from the sequence of the original substrate. This 
process, also known as proteasomal splicing, has been demonstrated in vivo so far only for four 
MHC class I-restricted epitopes
20–24
, leading to the assumption that proteasomal splicing activity is 
a rare event, although recent results obtained in vitro suggest that it is in fact part of the normal 
activity of proteasomes
25
. Because of some inherent technical difficulties and the unexpected 
novelty of proteasomal splicing, the biochemical models as well as the understanding of the 
relevance of proteasomal splicing activity were so far only partially investigated. A deeper study of 
this process would have also implications from the immunological point of view, taking into 
account that PCPS highly increases the antigenic diversity
26
. Indeed, proteasomes are not only 
responsible for the degradation of the greater part of the cytoplasmic proteins but they also generate 
the vast majority of virus- or self-derived peptides presented by the MHC class I molecules on cell 
surface
27,28
. This latter function is generally aided by the interferon-γ (IFN-γ)-induced synthesis of 
the PA28-α and PA28-β proteasome activator subunits as well as of the β1i, β2i, β5i alternative 
catalytic subunits (also known as LMP2, MECL-1 and LMP7, respectively) with concomitant 
formation of the immunoproteasome (i-proteasome). The different catalytic subunits confer to i-
proteasome differences in cleavage preferences and degradation rates, which however, vary from 
substrates to substrates
29
.  
Recently, it has been described a pivotal involvement of i-proteasome in cytokine-mediated 
inflammation in mice, because its depletion altered T cell receptor (TcR) repertoire formation, the 
number of CD8
+
 T cells in the spleen, T cell survival and early activation, differentiation into 
inflammatory effector cells, release of pro-inflammatory cytokines, such as IL-6 which plays a 
pivotal role also in cancer (see below), as well as response to oxidative stress
30–33
. 
Although the removal of oxidized proteins by proteasomes is clearly established
34–36
, recent works 
suggest that i-proteasomes are more prone than s-proteasome at eliminating them. Indeed, blocking 
expression of β1i by siRNA significantly reduces the adaptive response to mild oxidative stress in 
MEF cell lines
37
 whereas β1i -/- mice exhibit higher levels of protein carbonyls in brain and liver 
upon aging than those of their wild-type littermates
38
. In addition, Seifert and co-workers showed 
that i-proteasome is a key element for the clearance of oxidized proteins and aggresome-like 
induced structures upon INF-γ stimuli39. These independent observations, gathered by exploiting 
new i-proteasome specific inhibitors as well as i-proteasome knock-out (KO) mice, opened de facto 
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a new era in the investigation of i-proteasome functions, which were so far almost merely confined 
to antigen presentation. 
It is worth to mention that between s- and i-proteasomes a group of intermediate-type proteasomes 
does exist, which are characterized by different, and tissue-specific, combinations of standard and 
inducible catalytic subunits, and probably by different post-translational modifications, able to alter 
their proteolytic activity, sensitivity to inhibitors and outer surface charge
40–42
. At last, but not least, 
the group of Tanaka described another isoform of β5 subunit (β5t) specific for thymus, which 
characterizes the so called thymus proteasome (t-proteasome), the third main isoform of 
proteasomes, having specific functions in the positive/negative selection of thymocyte and in CD8
+
 
T cell development
43,44
. 
3.2 Why is i-proteasome a potential therapeutic target? 
The research for specific modulators of the i-proteasomes activity is a very hot topic of today‟s 
biology for several reasons. The first one, and likely most relevant, is that i-proteasome is highly 
expressed in normal conditions only by specific cells types of the human body, such as those 
involved in immune-related function or few organs like the liver
45
, whereas the majority of cells 
barely have i-proteasome. The most famous inducer of i-proteasome synthesis is IFN- , usually 
secreted by cells during inflammation, although different studies suggested also other mechanisms, 
such as the activation of Toll-like receptor-4 (TLR-4)
46,47
. In pathological situation like 
neurodegenerative diseases, inflammatory processes induce i-proteasome synthesis in cells (e.g. in 
neurons) where normally i-proteasomes are absent
48–51
. Therefore, this disease-related expression of 
i-proteasome becomes a potential marker of pathological processes (potentially exerting both 
beneficial and detrimental effects) and possibly a therapeutic target.  
Studies carried out on animal models showed that the inhibition or the absence (in 5i KO mice, for 
example) of i-proteasomes could either ameliorate or worsen the course of the disease in a disease-
specific manner
31,32,52
. Although the specific enhancement of the i-proteasome activity could likely 
be an appealing strategy for future therapies of selected diseases, the research in this direction is 
dampen by the absence of effective and treatment-compatible i-proteasome enhancers. Therefore, 
investigations on this topic are at present carried out only with i-proteasome inhibitors. These 
studies highlight two issues that must be carefully considered: the specificity of the inhibitors for 
the i-proteasome subunits and the potential presence of compensatory mechanisms activated in i-
proteasome KO mice. The first issue will be discussed in next paragraph. The latter issue, on the 
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contrary, has been raised by Muchamuel et al. by suggesting that the increased amounts of 5 and 
decreased 1i and 2i subunits in 5i KO mice compared to wild type mice may mask the 5i-
specific functions in complex cellular processes such as inflammatory responses
31
. 
3.3 I-proteasome as target for cancer therapy. 
Cancer development is a multifactorial process, which involves various genetic alterations including 
the activation of oncogenes, inactivation of tumour-suppressor genes, disregulation of cell cycle 
progression and apoptosis, as well as modification of immunosurveillance
53
. Because of the crucial 
role of proteasomes in controlling many of these biological and metabolic processes as well as the 
production of MHC class I-restricted epitopes responsible for CD8
+
 citotoxic T cell (CTL) 
activation
54
, this protease has become an attractive target for the treatment of malignancies
55–58
  
(Table 3.1). A number of preclinical studies showed that tumour cells are often more sensitive to 
proteasome blockade than normal cells and different mechanisms have been hypothesized
59
. For 
example, many types of malignant cells rapidly proliferate and might accumulate defective proteins 
at a much higher rate than normal cells, thereby  increasing their dependency on proteasome as 
disposal mechanism
58
. Moreover, inhibition of proteasome causes an inactivation of NF- B 
pathway, which is involved in maintaining drug or radiation resistance in cancer cells, and it might 
reverse or bypass some alterations of cell-cycle and apoptotic checkpoint that lead to 
tumourigenesis
59
. In addition, while the activity of s-proteasome is generally found to be up 
regulated in cancer cells
60
, the levels of i-proteasome seem to vary depending on tumour types. In 
particular, i-proteasome is induced in haematological malignances, such as Multiple Myeloma 
(MM); therefore, the selective inhibition of this proteasome isoform may increase the effectiveness 
of proteasome blocking  and alleviate side effects associated to non selective inhibitors of specific 
proteasome isoforms such as bortezomib, carfilzomib and NPI-0052
61
 (Figure 3.1 and Table 3.2). In 
accordance, first-generation i-proteasome inhibitors have been developed and tested in vitro and in 
animal model trials. Moreover, considering the involvement of proteasomes in MHC class I-
restricted epitope production and the different contribution of s-proteasome, i-proteasome as well as 
intermediate type proteasomes to process specific antigens, the selective inhibition of these different 
isoforms could play a crucial role in CTL-based immunotherapy, as described below
62
. 
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Disease family Disease 
Type of i-
proteasome 
modulation 
Used 
inhibitor 
Tumours MM Inhibition PR-924
63
 
 MM Inhibition IPSI-001
61
 
 Prostatic cancer Inhibition UK-101
64,65
 
Table 3.1. Pathologies where an i-proteasome specific inhibition as therapy has been tested. The list includes the main 
pathologies where an i-proteasome inhibition has been tested. MM=Multiple Myeloma. 
3.3.1 I-proteasome in Multiple Myeloma 
MM is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma 
cells in the bone marrow microenvironment, accounting for approximately 1% of neoplastic 
diseases and 13% of haematologic cancers. Myeloma arises from an asymptomatic premalignant 
proliferation of monoclonal plasma cells derived from post-germinal-center B cells; multistep 
genetic and microenvironmental changes lead to the transformation into a malignant neoplasm. In 
particular, primary early chromosomal translocation occurs at the immunoglobulin switch region, 
while subsequent rearrangements, gene mutations and epigenetic dysregulation have been reported 
to affect disease progression, by altering the expression of several genes including adhesion 
molecules as well as responses to growth stimuli in the microenvironment. Interaction between 
myeloma cells and bone marrow or extracellular matrix increases tumour growth, survival and drug 
resistance, through the production of cytokines and growth factors such as IL-6, IL-10 and vascular 
endothelial growth factor among others
66
. At present, the anti-myeloma therapeutic regimes are 
based on the different combination of immunomodulatory drugs (e.g Dexamethasome, 
Lenalidomide, Prednisone) and the proteasome inhibitor bortezomib, thereby leading to the 
disruption of several signaling pathway
67
. In particular, proteasome inhibition stimulate multiple 
apoptotic pathways, including the induction of endoplasmic reticulum (ER) stress response, and by 
inhibiting the NF- B pathway, it down-regulates the productions of angiogenesis factors, cytokines 
such as IL-6  and cell adhesion molecules in the  microenvironment
58,66
. However, considering the 
adverse effects related to the generalized proteasome inhibition mediated by bortezomib (e.g. 
haematological toxicity and peripheral neuropathy) and the up-regulation of i-proteasome in 
primary MM patient (CD138
+
) tumour cells
63
, a number of first-generation i-proteasome inhibitors 
have been tested in vitro and in animal models, showing anti-myeloma activity, mediated by several 
mechanisms. The selective inhibition of β5i subunit (e.g by PR-924 or PR-957, see below) blocks  
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growth and triggers apoptosis in MM cell lines and MM patient‟s primary cells, without affecting 
normal peripheral blood mononuclear cells. Moreover, it allows to overcome bone marrow stromal 
cells mediated drug resistances, even in presence of IL-6, which is a pro-survival factor not only for 
for MM but also for other kind of tumours, such as breast cancer
68
. Additionally, it inhibits tumour 
growth in both human plasmacytoma xenograft and SCID-hu mouse model, by decreasing the 
levels of IL-6, increasing apoptosis and inhibiting angiogenesis
63
. Noteworthy, an inhibition of the 
presentation of tumour epitopes that are β5i-dependent has also been reported31. The same anti-
proliferative activity has been showed in vitro by inhibiting the 1i subunit (e.g by IPSI-001, see 
below) in lymphoid-derived tumour cells lines and MM patient-derived samples. This effect is 
exerted by the combined activation of the intrinsic and extrinsic apoptotic pathway and the 
inhibition of NF-κB signaling. Moreover, an overcome drug resistance to doxorubicin, melphalan 
and bortezomib as well as an improved toxicity profile in nonhematopoietic tissues have been 
described
61
. 
3.3.2 I-proteasome in solid tumours.  
At present, no data are available on the application of i-proteasome specific inhibitors to other kind 
of haematological malignancies such as acute myeloid leukemia (AML) and solid tumors, although 
the selective inhibition of  the 1i subunit (i.e. by UK-101, see below) led to growth-inhibitory 
activity in prostatic cancer cells
64,65
. In these tumours, a heterogeneus expression of the antigen-
processing machinery (APM), including i-proteasome subunits, is observed and often correlates to 
the progression of disease and the immune response escape
53
. Indeed, in bone marrow biopsies of 
AML patients multiple defects in APM expression were reported and remarkably a progressive 
downregulation of APM was seen from initial diagnosis to relapse
69
. In renal carcinoma cells lower 
levels of 1i and 5i subunits as well as of the epitope transporters into ER (i.e. TAPs) have been 
found and they were more pronounced in metastatic lesions than primary tumour
53
. The same 
scenario has been observed in hepatocellular carcinoma cell lines
70
 and primary malignant 
melanoma lesions, associated with lack of spontaneous regression
71
 whereas mice lacking 1i 
subunit develop spontaneous uterine leiomyosarcoma
72
. An up-regulation of i-proteasome and an 
increased CTL response against tumour antigens have been observed in vitro in hepatocarcinoma 
cell lines after the administration of INF-
70
, suggesting that in certain cases restoration rather than 
inhibition of i-proteasome functionality could be effective in anti-tumour induced-response, by 
enhancing the production of tumour-specific MHC class I-restricted epitopes. 
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Figure 3.1. Chemical structures of promiscuous proteasome inhibitors. 
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Structure 
Selectivity Inhibition 
mechanism Subunit Activity 
1  All All reversible 
2 β5, β5i CT-like irreversible 
3 β2, β5, β5i, β2i CT-like>T-like>C-like irreversible 
4 β5, β5i CT-like irreversible 
5 β5, β1i CT-like reversible 
6 All All irreversible 
7 β1, β1i C-like irreversible 
8 β2 T-like irreversible 
9 β5, β5i CT-like irreversible 
10 β5 CT-like reversible 
11 β1, β2, β5 CT-like>T-like>C-like irreversible 
12 β5 CT-like reversible 
13 β5 CT-like>T-like, C-like reversible 
14 β2>β5>β1 T-like>CT-like>C-like irreversible 
15 β2>β5>β1 T-like>CT-like>C-like irreversible 
16 β5>β1, β2 CT-like>C-like, T-like irreversible 
17 β5>β1, β2 CT-like>C-like, T-like irreversible 
18 All All irreversible 
19 β5 and β2 CT-like>T-like irreversible 
20 β5>β1,β2 CT-like>C-like, T-like reversible 
21 β5 CT-like reversible 
22 β5 CT-like non covalent 
23 β5 CT-like reversible 
24 β5>β2, β1 CT-like> T-like, C-like non covalent 
25 β5 CT-like  
26 β5 CT-like  
27 β1 / β5 C-like / CT-like irreversible 
28 β5 CT-like non covalent 
Table 3.2. Activity profiles of promiscuous inhibitors of s- and i-proteasomes. Structure enumeration of proteasome 
inhibitors refers to what reported in Fig. 3.1. Proteasome activities, as defined with short-fluorogenic substrate assay, 
are shortened as following: CT-like = chymotrypsin-like, T-like = trypsin-like, C-like = caspase-like. 
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3.3.3 I-proteasome as a target for immunotherapy? 
The concept of using vaccination in the treatment of cancer has been tied to the history of vaccines 
themselves. However, the major interest in it has recently grown with the increasing understanding 
of the role that the immune system (IS) plays in shaping the biological behavior of cancer, including 
the identification of tumour antigens recognized by CTLs
73
. As above mentioned, the MHC class I-
restricted antigen presentation is generally enhanced after IFN-  stimuli by inducing the expression 
of i-proteasomes, PA28- , TAPs and MHC class I molecules
29
. It has been proposed that i-
proteasome increases the production of MHC class I-restricted epitopes because of its higher 
inclination for generating peptides with hydrophobic and basic C-termini, which shall have a better 
affinity for the APM
74
. Nevertheless, the group of Van den Eynde reported some examples of MHC 
class I-restricted tumour (self)-epitopes that were better generated by s-proteasome than i-
proteasome
75–78
. They speculated that s-proteasome could better generate self-epitopes in contrast to 
i-proteasome more efficient in viral epitope production
75
. This difference between s- and i-
proteasome might have fallouts on CD8
+
 T cell-mediated immune response at different levels, 
including thymocytes development, tolerance induction, CTL activation as well as cancer 
immunotherapy. Although this theory is quite appealing, we believe that the limited number of self- 
and viral-epitopes properly investigated so far does not allow to statistically confirm it. In addition, 
this theory recently evolved because the group of Van den Eynde showed also that two tumour 
epitopes of MAGE-A*03 and –A*10 proteins are processed exclusively by intermediate type 
proteasomes, which are variabily expressed in tumour, dendritic cells and in normal tissues
18,79,80
.  
In summary, the results obtained in the last decade suggest that the repertoire of antigens presented 
by a given cell is strongly affected by its proteasome content, composition as well as the levels of 
their regulators, which could modify cleavage properties of protein substrates
81
. This observation 
could have strong implications on cancer immunosurveillance although further investigations are 
mandatory to define the role of different protesome isoforms in immunotherapy against cancer. 
3.4 I-proteasome as target for neuropathologies 
Although in young healthy human central nervous system (CNS) i-proteasomes are almost absent, 
they have been detected in cells of different CNS areas from elderly subjects as well as from 
patients affected by Alzheimer (AD) or Huntington (HD) diseases
49,51
, Multiple Sclerosis (MS) with 
a concomitant expression of the PA28-  complex
50
 and very recently in Temporal Lobe Epilepsies 
(TLE)
48
 (Table 3.1). The induction of i-proteasome and PA28-  expression in brain could have 
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effects on different pathways because UPS regulates in neurons, for example, the pre- and post-
synaptic plasticity and the protein turnover
82
. Processes and mechanisms responsible of cerebral i-
proteasome synthesis are still unknown. Neuroinflammation could be the trigger of i-proteasome 
expression as we hypothesized for aging, AD, MS and TLE
48–50
, which will be briefly here 
discussed as example of age-related (i.e. AD) or autoimmune (i.e. MS) neurodegenerative diseases 
and epilepsies (i.e. TLE). It is worthy to note that i-proteasome synthesis induction could be limited 
to CNS or be the result of a phenomenon started in periphery and transferred to CNS, as it might 
occur during the onset of MS. Accordingly, IS regulation in other organs could have implications 
also at CNS level, including the regulation of i-proteasome expression. For example, a cross-talk 
between brain and gut with implications for the IS has been proposed recently in studies on 
experimental autoimmune encephalomyelitis (EAE)
83–85
. 
3.4.1 Alzheimer disease. 
AD is a devastating neurodegenerative disorder of the CNS occurring most frequently in later stages 
of adulthood. AD is associated with a specific pattern of pathological changes in brain that result in 
neurodegeneration and progressive development of dementia. These pathological hallmarks of AD 
are neuronal loss accompanied by intraneuronal neurofibrillary tangles formed of tau-based paired 
helical filaments (PHFs) and extracellular senile plaques of -amyloid
86
. It has been reported that 
PHFs inhibit proteasome activity and it has been suggested that this inhibition may induce neuronal 
damage in AD
87
. Furthermore, UPS is also involved in the control of the physiological maturation 
of the -amyloid precursor protein by modulating the intracellular concentration of presenilins
88
. 
An inhibition of proteasome activity in crude extracts from AD affected brain areas has been 
described, whereas an investigation carried out on 20S proteasome purified from the frontal 
neocortex of AD patients suggested that the observed drop of 20S proteasome activity in AD tissue 
could be due to the presence of inhibitory molecules more than to an intrinsic decrease of the 20S 
proteasome functionality
87,89,90
. 
AD occurs usually in elderly brain, where i-proteasome expression is already present in different 
cells types, maybe as a result of the inflamm-aging phenomenon and/or as attempt to cope with the 
increasing oxidative stress
91
. I-proteasome expression is further induced in hippocampi (but not in 
cerebellum) of AD patients
49
 and its presence varies among different neuronal sub-types. It has 
been speculated that i-proteasome expression might be an attempt to tackle the accumulation of 
oxidised proteins and phosphorylated tau that occur during AD progression, since they are both 
preferentially degraded by i-proteasome
39,92
.  However, the few available information about the role 
28 
 
of i-proteasome in AD does not allow us to estimate if an inhibition of i-proteasome function would 
lead to a progression or a reduction of the neurological damage. In addition, AD clinical symptoms 
emerge when the neurological damage is already pronounced; therefore, we might speculate that a 
modulation of i-proteasome function at the early stages of the disease could have different effects 
(even opposite) than a modulation in the late stages of AD. 
3.4.2 Multiple Sclerosis. 
MS is the most common autoimmune disorder of the CNS. It is characterized by multifocal areas of 
demyelization (plaques), chronic inflammation and damage to oligodendrocytes and neurons. The 
cause of MS is still unknown and disease pathways are poorly understood. However, the association 
of HLA-DRB1*15 and other HLA class I (e.g. HLA-A*02 and HLA-A*03) and class II alleles, the 
presence of autoreactive T lymphocytes together with other inflammatory cells and cytokines in 
active MS lesions suggest an autoimmune pathogenesis. Accordingly, EAE, a classical mouse 
model for MS, can be induced by the administration of myelin antigens or CD4
+
 and CD8
+
 T 
lymphocytes specific for those antigens
93–95
. It has been proposed that the first bout of the disease is 
mediated by CD8
+
 T cells while the first relapse and MS progression are mediated by CD4
+
 T cells 
through different mechanisms such as antigen release and epitope spreading
96
. 
Although preliminary observations on white and grey matters of MS patients suggested that 20S 
and 26S proteasomes activity is decreased compared to controls
97
, no information are so far 
available on proteasome activity in plaques, although an accumulation of i-proteasome has been  
observed
50
. In CNS of subjects affected by MS, i-proteasomes are expressed in different cell types 
such as oligodendrocytes, astrocytes, macrophages/microglia, infiltrating lymphocytes and, weakly, 
in neurons as demonstrated by double IHC assays. A similar expression has been described also for 
the subunit  of the PA28 complex. Intriguingly, the polymorphic variant HH at the codon 60 of 
1i subunit was significantly less present in a sizeable Italian MS population (OR = 0.44) restricted 
to females carrying the HLA-A*02 allele
50
. The Authors correlated this genetic data to the 
observation that a HLA-A*02-restricted epitope (MBP111-119), which activates memory T cells 
preferentially in blood of MS patients
98–100
, was produced in lower amount during  in vitro digestion 
by 20S i-proteasome carrying the variant HH at the codon 60 of 1i subunit. Authors speculated 
that a lower production and presentation of this epitope as well as other myelin epitopes bound to 
the HLA-A*02, could reduce the probability to disrupt the physiological tolerance (central or 
peripheral) of myelin-specific CTLs and/or their cytotoxicity towards oligodendrocytes, thereby 
restraining the MS onset
50
. The i-proteasome activity and the 1i R60H polymorphism might have 
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implications also at thymic level during the selection of myelin –reactive thymocytes although no 
exhaustive information is available to this regard. 
Furthermore, the study of Seifert and colleagues suggested another i-proteasome-related mechanism 
that could affect the MS onset. Indeed, they showed that i-proteasome is essential for an efficient 
clearance of oxidised and polyubiquitylated proteins upon IFN-  induced oxidative stress, thereby 
preserving protein homeostasis during inflammation. Accordingly to this observation, they reported 
that 5i ko mice showed an earlier onset and worst clinical score than wild type mice in an EAE 
model
39
. Although these two studies would suggest that i-proteasomes may influence onset and 
progression of MS affecting both the myelin-specific CD8
+
 T cell activity and the response of 
different cell types to the inflammatory aggression both in periphery and in the CNS, further 
independent confirmations are needed before drawing a model connecting i-proteasome and MS 
which could have a remarkable spin-off for future therapeutic approaches to the disease.   
3.4.3 Temporal Lobe Epilepsy. 
Epilepsy is a neurological disorder that affects about 50 million people worldwide and is 
characterized by an enduring predisposition to generate seizures as well as by emotional and 
cognitive dysfunctions. About 30% of epileptic patients are defined pharmacoresistant since they do 
not adequately respond to therapies and in these patients, affected by TLE, the surgical removal of 
the epileptic focus is often the only therapeutic option to achieve seizure control
101
. 
The evidences available from experimental and clinical findings support a crucial role of immune 
and inflammatory processes in the aetiopathogenesis of epilepsy
47
. Pronounced inflammatory 
processes have been described in human epileptogenic brain tissue from TLE and epilepsies 
associated with malformations of cortical development, where seizures are often refractory to 
anticonvulsant treatments
102
.  
Pharmacological studies in experimental models and the use of transgenic mice with perturbed 
cytokine systems showed that proinflammatory cytokines (e.g. IL-1 , TNF- ), danger signals (e.g. 
HMGB1), complement factors and prostaglandins significantly contribute to seizure activity and 
cell loss, and that inhibition of the production of these molecules or blockade of their receptors (e.g. 
ILR1, TLR-4), significantly reduced seizure activity
103
. 
Recently, i-proteasomes have been detected in cortex and hippocampus of patients affected by 
different TLE forms
48
. By IHC staining i-proteasomes were revealed in glia and neurons of TLE 
hippocampi whereas controls showed positivity to 1i and 5i only in luminal endothelial cells, as 
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observed in other studies
49,50
. Intriguingly, the neuronal i-proteasome expression differs between 
TLE forms. Furthermore, no IFN-  was detected in TLE specimens suggesting that in this disease i-
proteasome synthesis is induced by a different mechanism. A good candidate could be TLR-4, 
which can be triggered by LPS treatment, a well-known i-proteasome inducer. Thus, taking into 
account the role that TLR-4 plays in the disease, we might speculate that i-proteasome is one of the 
molecules induced/activated by TLR-4 pathway that mediate the effects that this receptor has 
during epileptogenesis. Further investigations are however mandatory to address this issue as well 
as to understand the role of i-proteasome in the different neuroinflammatory processes involved in 
epilepsy. 
It is worth to note that so far no studies have exploited the availability of i-proteasome ko mice by 
crossing them with disease animal models (e.g. APP/PS1 model for AD) or inducing a disease-
associated symptoms by drugs such as pilocarpine or kainite (as epilepsy models), respectively. We 
surmise that these types of studies will provide breakthrough information on the disease 
aetiology/progression and the involvement of i-proteasome in the pathological mechanisms. 
3.5 An overview of selective s- and i-proteasome inhibitors and 
enhancers. 
Despite the efforts made in recent years to discover selective inhibitors for either s-proteasome or i-
proteasome, only six compounds showing some selectivity (two for the s-proteasome, PR-893 and 
PR-825, and four for the i-proteasome, PR-924, PR-957, IPSI-001 and UK-101) have been 
described (Table 3.2 and Figure 3.2). PR-893 (compound 1 in Fig. 3.2) is a tripeptide epoxyketone 
which shows a selectivity of 20 folds for β5 over β5i subunits104. This molecule was used by Parlati 
and co-workers to prove, in their pioneering study, the relationship between the selective inhibition 
of subunits (β5 and β5i) with chymotrypsin-like (CT-like) activity and the antitumour response in 
tumour cells of haematological origin. The same reactive portion of PR-893 can be found in PR-825 
(compound 2 in Fig. 3.2), an analogue of carfilzomib (compound 2 in Fig. 3.1), which has been 
synthesized by Zhou et al. by varying the P2, P3 and N-Cap of bortezomib
105
. These variations gave 
rise to an inhibitor of proteasomal CT-like activity, which is about 14 folds more selective towards 
β5 as respect to β5i. On the other hand, two selective inhibitors related to carfilzomib (compound 2, 
in Fig.3.1), namely PR-924 (comp. 3, Fig. 3.2) and PR-957 (comp. 4, Fig. 3.2), have been 
developed to target β5i subunit of the i-proteasome106. As in the case of the above-mentioned s-
proteasome inhibitors, these two compounds are tripeptide epoxyketones. Their structure differs 
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from s-proteasome selective inhibitors for the presence of three marked aromatic and hydrophobic 
pharmacophoric features. In particular, both PR-924 and PR-957 have two aromatic moieties in the 
proximity of the reactive group, i.e. epoxyketones phenylalanine instead of epoxyketone leucine of 
PR-893 and PR-825 as well as bulkier tryptophan (PR-924) and tyrosine (PR-957) instead of 
smaller side-chain amino acids for PR-893 and PR-825. Equally, the N-protecting groups are also 
more hydrophobic and large as respect to s-proteasome inhibitors. All these hydrophobic/aromatic 
features are expected to interact with specific moieties of the β5i binding site and, as discussed 
below, these may constitute the molecular reason for the i-proteasome selectivity over s-proteasome 
catalytic activity. In fact, PR-957 is reported to be 20- to 40- more selective for murine β5i over β5 
and β1i subunits and, at the concentration which allows minimal impact on other subunits, it 
inhibited the presentation of β5i-dependent epitopes31. Equally, PR-924 was shown to be 100-fold 
more selective for human β5i and less selective for CT-like activity of β5 as compared to 
bortezomib and carfilzomib
63
. The selective inhibition of i-proteasome has been obtained also with 
a dipeptide aldehydes compound, IPSI-001 (compound 5, Fig. 3.2) that targets the β1i subunit and 
inhibit i-proteasome C-like and CT-like activity in vitro in lymphoid-derived tumour cells lines and 
MM patient-derived samples. Similarly to PR-924 and PR-957, IPSI-001 has three hydrophobic and 
extended features such as the carboxybenzyl N-protecting group and the n-propyl side chain close 
to the reactive aldehyde. Finally, another β1i specific inhibitor, UK-101, (compound 6, Fig. 3.2) has 
been developed by Ho and co-workers, demonstrating growth-inhibitory activity in prostatic cancer 
cells expressing higher level of β1i with no effect on s-proteasome function64,65. UK-101, like IPSI-
001, is also a dipeptide with a tert-butyldimethylsilyl group attached at the C-terminal hydroxyl 
group
65
. All the above-mentioned s- and i-proteasome inhibitors covalently modify the catalytic N-
terminal Thr of the proteolytic β subunits thereby affecting specific activities by means of covalent 
reversible or irreversible inhibition mechanisms (Table 3.3). Considering the large number of 
promiscuous inhibitors of s- and i-proteasome, which can bind reversibly or irreversibly the 
catalytic Thr, such as epoxyketones, aldehydes, vinylsulfones, β-lactones, boronic acids, 
isocoumarins and Michael acceptors (Fig. 3.1 and Table 3.2), it should be pointed out that only 
epoxyketones and aldehydes have been reported as i- and s-proteasome specific inhibitors 
(compounds 1-6 in Fig. 3.2 and Table 3.3). In this regard, it should be noted that, while some efforts 
have been done to modify the reactive threonine-trap of s-proteasome inhibitors
107,108
, no similar 
strategies have been yet explored to modify known specific i-proteasome scaffolds with other 
reactive groups. It is therefore unclear whether other Thr-traps may be conveniently used for the 
design of novel i-proteasome specific inhibitors. Similarly, it is interesting to note also that non-
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peptide-like compound such as Salinosporamide (compound 11 in Fig. 3.1), Belactosin (compound 
16-17 in Fig. 3.1) and Betulinic acid derivatives (compound 22 in Fig. 3.1) have been so far only 
described among promiscuous s- and i-proteasome inhibitors (Fig. 3.1). Even in this case, it is still 
to be ascertained whether it is possible to optimize classes of non-peptide-like compounds in order 
to reach some selectivity either for s- or i-proteasome. In this context, new insights on 
immunoproteasome structure obtained either by modelling results (see next paragraph) or new 
crystallographic resolutions promise to be highly relevant for the rational design of novel selective 
inhibitors. Although the inhibition mechanism of proteasomes has been extensively reviewed by 
several authors
106,109–112
, few information about mechanisms of activation or reversible inhibition 
are available. For example, betulinic acid derivatives (compound 22 in Fig. 3.1) were proved to 
inhibit CT-like activity
113
  but there is no specific information about their inhibition mechanisms, as 
well as for Argyirn A (compound 24 in Fig. 3.1)
114
. On the other hand, Gallastegui et al. 
demonstrated, by resolving the crystal structure of s-proteasome in complex with the most potent 
hydroxyurea derivative (PDB ID: 3SHJ)
115
, that new hydroxyurea derivatives (compound 28 in Fig. 
3.1) bind non-covalently the site with CT-like activity. In contrast to the development of 20S 
inhibitors, drug-like molecules that can activate or enhance proteasome activity are, at present, rare 
and not well characterized, even if they could represent an appealing strategy for specific diseases 
in which proteasome activity has to be increased to cure the patient. Apart the role of PA28, PA700 
and PA200 regulators in proteasome activation, several type of small molecules including SDS, 
lipids (oleic and linoleic acids) and peptide–based compounds were shown to activate proteasome at 
relatively high concentrations
116
. On the contrary, oleuropein (compound 8, Fig. 3.2), 
Phaeodactylum tricornutum algae extract and betulinic acid (compound 7, Fig. 3.2) can activate 
proteasome at low micromolar concentration.  Oleuropein is the major component isolated from the 
Olea europaea, it is able to increase in vitro all three proteolytic activities and delay replicative 
senescence of human embryonic fibroblast
117
. The same results have been obtained by 
Phaeodactylum tricornutum algae extract, which  stimulates all three proteolytic activities of 
proteasome in vitro and in human keratinocytes thereby reducing the level of oxidized proteins
118
. 
Conversely, betulinic acid, a triterpene derived from many plant species, preferentially activates the 
CT-like activity of proteasome
119
, even if inhibitory effects have also been reported as above 
described. Finally, Chondrogianni and co-workers identified quercetin (compound 9, Fig. 3.2) and 
its derivative, namely quercetin caprylate (QU-CAP) as a proteasome activator with anti-oxidant 
properties that can influence cellular lifespan, survival and viability of HFL-1 primary human 
fibroblasts. Moreover, when these compounds were supplemented to already senescent fibroblasts, 
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a rejuvenating effect was observed
120
. The mechanism of action of all these compounds is supposed 
to be linked to conformational changes of the channel gates regulated by the  subunits of the 
proteasome although further investigations are needed to characterize their enhancer properties. In 
addition, recent and ongoing research aim to elucidate the roles of other components of the UPS has 
identified several enzymes, beside the 20S catalytic core, that can be additional targets for 
therapeutic intervention by small-molecule modulators
121
. In particular, an enhancement of 
proteasome activity by a small-molecule inhibitor of the DUB USP14 has been reported
122
, as well 
as an anticancer activity of another compound which inhibits both UCHL5 and USP14 enzymes
123
, 
suggesting that the deubiquitinating activity of the PA700 regulator could represent a new 
anticancer drug targets. 
3.6 Human immunoproteasome model. 
Despite the importance of i-proteasome as an emerging biological target for cancer and 
neuropathologies, until 2013 no crystallographic structure of the human form has been solved. A 
possible strategy to compensate that lack of knowledge was the generation of in silico human i-
proteasome models, which could provide helpful hints for the development of selective i-
proteasome modulators. Accordingly, we generated the human model of the whole i-proteasome by 
starting from the X-ray structure of the mammalian 20S proteasome (PDB id: 1IRU) and 
substituting of the six catalytic subunits of the inner rings with the related i-proteasome subunits 
(Table 3.4).  
At first we checked the similarity between  subunits in the two inner rings of the proteasome 
structure. Root mean square deviation (RMSD) for each couple of homolog-subunits was found to 
be in the range 0.6-1.3 on all atoms, thereby indicating that homolog- -subunits of the two inner 
rings can be considered equivalent. The raw models of  i-subunits were taken from the 
SwissModel repository
124
 and aligned to chain H, I, L for 1, 2 and 5, respectively. The same 
models were used also to represent the i-proteasome subunits of the other inner ring. The entire i-
proteasome model was generated by substitution of the six catalytic chains and followed by several 
structural corrections/refinements such as hydrogen addition, water and ions removal, manual 
charges corrections, addition of missing side chains and optimization of hydrogen bonds. In order to 
analyze at the molecular level the aminoacidic differences between s- and i-proteasome we reported 
in Fig. 3.3 and Table 5.3 a pair-wise comparison of the  subunit catalytic pockets of the 
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mammalian s-proteasome crystallographic structure (PDB id: 1IRU) and the model of human i-
proteasome that we derived.  
 
Figure 3.2. Chemical structures of selective s- and i-proteasome inhibitors and activators of proteasomes. 
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Compound 
Selectivity 
Mechanism and 
biological effect 
Subunit Activity 
1 β5 CT-like irreversible inhibitor 
2 β5 CT-like irreversible inhibitor 
3 β5i CT-like irreversible inhibitor 
4 β5i CT-like irreversible inhibitor 
5 β1i 
CT-like > C-like > T-
like 
BrAAP 
reversible inhibitor 
6 β1i CT-like irreversible inhibitor 
7 α
a  activator 
8 α
a  activator 
9 α
a  activator 
 
Table 3.3. Activity profiles of s- and i-proteasome inhibitors as well as proteasome enhancers. Inhibition form, 
inhibited proteasome activities and relative references are reported. Proteasome activities, as defined with short-
fluorogenic substrate assay, are shortened as following: CT-like = chymotrypsin-like, T-like = trypsin-like, C-like = 
caspase-like. Structure enumeration of proteasome inhibitors refers to what reported in Fig. 3.2. αa: the mechanism of 
these compounds has been hypothesised to be related to conformational change perturbations of α-type subunits. 
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Figure 3.3. Comparison of s-proteasome and i-proteasome β-subunits in complex with bortezomib. S-proteasome 
subunits were taken from the crystallographic structure of the human 20S proteasome (PDB id: 1IRU) while i-
proteasome subunits were derived by our model (see above). Initial binding poses of bortezomib (compound 1 in  Fig. 
1) were taken by the crystal structure of the yeast proteasome (PDB id: 2F16) aligned with correspondent subunits of 
the human proteasome (PDB id: 1IRU) and followed by ligand minimizations. Contour maps were generated with the 
software SiteMap [136], thereby producing hydrophobic (yellow regions), donor (blue regions) and acceptor (red 
regions) potentials. Contour maps represent the ideal region of the space where a corresponding ligand feature should 
be located in order to interact optimally with the subunits. 
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The catalytic binding sites of s- and i-proteasome generally show a similarity in shape and volume 
between β1, β2 and β5 and their corresponding β1i, β2i and β5i subunits. This simple fact might 
suggest that ligands with similar shape and volume properties fit equally in s- and i-proteasome 
homologue subunits. However, a deeper structural analysis shows that non-negligible differences 
between s-proteasome and i-proteasome are present in the aminoacidic composition of some of the 
catalytic pocket residues. In particular, we analyzed residues of the binding site that differ from s- to 
i-proteasome chains observing that β1 and β1i subunits show the higher degree of variability since 
ten residues differ in the substrate binding site (Fig. 3.3 and Table 5.3). On the other hand, five 
residues differ from β5 and β5i subunits whereas only four residues change from β2 to β2i subunits. 
Most interesting is to analyze the differential nature and position of these changes vis-à-vis to the 
binding of putative s- or i-proteasome inhibitors. We did such analysis by taking advantage of the 
structural information available from co-crystallized structure of bortezomib with yeast s-
proteasome (PDB id: 2F16). In Fig. 3.3 we graphically reported the location of the aminoacids 
listed in Table 5.3 and depicted binding site differences in terms of contour maps that represent the 
ideal region of the space where a ligand feature should be located in order to interact optimally with 
the single subunits. In some cases differences involve relevant changes of aminoacid properties that 
are likely to be important for the binding of putative selective inhibitors. For instance Arg45 of the 
β1 subunit is substituted to a Leu45 in the β1i subunit. This change implies the existence of a 
noticeable hydrophobic region in the binding site of the β1i subunit (yellow region, Fig. 3.3) that is 
not present in the β1 subunit due to the polar nature of the arginine residue. Despite such a 
difference occurs in the binding site of both subunits, bortezomib seems not to be influenced by this 
change and this might constitute one of the reasons behind the promiscuous nature of this inhibitor 
towards s- and i-proteasome. Another major difference involves residues of Ala27 and Ser28 of the 
β5 subunit, which are inversed in the β5i subunit, i.e. Ser27 and Ala28.  This simple inversion 
relocates the hydrophilicity of the serine residue thereby becoming more accessible for the putative 
binding of ligands. Even in this case the non-selectivity of bortezomib may be explained by the fact 
that its binding is not influenced by such aminoacidic switch, although selective lead compounds 
might be developed in light of these considerations. In contrast, β2 and β2i subunits seem to be very 
similar in terms of aminoacidic properties. This fact is graphically reflected by similar shapes and 
colours of the contour maps of Fig. 3.3. Thus, from these data, it appears particularly challenging to 
exploit differential binding site composition of β2 and β2i subunits in order to conceive selective 
inhibitors. This consideration may also explain why no selective s- or i-proteasome inhibitors 
targeting the trypsin-like (T-like) activity have been discovered so far. Finally, by comparing β1, β2 
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and β5 subunits it is interesting to note that both in the crystal structure of the yeast proteasome 
(PDB id: 2F16) as well as in our i-proteasome model, bortezomib assumes a markedly different 
molecular conformation in β2 and β2i while other subunits, i.e. β1/β1i and β5/β5i seem to 
accommodate the ligand with the same binding mode (Fig. 3.3). Huber et al.
125
 published several 
crystal structures of the yeast 20S proteasome and of the mouse 20S s-proteasome and i-proteasome 
in presence or absence of the i-proteasome specific inhibitor PR-957 (compound 4 in Fig. 3.2; PDB 
ids: 3UN4, 3UN8, 3UNB, 3UNE, 3UNH and 3UNF). Through the analysis of the crystallographic 
structure the authors identified a unique catalytic feature for the i-proteasome β5i active site and, 
together with conformational changes occurring upon ligand binding, could rationalize the 
selectivity of PR-957 towards the β5i subunit. Importantly, the superposition of the above-described 
crystallographic subunits β1i, β2i and β5i with those obtained by our human i-proteasome model 
shows a striking consistency, thereby underlining the importance to obtain structural and/or 
modelling data as an effective tool for the identification of potential small-molecule lead structure, 
as described below. 
3.7 Computer-aided drug design approaches 
Few approaches of computational drug design have been applied in the last years for the discovery 
of new lead compounds able to inhibit s-proteasome
126–128
. For instance, Reboud-Ravaux and 
colleagues carried out a multistep structure-based virtual ligand screening strategy and were able to 
identify several novel lead compounds inhibiting s-proteasome with micromolar range activity and 
reported cytotoxicity on human tumour cell lines
127,129
. It is worth noting that no computer-aided 
drug design techniques have been yet reported for the discovery of selective i-proteasome 
inhibitors. In this context, likely, new insights on i-proteasome structure obtained by computational 
modelling
128
, including the present work, or by means of new crystallographic evidences
125
, might 
constitute a new way to deploy chemoinformatic techniques such as docking or  pharmacophore 
high-throughput virtual screenings
130,131
 on large database of chemicals compounds
132,133
. In 
particular, it appears that differences of aminoacids (Fig. 3.3 and Table 5.3) in the s- and i-
proteasome β subunit binding sites (especially β1 versus β1i and β5 versus β5i) might effectively 
constitute the molecular basis for the development of novel s- and i-proteasome specific inhibitors, 
keeping however into account that the design of highly-specific inhibitors may still result in 
challenging tasks because of the major similarities in the β subunit catalytic sites.  
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Proteasome 
subunit – gene 
name 
Common 
Name 
Uniprot code 
Chain name 
(PDB id:  
1IRU) 
Immuno-
proteasome 
subunit – gene 
name 
Common 
Name 
Uniprot code 
PSMB6 1 P28072 H/V PSMB9 1i P28065 
PSMB7 2 Q99436 I/W PSMB10 2i P40306 
PSMB5 5 P28074 L/Z PSMB8 5i P28062 
Table 3.4. S- and i-proteasome catalytic subunit nomenclature. 
 
Subunits Proximal residues (within 5Å from bortezomib pose) 
 20 21 22 23 27 28 31 45 46 48 52 95 97 116 
β1 T T T  A  T R   T M G M 
β1i V S A  V  F L   A S H G 
β2   E G      T T    
β2i   N D      V A    
β5  T   A S   A G     
β5i  S   S A   S C     
Table 3.5. Proximal amino acidic differences in the catalytic binding sites of s- and i-proteasome β-subunits. 
3.8 Hit Identification 
Since the growing amount literature data suggesting the pivotal role of i-proteasome in different 
cellular pathways, including apoptosis and inflammation, a selective modulation of i-proteasome, 
by inhibiting or enhancing its activity, directly with small-molecule modulators or indirectly, e.g. by 
regulating E3 and DUB enzymes, could represent a promising strategy to counteract these 
pathologies. At the time of this study, medicinal chemistry efforts identified a small number of low 
molecular-weight inhibitors that are able to modify 20S s- and i-proteasome functions, but only few 
examples of selective i-proteasome inhibitors was developed. So we started an hit identification 
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campaign to find new selective i-proteasome inhibitors using virtual screening methodologies. The 
available x-ray structure of human proteasome (PDB code 1IRU) and the generated model of i-
proteasome, after a standard protein preparation procedure, were used as template to virtually 
screen the Asinex compound dataset, as prepared in the CoCoCo database
132,133
, comprised of 
approx. 1.2M compounds. The docking grids were centered on each of the three catalytic subunits 
(β1, β2, β5) of both standard and i-proteasome, for a total of 6 different docking runs. The results 
were collected and merged, to obtain a unique list of molecules (w/o duplicates) reporting the 
docking score versus each of the 6 receptor structures. 
The first hundreds hits were visually inspected to select a reduced list of compounds to be 
purchased and tested. However, only a small number of molecules were present in the first 1000 
molecules of the final ranked list in more than one receptor (approx. 250 molecules out of a total 
6000), therefore the selectivity between the different grids was not considered as a primary 
selection criteria. The selection was then focused on the results obtained from the docking on β5i 
subunit that showed major differences compared with its homologue subunit in standard proteasome 
(see above), therefore offers more chances of success in finding selective compounds. The x-ray 
structures of mouse i-proteasome in complex with compound PR957 (PDB code 3UNF) was used 
to derive specific binding features of selective inhibitor that were used as selection criteria for 
docking output; in particular, the final docking list of β5i was filtered requiring for the presence of 
hydrogen bond interaction with SER27 (ALA in β5c) and aromatic interactions with MET45 
(present also in β5c but in a different conformation, and responsible of PR957 selectivity as 
explained by Huber et al
125
). In the selection process the presence of several specific interaction 
with other key residues in the active site was also considered (in particular THR1, GLY47, ALA49, 
ASP125 and SER21); non-modified peptides was discarded due to less favorable pharmacokinetic 
properties, and special attention was put on non-peptidic molecules. Finally, sample availability 
from compound providers was also verified, leading to a final list of 11 compounds that were 
purchased and experimentally tested (Table 6.3). Experimental test were performed in the 
Laboratory of Prof. Claudio Franceschi (University of Bologna). A specific assay exploiting 
caspase-like, trypsin-like and chymotrypsin-like activities was developed (see experimental section) 
and used to assess the effect of the selected compounds on i-proteasome. Among the 11 compounds 
tested, 2 led to a significant inhibition of i-proteasome activity, namely compound 1 and compound 
6, thus giving a remarkable hit-rate obtained with the virtual screening protocol. Nine compounds 
resulted inactive at the concentration used in the assay. Figure 4.3 reports the predicted binding 
modes of the two active molecules identified with the virtual screening. 
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ID Structure  ID Structure 
1 
 
 7 
 
2 
 
 8 
 
3 
 
 9 
 
4 
 
 10 
 
5 
 
 11 
 
6 
 
   
Table 3.6. Structures of selected compounds after the first virtual screening.  
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Figure 3.4. Predicted binding modes of compounds 1 (A) and 6 (B). 
 
A 
B 
THR1 
SER27 
MET45 
THR1 
SER27 
MET45 
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ID Structure  ID Structure 
1a 
 
 6a 
 
1b 
 
 6b 
 
1c 
 
 6c 
 
1d 
 
 6d 
 
1e 
 
 6e 
 
1f 
 
 6f 
 
Table 3.7. Structures of selected compounds after the second virtual screening.  
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Figure 3.5. Short fluorogenic peptides in vitro assays where LLVY represents the chymotryptic-like catalytic activity, 
VGR the tryptic-like and the LLE the caspase-like. Compound were tested at concentration 1, 10, 100 µM, for 60min at 
37°C, with preincubation with s- and i-proteasome at room temperature. 
Compound 1 is an hydroxypirimidine derivative, while compound 6 is a symmetric tosyl-cystine 
derivative; both compounds are predicted to bind the β5i subunit close to the catalytic residue 
THR1, similar to the binding mode of other known inhibitors such bortezomib or PR957, even if 
these molecules doesn‟t show any reactive groups, and therefore form non-covalent reversible 
interactions in the active site. Both are predicted to establish hydrogen bond interactions with THR1 
and SER27, and fill the putative selectivity pocket in front of MET45 with an aromatic moiety. 
Compound 6 is predicted to establish an extended hydrogen bond network involving also ALA20, 
SER21, CYS48.  
To obtain a better understanding of the structure-activity relationship of this interesting hit 
compounds identified in first screening, and to improve its potency and selectivity, we screened the 
same collection of commercial compounds to identify analogues that could be easily purchased and 
tested. These derivatives were selected from the database using different substructure searches, 
considering the possible modifications on each fragment of the reference structure, and checking 
sample availability from compound providers. The list of selected compound is reported in Table 
7.3. 
Compound 6 Compound 6e 
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Figure 3.6. Predicted binding modes of compounds 6 (A) and 6e (B). 
A 
B 
THR1 
SER27 
THR1 
SER27 
MET45 
MET45 
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All derivatives were tested using the same experimental conditions of reference compounds. The 
derivatives of compound 1 (compounds 1a-f in Table 7.3), despite very high structural similarity 
with reference compound 1, showed very limited or none inhibition of both standard or i-
proteasome; this results indicates the occurrence of a false positive in the first activity measurement, 
probably due to experimental errors or unpredictable effects of the molecule (e.g. alteration of 
fluorescence level unrelated to target inhibition). The derivatives of compound 6 were selected 
using two different criteria: modification of cystine group, to test whether the presence of only the 
tosyl group would able to induce inhibition of proteasome activity (compounds 6a-c in Table 7.3), 
and modifications of tosyl group (compounds 6d-f in Table 7.3) while preserving the cystine 
moiety. Compounds 6a-c all showed no inhibition, clearly stating the need of cystine function for 
activity; on the contrary, compounds 6d-f all showed moderate inhibition of both standard and i-
proteasome, even if slightly lower compared to reference compound 6.The activity data of most 
interesting compounds found during the screening are reported in Figure 5.3.  
Predicted binding mode of compound 6e (Figure 6.3), the most interesting of this series, is similar 
to the reference compound 6. In fact, the hydrogen bond interaction with key residue THR1 is 
established through carboxylic group, that replaces the sulfonyl group in compound 6, and the 
aromatic interaction in the MET45 is maintained; an additional charge interaction is formed by an 
o-nitro group with LYS33, while the other one is favorably placed in a solvent-exposed area of the 
active site. This compound showed an interesting inhibitory activity on all catalytic functions of 
proteasome, but a proven also a small selectivity towards i-proteasome, in particular in the caspase-
like activity; however, both selectivity and potency of the identified chemical scaffolds should be 
further improved. 
3.9 Conclusion and perspective 
We carried out virtual screening by using structural information available and searched on large 
database of commercial chemicals. We selected 23 compounds by visual inspection and, after 
purchase, we have tested them to select novel and reversible scaffolds able to inhibit s- and i-
proteasome. We identified new moderately active and selective non-peptidic compounds. Their 
scaffolds hold premise for the development of novel improved and selective i- and –proteasome 
inhibitors. 
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3.10 Experimental Section 
In silico techniques 
The available X-ray structure of human proteasome (PDB code 1IRU) and the generated model of i-
proteasome were used as a template for virtual screening purposes. These structures was prepared 
with standard preparation procedures (protein preparation wizard) as included in the software 
package Maestro
134
. The docking software Glide
135
 was used to perform a high-throughput virtual 
screening experiment. Docking grids were generated using default parameters and centred on 
structure of minimized PR957, the dimension of the grid was calculated on this ligand. Standard 
precision (SP) docking was used to perform a first round of virtual screening. The top 1500 
molecules, sorted by Glide score, were further refined with the extra-precision (XP) docking. 
Docking results were ranked based on the Glide score and the first 1000 hits were considered for 
visual inspection. 
Compound Sources. We screened in silico the Asinex subset of the CoCoCo databases. Selected 
molecules were purchased in milligram quantities from chemical vendor. Purity of compounds was 
>= 95%, as declared by the chemical vendor. 
Biological assays (Laboratory of Prof. Claudio Franceschi, University of Bologna) 
Proteasome activity assay. Proteasome activities were measured on 20S proteasome purified from 
Lymphoblastoid cell lines, according to Mishto et al.
136
, as well as on commercially available 20S s- 
and i-proteasome (Biomol and Viva bioscience respectively) by the fluorogenic substrates Suc-
LLVY-MCA, Bz-VGR-MCA and Z-LLE-MCA, specific for chymotrypsin- (CT-), trypsin- (T-), 
and caspase-(C-) like activities, as described elsewhere
49,137
. Briefly, 0.1 μg of 20S proteasomes 
were incubated with 400 μM of Suc-LLVY, 200 μM Z-LLE-MCA and 600 μM of Bz-VGR-MCA 
in TEAD buffer, at 37 °C, in presence or absence of 1, 10 and 100 μM of compounds  The 
enzymatically released MCA was fluorometrically measured at 360 nm excitation and 460 nm 
emission and monitored at 0‟, 30‟, 60‟, 90‟, 120‟ Proteasome activity was expressed as specific 
activity (nmol of free MCA/min per mg protein) and the percentage of inhibition in presence of 
each compound tested was calculated. 
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4. Sirtuins in drug discovery 
4.1 Sirtuins: at the crossroad of metabolism, cancer, and inflammation 
Sirtuins are enzymes that require nicotinamide adenine dinucleotide (NAD
+
) to catalyze their 
reactions
138–141
. The latter include activities as mono-ADP-ribosyltransferases
142
 or as deacetylases. 
In mammals, seven sirtuins have been identified, of which two are predominantly nuclear, SIRT6 
and SIRT7, two are nuclear and cytosolic, SIRT1 and SIRT2, and three are mitochondrial, SIRT3-5. 
Sirtuins have been ascribed roles in numerous physiological and disease conditions, including 
aging, metabolism, circadian clock regulation, nutritional behavior, but also cancer and 
inflammation
140,143
. Due to their broad involvement in key biological functions, sirtuins are 
considered appealing targets for the development of pharmaceuticals. 
4.2 Sirtuins and cancer 
The sirtuins for which a role in cancer has been proposed include SIRT1, SIRT2, SIRT3, SIRT6 
and SIRT7. In genetic mouse models, SIRT1, SIRT2, and SIRT3 were shown to act as tumor 
suppressors
144–147
. In the case of SIRT1, its activity as a tumor suppressor has been ascribed to its 
capacity to deacetylate and consequently inhibit the RelA/p65 subunit of NF-kappaB
148
, a 
transcription factor with antiapoptotic and pro-inflammatory activity. Moreover, studies show that 
SIRT1 also deacetylates β-catenin and thereby suppresses its ability to activate transcription and 
drive cell proliferation
149
. Disruption of SIRT2, which is a tubulin deacetylase
150
, in the mouse was 
found to increase the levels of mitotic regulators, such as Aurora-A and -B, aneuploidy, and mitotic 
cell death
146
. SIRT2-deficient mice developed gender-specific tumorigenesis, with females 
developing mammary tumors and males developing hepatocellular carcinoma. Moreover, human 
breast cancers and hepatocellular carcinomas were reported to exhibit reduced SIRT2 levels as 
compared with normal tissues. SIRT3 was proposed to oppose cancer development through its role 
in mitochondrial metabolism, reactive oxygen species production and genome stability
145,147
. Its 
deficiency was shown to favor cell transformation in response to oncogenic Ras or Myc and to lead 
to HIF-1α stabilization with consequent induction of the Warburg effect. SIRT6 has also been 
suggested to act as a tumor suppressor since its acute overexpression in cancer cell lines of different 
histology was found to induce apoptosis
151
. Interestingly, this biological activity of SIRT6 appears 
to be linked to its mono-ADP-ribosyltransferase but not to its deacetylase activity. Finally, SIRT6 
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anticancer activity could also be ascribed to its capacity to negatively regulate NF-κB and HIF-
1α152,153, the latter being a transcription factor that promotes the expression of glycolytic and pro-
angiogenic genes. 
The apparent consistency of this picture is complicated by evidence that these same sirtuins may 
actually favor certain aspects of neoplastic growth and that, at least in certain instances, their 
inhibition may be preferable to their activation. Numerous reports indicate that SIRT1 also has 
cancer-promoting functions which include deacetylation and inactivation of p53
154,155
 and of 
proapoptotic FOXO transcription factors
156
, deacetylation of Ku-70 with consequent sequestration 
of Bax away from mitochondria
157
, as well as inhibition of senescence and of apoptosis in c-Myc- 
and in PML-driven cancers
158,159
. Accordingly, many studies attribute direct anticancer activity to 
SIRT1 inhibitors or show how such compounds sensitize cancer cells to anticancer agents or to 
oxidative stress
160–166
. Similar results were also reported for SIRT2. SIRT2 downregulation or 
chemical inhibition were found to induce anticancer effects that include p53 accumulation, cell 
cycle arrest and apoptosis
167–169
. In a recent study, the antileukemia effects of SIRT2 inhibition 
(with AC93253) were accompanied by Akt acetylation, de-phosphorylation, and consequent 
inhibition
170
. Interestingly, evidence exists that SIRT2 inhibition could be counterproductive in 
certain instances, such as upon treatment with microtubules inhibitors
171
. Namely, SIRT2 
downregulation appears to make cancer cells resistant to these agents by prolonging chronic mitotic 
arrest. Also SIRT3‟s role as a tumor suppressor does not seem to extend to all types of cancer. In 
particular, in oral squamous cell carcinomas, SIRT3 was found to be overexpressed and its 
downregulation had antiproliferative activity and sensitized carcinoma cells to radiation and to 
cisplatin
172
. Finally, in the case of SIRT6, studies show that this enzyme is crucial for telomere 
maintenance, DNA repair and genome stability
173,174
. Thus, SIRT6 inhibitors could conceivably be 
used to sensitize cancer cells to chemotherapeutics or radiotherapy
175
. Moreover, SIRT6 promotes 
TNF synthesis by a mechanism that appears to entail the enhancement of the efficiency with which 
TNF mRNA is translated
176,177
. TNF plays a central role in some of the systemic manifestations of 
cancer, such as fever and cachexia, and its role in shaping the tumor microenvironment is 
acknowledged
178
. SIRT6 inhibition could theoretically serve the purpose of reducing the levels of 
this unwanted mediator of cancer-induced inflammation and thereby interfere with invalidating 
systemic manifestations of disease.  
Finally, a recent study suggests that SIRT7 may promote tumorigenesis by deacetylating lysine 18 
of histone H3, thereby repressing genes with tumor suppressor function
179
. SIRT7 was found to be 
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stabilized at target promoters by interaction with the ETS family transcription factor ELK4. 
According to these authors, H3K18 deacetylation by SIRT7 would be necessary to maintain 
essential features of cancer cells, such as anchorage-independent cell growth and loss of contact 
inhibition. Indeed, in line with this model, SIRT7 depletion reduced the tumorigenicity of human 
cancer xenografts in mice. 
Overall, while it is eventually becoming clear that sirtuins play important roles in cancer 
pathophysiology, the final judgment as to whether a defined sirtuin should be blocked or rather 
activated in order to achieve a therapeutic benefit may vary depending on the type of cancer, its 
molecular features, stage of disease, and clinical manifestations. Either way, a crucial step in the 
pursuit of sirtuin-targeting approaches is the identification of compounds that could be used to 
specifically modulate sirtuin activity in vivo. 
4.3 Sirtuin inhibitors 
Although sirtuins emerged in the last years as therapeutic targets for small molecule-based 
interventions, a relatively small number of highly active molecules have been developed so far. The 
available inhibitors belong to several structural classes that reflect both different drug discovery 
strategies and the complexity of the catalytic machinery of these enzymes. The simplest approach 
used to identify novel active compounds was the evaluation of substrate and/or product mimetics. 
Among the first compounds studied were the endogenous inhibitor nicotinamide (1, Figure 4.1), 
which is a product of the deacetylation reaction, and its derivatives. Because of its simple chemical 
structure, nicotinamide is a micromolar non-competitive inhibitor of SIRT1 and SIRT2
180
 that 
interact with the pocket C in the binding site. Similarly, slightly modified NAD
+
 molecules such as 
carbamido-NAD
+
, compete with NAD
+
 for the cofactor binding site. SIRT1 inhibition with 
nicotinamide was reported to have anticancer activity in B-cell chronic lymphocytic leukemia and 
in prostate cancer
164,181
. However, nicotinamide and the NAD
+
 analogs have limited therapeutic 
potential as demonstrated by unsuccessful searches for more potent inhibitors of this class
182,183
. 
Several active molecules were designed starting from substrate peptides, such as small fragments of 
p53 protein that were modified in order to block or reduce the catalytic activity. Thioacetyllysine 
derived inhibitors and other modifications of acetylated lysine residue have been demonstrated to be 
potent sirtuin inhibitors
184–191
. A recent study highlighted SIRT5 preference to catalyze the 
hydrolysis of malonyl and succinyl group from the lysine residue rather than acetyl group, 
demonstrating that this preference could be used to the design of selective inhibitors
192
. A 
phenotypic screen of a small compound library led to the discovery of sirtinol (2, Fig. 4.1), a 
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hydroxynaphthaldehyde derivative that is active on different sirtuin isoforms
193
 and has cytotoxic 
activity against cancer cells of different origin, including breast, lung, prostate and leukemia 
cells
162,167,181,194
. A number of subsequent structure-activity relationship studies were carried out in 
search of derivatives of this molecule with improved activity and/or properties. Some examples are 
salermide (3, Fig. 4.1)
195
, cambinol (4, Fig. 4.1)
160
 and splitomicin (5, Fig. 4.1)
196
. With the 
exception of splitomicin, which is not active on human sirtuins
197
, also these compounds were 
reported to have anticancer properties
160,167,195,198
. A series of thiobarbiturates derivatives that are 
similar to cambinol and inhibit SIRT1 and SIRT2 at micromolar concentrations, was identified 
through a structure-based virtual screening approach followed by binding energy estimation and 
biological testing (6, 7 and 8, Fig. 4.1)
199
. A large high-throughput screening effort led to the 
discovery of a series of indole compounds as interesting inhibitors of SIRT1, including one of the 
most potent and selective compounds known so far, EX-527 (11, Fig. 4.1). This compound inhibits 
SIRT1 at nanomolar concentrations and shows remarkable selectivity over SIRT2 and SIRT3, as 
well as good pharmacokinetic properties
200
. It was found that EX-527 cooperates with HDAC 
inhibitors to induce apoptosis in leukemia cells
162
. However, due to its selectively for SIRT1 and to 
its poor activity on other sirtuins, the anticancer activity of this inhibitor as a single agent appears to 
be weak
167
. 
Starting from the rationale that sirtuins and protein kinases contain an adenosine binding site, a 
series of known kinase inhibitors was tested against SIRT2 revealing bisindolylmaleinimides and 
indolinone as interesting scaffolds that are able to exert biological activity. The most interesting 
compounds, Ro31-8220 (9, Fig. 4.1) and GW5074 (10, Fig. 4.1) showed SIRT1/SIRT2 inhibitory 
properties in the low micromolar range
201
.  
Suramin (12, Fig. 4.1), an adenosine receptor antagonist, was discovered as a potent inhibitor of 
SIRT1/SIRT2 while searching for sirtuin activators
202
. This molecule inhibits SIRT1/SIRT2 at 
nanomolar concentrations and appears to be selective for SIRT1. Suramin has anticancer activity 
and has been studied in clinical trials
203
. However, it is still unclear to which extent such activity is 
due to sirtuin inhibition or, instead, to other modes of action, such as adenosine receptor activation 
or ceramide accumulation
204
. The optimization of the suramine scaffold led to NF675 (13, Fig. 4.1) 
which is the most potent and selective molecules in this series, showing a 20-fold selectivity ratio 
for SIRT1 over SIRT2
205
. The binding mode of suramin was investigated by co-crystallization with 
human SIRT5
206
. This structure highlights that suramin binds SIRT5 by occupying the nicotinamide 
ribose pocket (B-pocket), the nicotinamide pocket (C-pocket) and part of the substrate-binding site. 
52 
 
Although this compound shows interesting potency and selectivity profile, its modest drug-likeness, 
especially given its high molecular weight and its anionic nature, limits the therapeutic applications.  
Several other compounds with various structural cores were reported to inhibit sirtuins at 
micromolar concentrations, such as tenovins
161
, AGK2
207
, 1,4-dihydropyridines
208
, 
bisnaphtalimidopropyl derivatives
209
, AC-93253
169
, and a series of natural products such as 
aristoforin
210
, amurensin G
211
, polyphenols
212
 and tanikolide
213
. Among these, tenovin-1 and 
tenovin-6 were reported to have strong anticancer activity that is associated to p53 activation
161
. 
4.4 Sirtuins activators 
Because sirtuins have been involved in several physiopathological conditions that include aging, 
metabolism and nutritional behavior
214
, a major interest has been to define possible 
pharmacological actions that could activate sirtuin activity. The first small molecules that were 
reported as activators of SIRT1 were polyphenolic compounds such as resveratrol, piceatannol, 
butein, quercetin, and myricetin (respectively compounds 1-5 in Figure 4.2)
202
. More potent and 
chemically diverse activators were subsequently reported, known as SRT1460, SRT1720 and 
SRT2183 (compounds 6-8 in Figure 4.2)
215
, while a recent study reported allosteric modulation of 
SIRT1 by nonpolyphenolic compounds
216
. Most of these compounds were reported to have 
anticancer activity
217,218
. However, it should be noted that their mechanism of action is still 
unclear
219,220
 and a matter of controversy is the fact that sirtuin activation could frequently only be 
demonstrated with fluorescently tagged substrates
221–224
. Such activation might be ascribed to other 
in vivo and in vitro effects that are not mediated by SIRT1. Alternatively, increased SIRT1 activity 
in response to these compounds may be indirect, i.e. reflect the activity of these agents on proteins 
that are SIRT1 interactors in the cell. Recent works by Park et al.
225
 and Price et al.
226,227
 investigate 
further the role of resveratrol. In the first study authors show that resveratrol indirectly activates 
Sirt1 in vivo due to its effect on cAMP signaling, in particular activating the cAMP-Epac1-AMPK-
Sirt1 pathway; it is also speculated that other known putative Sirt1 activators such as SRT1720, 
SRT2183, and SRT1460, because of their similarity in metabolic effects, should act in a similar way 
of resveratrol. The second work establish a connection between SIRT1 and resveratrol by providing 
evidence that increased mitochondrial biogenesis and function, AMPK activation, and increased 
NAD
+
 levels in skeletal muscle are obtained when mice are treated with a moderate dose of 
resveratrol. 
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Figure 4.1. Sirtuins inhibitors. 
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Figure 4.2. Sirtuins activators. 
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5. Development of a Sirtuins selectivity model 
In the last decade, several three-dimensional structures of sirtuin homologs have been deposited in 
the Protein Data Bank, ranging from archaea to humans, providing a major understanding of 
structural features, catalytic mechanisms and substrate specificity of these enzymes
228
. Several 
bacterial Sir2 structures, and human SIRT1, SIRT2, SIRT3, SIRT5 and SIRT6 are available 
whereas, presently, no structures has been solved for human SIRT4 and SIRT7 yet
229
. Despite this 
large amount of structural information, only a relatively small number of active compounds have 
been identified to date, often showing limited potency and isoform selectivity
230
. Similarly, few 
three-dimensional structures of sirtuin have been solved with activators or inhibitors, reflecting the 
complexity of the catalytic machinery and the subtle mechanisms of pharmacological modulation of 
these enzymes.  In particular, EX527 (1, Figure 5.1), an inhibitor that combines good potency with 
significant isoform selectivity was co-crystallized with SIRT1
231
 and SIRT3
232
; SIRT3 structure is 
also available in complex with three potent but not selective inhibitors (2-4, Figure 5.1) identified 
from a large library screening
233
, with SRT1720 (5, Figure 5.1), a compound that was described as 
SIRT1 activator and SIRT3 inhibitor
234, and also with 4‟-bromo-resveratrol235 (6, Figure 5.1). 
SIRT5 was solved in complex with suramin (7, Figure 5.1), a potent inhibitor of SIRT1/SIRT2
236
, 
and the crystal structure of human SIRT2 was solved in complex with a macrocyclic peptide 
inhibitor
237
. Very recently, the SIRT3/SIRT5 complexes with piceatannol and resveratrol (8-9, 
Figure 5.1), two of the known sirtuin activating compounds (STAC
238
), revealed the mechanism of 
direct sirtuin activation
239
. While these three-dimensional structures highlighted the basis for 
inhibitor/activator binding and laid the foundations for the rational design of new and more potent 
compounds, additional efforts are needed to shed light on the more complex problem of isoform 
selectivity. The development of specific modulators able to interact with a single sirtuin isoform, or 
at least with a small subset, could be extremely useful to better understand the biological role of 
each sirtuin and, at the same time, could facilitate the identification of new therapeutic agents. In 
fact, the small molecules so far reported as sirtuin activators or inhibitors are often tested against a 
limited set of sirtuin isoforms, usually SIRT1/2/3, and their selectivity profile is usually explained 
by using approximate models. A previous study by Schlicker et al.
240
 described the structure-based 
identification of new classes of isoform specific inhibitors, showing that three-dimensional sirtuin 
structures in the non-inhibited state could be successfully used to highlight differences between 
isoforms and could help the development of new selective inhibitors. However, the selectivity 
determinants for the modulation of the sirtuin catalytic cores are still unclear.  
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Figure 5.1. Ligands that have been solved in complex with sirtuin structures. 
In this study, we aimed to gain insights into the isoform specificity of different sirtuins and to 
identify the functional hot-spots that could be used to guide structure-based design efforts for the 
identification of new selective sirtuin modulators. To this end, we developed a comprehensive 
selectivity model based on sequence and structure-based alignments, and characterized sirtuins 
through a detailed analysis of the pharmacophoric properties of the catalytic site in terms of residue 
differences of each family member. The model was built by including all three-dimensional 
structures of the human sirtuin family available in the PDB, supplemented by homology models for 
those isoforms that have not been solved yet. Differences in terms of key residues in the active site 
and the effects of conformational variations were analyzed and the results reported in simple tables 
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and graphs that illustrate at a glance residues that most likely are involved in selectivity and the 
pharmacophoric features that should be considered in the design of new selective ligands. 
5.1 Sequence and structural comparison of the catalytic cores 
Sirtuins contain a conserved catalytic domain of approximately 250 amino acids, responsible for 
NAD
+
 and substrate binding and deacetylase activity. Additionally, these proteins possess N- and 
C-terminal regions, variable in length and sequence, whose role in sirtuin biology is still unclear, 
although an effect on substrate specificity was speculated
228
. 
The structure of the catalytic core consists of a large Rossmann-fold domain, typical of NAD
+
- 
binding proteins, a small zinc-binding domain, and a number of flexible loops that keep together the 
two domains. The binding sites of cofactor and substrate are located in a wide cleft at the interface 
between the large and the small domains. The sequence alignment of the catalytic core region 
(deacetylase domain) of the human sirtuin family (Figure 5.2) reveals a good level of sequence 
conservation, with the highest identity observed for residues responsible of cofactor binding and 
catalytic activity. A principal component analysis (PCA) of this alignment (Figure 5.3) clearly 
shows the presence of three different clusters: a first one including SIRT1, SIRT2 and SIRT3, a 
second one composed by SIRT6, SIRT7 and, slightly isolated, SIRT4, while SIRT5 completely 
differs from the other sirtuins. Consistently, the calculated pairwise sequence identity is the highest 
among the first cluster and between SIRT6 and SIRT7 (between 40% and 51%), while it is less than 
30% for any other sequence pair. The large domain is characterized by a high level of structural and 
sequence similarity among various sirtuins; it is formed by a central -sheet surrounded by six -
helices, except for SIRT2, which exhibits an additional long insertion of approximately 20 residues 
forming an additional -helix. This domain possesses many of the specific requirements for NAD
+
-
binding, such as the well known G-X-G motif
241
, important for the recognition of the phosphate 
group, and charged residues to bind the two ribose groups. The NAD
+
 adenine base binds the C-
terminal half of this domain while the nicotinamide enters the N-terminal part, as typical in inverted 
Rossmann-fold domains
242
. The small domain is the most diverse region in terms of primary 
sequence and conformation; it is formed by two long insertion in the Rossmann-fold domain, and 
consist of a three-stranded antiparallel -sheet, a variable -helical region, and a Zn
2+
 cation 
coordinated by the  sulphydryl group of four strictly conserved cysteine residues. The presence of 
the zinc ion is required to ensure enzyme functionality
243
, although it does not directly participate in 
the catalytic mechanism of sirtuins. This domain shows the greatest variability in terms of three-
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dimensional structure among human sirtuins, and its relative position to the large domain depends 
also on the presence of substrate and on NAD
+ 
conformation
244
. Several variations are found in the 
primary sequence of the small domain. First, SIRT6 and SIRT7 contain a deletion which results in 
the lack of the helix bundle found in other sirtuins. This bundle is replaced by a short loop forming 
few interactions with the zinc-binding module. The presence of this unique feature may provide a 
possible explanation for the conformation of the zinc-binding domain in these two sirtuins, which, 
in turn, may be responsible for the observed lower catalytic activity of SIRT6
245
. SIRT6 also shows 
a ten-residue insertion between the second set of cysteines, resulting in a further long loop. 
Secondly, the two mitochondrial sirtuins SIRT4 and SIRT5 exhibit a unique insertion in the small 
domain comprising a short helix and a 16 residues loop, that may be important for subcellular 
localization
236
. Finally, SIRT1 contains a 5 residues insertion adjacent to the last zinc-binding 
cysteine providing a distinctive small loop in this domain. The remarkable diversity in the small 
domain may have an important role in regulating key properties, such as substrate specificity and 
enzyme localization, highlighting this domain as an attractive potential binding site for selective 
sirtuin modulators. The cofactor binding loop, often referred to as the “flexible loop”, is the largest 
of the four loops linking together the large and the small domains, and it is one of the most flexible 
regions of the enzyme. This loop appears to be disordered in the unliganded sirtuin structures but it 
undergoes significant conformational changes upon binding of NAD
+
 or other reaction 
intermediates and could adopts multiple conformations depending on the bound ligand 
228
. When 
NAD
+
 is bound, this loop adopts a fairly “open” conformation, and several residues mediate 
important interactions between the nicotinamide moiety of the cofactor and the enzyme. When the 
active site is not occupied by the nicotinamide moiety, as in the case of the reaction product 2'-O-
acetyl-ADP-ribose (2'-OAADPr), the loops assume a more “closed” conformation, with a partial 
occlusion of the nicotinamide binding pocket, precluding NAD
+
 to bind in a productive 
conformation. In human sirtuins, the conformational changes in the cofactor binding loop are 
observed in three-dimensional structures of SIRT3 and SIRT5 whereas in SIRT6,the cofactor 
binding loop is replaced by a single helix that appears to be ordered in both complexes with ADPR 
and 2'-N-acetyl-ADP-ribose (2'-NAADPr), indicating that the binding pocket is less flexible and 
that its conformation is not susceptible to changes upon binding of different ligands
245
.  
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Figure 5.2. Sequence alignment of the deacetylase domain of human sirtuins. Residues are colored by sequence identity 
and boxes indicate special residues: pink for NAD+-binding region, cyan for zinc-binding cysteines, and grey for 
catalytic histidines. 
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Figure 5.3. Principal component analysis of sirtuins sequence alignment. The picture reports the score plot obtained 
from the first two principal components (t[1]/t[2]). 
5.2 Structural comparison of the binding sites 
The NAD
+
 binding site can be divided into three different pockets: an adenine binding pocket 
(pocket A), a nicotinamide ribose binding pocket (pocket B) and a nicotinamide moiety binding 
pocket (pocket C). Several cofactor interactions within these binding sites are generally conserved 
among different sirtuins. For instance, the adenine base establishes several van der Waals 
interactions including the two conserved glycines and various hydrogen bonds formed by the 
adenine nitrogens and polar residues such as glutamate, serine or threonine, while the hydroxyls of 
the adenine ribose mainly interact with a conserved asparagine residue. The phosphate group and 
the nicotinamide ribose moiety show a complex interaction network affected in both cases by the 
conformational variability of cofactor binding loop
228
. In particular, the nicotinamide ribose ring 
can adopt two slightly different conformations that may have implications in the supposed catalytic 
mechanism
246
. In the same way, conformational changes also occur in the pocket C, where the 
nicotinamide group can assume either a “non-productive” conformation, where it binds outside of 
the C pocket in a conformation that is not compatible with acetyl-lysine binding and the 
deacetylation reaction, or a “productive” conformation, in which the presence of an acetyl-lysine 
drives the nicotinamide moiety in the C pocket to establish interactions with invariant key residues. 
The substrate binding site is placed in a cleft between the large and the small domains. The 
backbone of the substrate peptide forms a -strand-like interaction, known as  staple with two 
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loops in the enzyme, one within the Rossmann-fold domain and one that links together the two 
domains, while the acetyl-lysine side chain makes several interactions within an hydrophobic tunnel 
and an hydrogen bond between the N-atom and a backbone carbonyl of a conserved valine residue 
(leucine for SIRT6). The correct formation of  staple interactions and acetyl-lysine binding tunnel 
are induced by the binding of the substrate peptide to its pocket by means of a rigid-body rotation of 
the small domain relative to the large domain
247
. 
5.3 Structural superposition of available three-dimensional structures 
All available three-dimensional structures of human sirtuins were downloaded from Protein Data 
Bank and were supplemented by models obtained from the Swiss-Model database of SIRT4 and 
SIRT7, whose crystallographic structures are not available yet
248–251
. With the exception of these 
two sirtuins, all other isoforms have between four and ten distinct three-dimensional structures 
solved. A total of 42 structures, in unbound form or in complex with different cofactors, substrates 
and/or small molecule modulators (Table 5.1) were retrieved from the PDB database. Structures 
were prepared and structurally aligned (see experimental section) in order to gain more insight into 
the differences and similarities among human sirtuins. After the structural alignment, a structure-
based sequence alignment was obtained for the residues falling into a range of 4 Å from a reference 
ligand. This allowed a close analysis of variations in the active site residues likely to be important 
for binding affinity and selectivity of new ligands. This kind of structural alignment could bring at 
the same time the information concerning conformational variations of the same residue in a 
different position or mutations of the residue among different sirtuin isoforms, i.e. different kind of 
residues in the same position. Figure 5.4 shows the alignment of active site residues for all 42 
available sirtuin structures in which all residues are aligned only considering structural 
superposition. Within the same sirtuin isoform, conformational variations of the catalytic core are 
mainly detectable in the cofactor-binding loop, while other residues remain almost unchanged. In 
the same way, conformational changes across different sirtuin isoforms were identified mainly in 
the same loop; however, assuming that every sirtuin isoform can adopt the same active site 
conformation depending on the bound ligand, the conformational variations appears not to be 
relevant in terms of ligand selectivity. Conversely, the comparison across various isoforms is 
mainly characterized by specific point aminoacidic differences which are relevant in terms of 
binding selectivity and are located on the whole structural alignment. In order to highlight the 
variations by specifically focusing on the catalytic core residues, a representative three-dimensional 
structure was selected for each sirtuin isoform and a simplified structural alignment was generated 
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in Figure 5.5. The representative structures were selected so as to obtain a set of three-dimensional 
structures with similar closed-form conformations, first considering the conformation of homology 
models generated for SIRT4 and SIRT7. The whole alignment was then divided in pockets A, B, C 
and substrate pocket, as defined above, to better depict the selectivity hot-spots. 
Each residue was classified according to the estimated importance to generate ligand selectivity: 
conserved residues, low significance and high significance residues (Figure 5.5). Conserved 
residues are understandably not relevant for selectivity while some aminoacidic differences were 
classified as low significant for selectivity when the variation was limited to similar residues (e.g. 
valine/leucine) or when the side chain of the residues was directed outside the active site and 
therefore not prone to affect the shape and the properties of the catalytic core and the putative 
binding of a ligand. The nicotinamide-ribose binding pocket (Figure 5.5B) shows the higher degree 
of conservation and only one residue is classified as important for the selectivity, although the 
aminoacidic difference is limited, i.e. F to Y, and involving only two sirtuins, namely SIRT4 and 
SIRT7. Conversely, the structural alignments of adenine binding pocket (Figure 5.5A) and 
nicotinamide binding pocket (Figure 5.5C) reveal a higher degree of difference, with 5 and 8 
significant residues, respectively. The substrate binding pocket is characterized by a significant 
conservation (Figure 5.5D) from SIRT1 to SIRT5, while SIRT6 and especially SIRT7 show 
differences that are the results of gaps sequence; nonetheless, four residues are predicted to have 
some effects on selectivity in this region. 
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Sirtuin Source Code Ligand(s) Notes 
SIRT1 PDB 
4I5I NAD and EX-527 analog  
4IF6 ADPR  
4IG9 -  
4KXQ ADPR  
SIRT2 PDB 
1J8F -  
3ZGO -  
3ZGV ADPR  
4L3O Cyclic peptide S2iL5  
SIRT3 PDB 
3GLT ADPR bound to AceCS2 peptide  
3GLS -  
3GLR acetyl-lysine AceCS2 peptide  
3GLU AceCS2 peptide  
4FVT AceACS peptide and Carba-NAD  
4HD8 Fluor-de-Lys peptide and piceatannol  
4FZ3 Acetyl-P53 peptide coupled with MCM  
4JSR Inhibitor 11c  
4JT9 Inhibitor 3  
4JT8 Inhibitor 28  
4BN4 ADPR  
4BN5 SRT1720 and Carba-NAD  
4BV3 NAD/ADPR and EX-527  
4BVB ADPR and EX-527  
4BVE 
Thioalkylimidate formed from thio-acetyl-lysine 
acs2-peptide 
 
4BVF 
Thioalkylimidate formed from thio-acetyl-lysine 
acs2-peptide 
 
4BVG 
alkylimidate formed from acetyl-lysine acs2-
peptide 
 
4BVH 2-O-acetyl-ADPR and EX-527  
4C7B Bromo-Resveratrol and Fluor-De-Lys peptide  
4C78 Bromo-Resveratrol and AceCS2 peptide  
SIRT4 SwissModel Q9Y6E7 - 
Based on Sir2 A. Fulgidus (1S7G), 
identity 31% 
SIRT5 PDB 
2B4Y ADPR  
2NYR Suramin  
3RIG Thioacetyl peptide  
3RIY Succinylpeptide and NAD  
4F4U Succinylpeptide  
4F56 H3K9 thiosuccinyl peptide bound with NAD  
4G1C Succinylpeptide and Carba-NAD  
4HDA Fluor-de-Lys peptide and resveratrol  
SIRT6 PDB 
3K35 ADPR  
3PKI ADPR  
3PKJ 2'-N-Acetyl ADPR  
3ZG6 H3K9 myristoyl peptide and ADPR  
SIRT7 SwissModel Q9NRC8 - 
Based on Sirt6 template (3K35), 
identity 42% 
Table 5.1. Three-dimensional structures of human sirtuins available from public domain (Protein Data Bank) 
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Figure 5.4. Structural alignment of available three-dimensional structures of human sirtuins. Residues are color-coded 
using Taylor classification. The red box highlights the area of the cofactor binding loop 
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Figure 5.5. Structural alignment of human sirtuins. The alignments were generated using residues in a range of 4Å from 
the ligand and considering a three-dimensional superposition. The residues were color-coded using Taylor classification 
and numbered following gene sequences taken from the Uniprot database. The last line of each alignment suggests the 
estimated importance of each residue in selectivity: black dot (•) indicates residues conserved in all sirtuins, while black 
minus (-) and red plus (+) indicates residues respectively with poor or higher probability to be involved in selectivity. 
A) Structural alignment of residues comprising adenine binding pocket (pocket A). B) Structural alignment of residues 
comprising nicotinamide-ribose binding pocket (pocket B). C) Structural alignment of residues comprising 
nicotinamide binding pocket (pocket C). D) Structural alignment of residues comprising substrate binding pocket. 
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Overall, we identified 18 residues in the active site (red plus in Figure 5.5) that could have a 
significant impact on ligand selectivity and that should be taken into account while designing new 
sirtuin modulators. The pharmacophoric features and the position in the active site relative to the 
cofactor and a reference inhibitor (SRT1720) was depicted in Figure 5.6 while the complete 
information about aminoacidic differences for all possible couples of sirtuin isoforms was reported 
in a double-entry table in Figure 5.7 that encodes similarities and differences among the whole 
sirtuin family. 
Complementary to the results obtained with the sequence alignment of the deacetylase domain, the 
structural superposition of sirtuin active sites reveal that catalytic cores can be divided into different 
clusters. SIRT1, SIRT2 and SIRT3 (group 1) are characterized by high similarity in the active sites, 
with few different residues located mainly in the adenine pocket and in the substrate pocket. 
Likewise, SIRT6 and SIRT7 (group 2) show significant similarity, with a total of 6 variable 
residues, while both SIRT4 and SIRT5 (group 3) show several aminoacidic variations compared to 
all other sirtuins. Based on these observations, it is possible to hypothesize the design of selective 
ligands for sirtuins belonging to different identified groups, while we predict that the selectivity 
within a single group is harder to achieve. For example, inhibitors of SIRT6 or SIRT7 could be 
likely selective versus SIRT1 or SIRT2 due to the important aminacidic differences that 
characterize the active site of these isoforms. On the contrary, ligands resulting in a high selectivity 
for SIRT1 over SIRT2, or SIRT6 over SIRT7, are expected to be difficult to obtain on the basis of 
the intrinsic similarities in their aminoacidic composition. Certainly this similarity does not 
preclude the possibility to obtain ligand selective that exploit other structural features such as 
preferential conformational behavior and specific shape of the catalytic core (see below). Figure 5.8 
depict these concepts showing the difference in the active site among sirtuins belonging to the same 
group (Figure 5.8A and Figure 5.8B) and belonging to different groups (Figure 5.8C). From the 
pharmacophoric point of view, the sirtuin active site (Figure 5.6) is characterized by a high number 
of hydrophobic interactions (green boxes), especially in proximity of the reference ligand SRT1720 
that lie in the nicotinamide and the substrate binding pocket. This is especially evident for SIRT1, 
SIRT2 and SIRT3 (group 1, as defined above). Taking into consideration the differences among 
each sirtuin isoform, these interactions are primarily replaced with polar interactions (blue boxes) or 
with sequence gaps (gray boxes), the latter implying the presence of small but significant variations 
in the shape and dimension of the catalytic core. On the contrary, the adenine binding pocket and 
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the nicotinamide-ribose binding pocket show mainly polar or charged features (blue and purple/red 
respectively), often involving hydrogen bonding with the cofactor molecule. In these cases, the 
differences among sirtuin isoforms involve charge shifting (positive to negative or vice versa) or 
substitutions with hydrophobic features; in both cases, the result is a variation of the surface 
properties of the active site.  
 
Figure 5.6. Pharmacophoric features of catalytic core residues of sirtuin family. The green line represents the active site 
surface and the blue dots the position of important residues in the catalytic core. For each dot a small table reports the 
residue number for each sirtuin, color-coded by pharmacophoric features: green for hydrophobic, blue for polar, purple 
for positive charge, red for negative charge and gray for absent residues or glycines. The green/blue cells represent 
tyrosine residues. Some residues can interact with both ligand and cofactor and are reported in both parts of the figure. 
A) Ligand interaction diagram of NAD+. B) Ligand interaction diagram of SRT1720. 
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Figure 5.7. Selectivity hot-spots table. Each cell reports the aminoacidic differences between a couple of sirtuins that 
are supposed to be important for selectivity. For each difference, the first residue refers to the sirtuin in the row and the 
second refers to the sirtuin in the column. 
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Figure 5.8. Structural comparison of SIRT1, SIRT2, SIRT6 and SIRT7. Residues classified as important for selectivity 
are drawn in thick tube. Reference ligands are reported to help the identification of active site pockets. A) Structural 
comparison of SIRT1 (cyan) and SIRT2 (orange). Reference ligand (purple) is NAD
+
 taken from PDB code 4I5I. B) 
Structural comparison of SIRT6 (dark green) and SIRT7 (lime green). Reference ligand (purple) is ADPR taken from 
PDB code 3K35. C) Structural comparison of SIRT1 (cyan) and SIRT6 (dark green), with the same reference ligands of 
A and B (purple). 
It is worth mentioning that compound selectivity for SIRT1 vs. SIRT2 was studied by previous 
works and several examples of fairly selective inhibitors were reported in the last few years
252–258
. 
The rationale for this selectivity was investigated using classical structural-activity relationships 
(SAR) and, occasionally, with the help of molecular modeling techniques that were used to predict 
the active site residues involved. The same techniques were recently applied by our group for the 
discovery of selective SIRT6 inhibitors
259
. Nevertheless, despite the amount of structural 
information appeared in the literature in the last years, the mechanisms underlining ligand 
selectivity towards cognate sirtuin isoform is still not fully understood. In fact, the selectivity could 
be the result of a combination of different effects not related to the single residue modifications in 
the active site but, for instance, different kinetic profiles, conformational changes of the proteins, 
presence of allosteric sites as well as subcellular location of protein targets and their level of 
expression in specific tissues. As an example, the isoform selectivity of EX-527 (1, Figure 5.1) 
appears to be based on kinetic differences of catalysis, suggesting that selectivity could also vary 
under different physiological conditions, such as substrate availability
232
. However, such effects are 
difficult to be estimated a priori and experimental determinations are needed elucidate selective 
behaviors, whereas aminoacidic composition that alter active site properties could be considered in 
structural analyses, like the one herein presented, that could be used for the rational design of new 
small-molecule modulators or for the development of analog compounds using standard SARs.  
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The structural model of human sirtuin family that we obtained clearly suggests several functional 
hot-spots that could be exploited to improve selectivity of newly identified sirtuin ligands. 
Nonetheless, it is important to note that approximations to generate this model have been taken into 
account and further experimental structural insights could contribute to refine our conclusions. In 
particular, it is important to note that conformational variations of the proteins, e.g the open and 
closed forms, could play a role in term of ligand selectivity while our model is based on the 
principle that all sirtuin family members can adopt both forms depending on the bound substrate, 
ligand and cofactor. Similarly, an experimental validation is still awaited for SIRT4 and SIRT7 that 
still have no three-dimensional structure representative in the Protein Data Bank and, for the time 
being, they needed to be modeled by homology. In the same way, the presence of allosteric sites, or 
ligands able to induce isoform-specific conformational variations have not been described yet. 
Finally, the model was built by including residues within a distance range compatible with 
reference ligands and cofactors (i.e. SRT1720 and NAD
+
) taken from the few crystallographic 
structures available; clearly, the discovery of additional ligands and their three-dimensional 
structure in complex with sirtuins might provide additional information on new interacting residues 
extending outside the range encompassed by our model. 
5.4 Conclusions 
The broad involvement of sirtuins in several pathological conditions has raised a strong interest in 
the development of specific inhibitors or activators to explore disease models that are dependent on 
sirtuin functions. Selective modulators, able to modify the enzymatic activity of single sirtuin 
isoforms could be used as chemical probes to elucidate the role of each sirtuin isoform in biological 
activities but also as a starting point to develop more efficient targeted therapies. Our study is the 
first effort to summarize in a comprehensive structural model the selectivity hot-spots among sirtuin 
family members, providing a simple tool to estimate the selectivity of a small molecule ligand 
between two or more isoforms. Starting from a putative binding mode of a ligand into the active site 
of one sirtuin isoform, experimental (i.e. X-ray or NMR) or molecular modeling (docking, 
molecular dynamics) techniques, could be used in combination to our model to allow understanding 
at a glance the active site residues that most likely are involved in ligand selectivity and how to 
design suitable pharmacophoric variations to improve the activity profiles. Although based on 
approximations and simplifications, this model constitute valuable tool to better understand the 
complexity of the sirtuin machinery and to advance the search for selective small-molecule 
modulators. 
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5.5 Experimental Section 
In Silico techniques 
Sequence alignment and principal component analysis. The sequences of the seven human sirtuins 
were retrieved from Uniprot database as reported in Table 5.2. The multiple sequence alignment 
was generated using T-Coffee method
260
 implemented in Jalview
261
, followed by a manual revision 
to ensure the maximum accuracy. The alignment was then exported in FASTA format and 
converted to CSV format, using a bash shell script, to make it suitable for further steps. The PCA 
analysis was carried out using Simca-P software version 11.2 (Umetrics, Sweden). All variables 
with zero variance (conserved residues) were automatically excluded from the model and the first 
two principal components were calculated and used to generate the score plot reported in Figure 
5.3. 
 
Seq 
Uniprot 
Code 
Tot 
Residues 
Catalytic 
HIS 
Nucleotide Binding Metal Binding 
Deacetylas
e Domain 
Sirt1 Q96EB6 747 363 261-280, 345-348, 440-442, 465-467 371,374,395,398 244 - 498 
Sirt2 Q8IXJ6 389 187 84-104, 167-170, 261-263, 286-288 195,200,221,224 65-340 
Sirt3 Q9NTG7 399 248 145-165, 228-231, 319-321, 344-346 256,259,280,283 126-382 
Sirt4 Q9Y6E7 314 161 62-82, 143-146, 260-262, 286-288 169,172,220,223 45-314 
Sirt5 Q9NXA8 310 158 58-77, 140-143, 249-251, 275-277 166,169,207,212 41-309 
Sirt6 Q8N6T7 355 133 52-71, 113-116, 214-216, 240-242 141,144,166,177 35-274 
Sirt7 Q9NRC8 400 187 107-126, 167-170, 268-270, 297-299 195,198,225,228 90-331 
Table 5.2. Human sirtuins sequences available in Uniprot database. 
Protein preparation. The crystal structures of human sirtuins (Table S1) were retrieved from PDB 
Database and submitted to a standard preparation procedures (protein preparation wizard) as 
included in the software package Maestro (Version 9.3, Schrödinger, LLC). Any water molecules, 
ions and crystallization mediums were removed (except for zinc ion) while substrates, ligands and 
cofactors were kept, if present. Each structure was optimized using PROPKA and minimized until 
an RMSD of 0.2 Å.  
Structure-based alignment. The prepared structures were then aligned using the Protein Structure 
Alignment tool included in Maestro, using backbone as reference atoms. The Multiple Sequence 
Viewer tool was then used to align sequences according to structure superposition, and to generate 
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an alignment based only on structure superposition and not on sequence conservation. The 
structural alignment was restricted by selecting residues falling into a range of 4 Å from reference 
ligands, namely the SRT1720 and Carba-NAD structures taken from PDB code 4BN5; these 
reference ligands are able to fill up completely all active site pockets, and therefore were chosen 
among the other available structures. Due to the large number of three-dimensional structure 
included in the model, and to the high level of complexity of the structural alignment, the results 
obtained of automated tools were excluded to avoid inaccuracies and processed thorough a manual 
revision of the alignment. The alignment reported in Figure 4 was generated starting from the global 
alignment by selecting 7 representative structures, one for each sirtuin isoform. In particular, the 
following PDB codes were selected: 4I5I (SIRT1), 3ZGV (SIRT2), 3GLT (SIRT3), 3RIY (SIRT5), 
3K35 (SIRT6), supplemented by the homology models for SIRT4 and SIRT5. 
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6. Discovery of new SIRT3 modulators 
SIRT3 emerged as a protein of particular interest to the aging field due to its mitochondrial 
localization and association with exceptional long lifespan in humans. SIRT3 deacetylates and 
activates many mitochondrial enzymes involved in fatty acid β-oxidation, amino acid metabolism, 
the electron transport chain (ETC), and antioxidant defenses
262
. 
 
Figure 6.1. Main physiological and pathological processes regulated by SIRT3262 
The study of mice with a targeted deletion of SIRT3 has been a valuable tool for clarifying the 
physiological role of SIRT3. One pivotal observation was a striking hyperacetylation of 
mitochondrial proteins in SIRT3−/− mice, a pattern not observed in SIRT4−/− or SIRT5−/− 
mice
263
. Moreover, incubation of mitochondrial extracts from SIRT3−/− mice with a recombinant 
wild-type form of SIRT3 effectively reversed this state of hyperacetylation. Collectively, these 
observations suggest that SIRT3 might be the main deacetylase in mitochondria. Keeping with its 
localization in mitochondria, SIRT3 is involved in the control of the mitochondrial ATP-production 
machinery through effects on the respiratory chain. A study in SIRT3−/− mice showed abnormally 
reduced (nearly 50%) ATP levels in tissues that normally exhibit high ATP levels, such as heart, 
liver, kidney and skeletal muscle; notably, tissues where the expression of SIRT3 is normally 
elevated
264
. This reduction in ATP levels was not observed in tissues such as the pancreas where 
SIRT3 is expressed at low levels. It is likely that SIRT3 regulates ATP levels through the regulation 
of respiratory complex I activity, given that: (i) several components of complex I show increased 
acetylation inSIRT3−/− mice; (ii) SIRT3 can physically interact with at least one of the known 
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subunits of complex I, the 39-kDa protein NDUFA9; and (iii) incubation of exogenous SIRT3 with 
mitochondria augments complex I activity. In addition to directly regulating the activity of the 
respiratory chain, SIRT3 participates in the production of reduced cofactors through activation of 
two enzymes: succinate dehydrogenase and IDH2 (isocitrate dehydrogenase 2), an NADP- 
dependent isoenzyme of IDH. Overall, SIRT3 appears to control the rate of mitochondrial ATP 
synthesis directly by controlling the activity and amount of mitochondrial respiratory and oxidative 
phosphorylation machinery. 
Investigations of the mechanism of carcinogenesis in mice lacking Sirt3 have resulted in several 
important observations regarding the mechanistic connection between aberrant mitochondrial 
metabolism and carcinogenesis: (i) Sirt3 regulates HIF-1a activity, resulting in an altered cellular 
metabolism that supports cell proliferation; (ii) Sirt3 directly regulates MnSOD enzymatic activity 
via acetylation, and the aberrant acetylation of MnSOD in cells lacking Sirt3 increases cellular 
ROS; and (iii) Sirt3 knockout mice develop estrogen-positive mammary tumors. Furthermore, 
SIRT3 expression is decreased in many different types of human cancers, and heterozygous loss of 
SIRT3 occurs in 40% of human breast malignancies, suggesting that knockout mice are the first 
murine model for the most common subtype of breast cancer observed in older, postmenopausal 
women
265
. SIRT3 exerts a profound protective action against oxidative stress-dependent 
pathologies; the identification of compounds capable of modulating SIRT3 activity is expected to 
provide promising strategies for ameliorating the aging-related metabolic syndrome such as cancer, 
cardiac dysfunction and neural degeneration. 
6.1 Targeting SIRT3 with structure-based drug design techniques 
In this study, we took advantage of the availability of SIRT3 crystal structure and performed a high-
throughput molecular docking screen with the goal of identifying selective chemical scaffolds able 
to modulate activity of SIRT3. At the time of this study, several different X-ray structures were 
available in public domain (see Table 5.1 in chapter 5) in apo form or in complex with cofactor 
and/or inhibitor molecules. 
When structurally compared, the structures showed to be similar in terms of the overall protein 
conformation but the shape of the active site modifies slightly depending on presence or absence of 
substrate and cofactor molecules. We therefore decided to use an “Ensemble Docking” approach in 
our virtual screening. Usually, docking software uses a rigid receptor model in which ligands are 
allowed to move flexibly but the protein remains rigid; because different ligand chemotypes may 
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induce different receptor conformations, as in the case of SIRT3, potent ligands whose chemotype 
induces one receptor conformation may score poorly against another receptor conformation. 
Ensemble docking mitigates this problem by allowing users to dock a single ligand library against 
multiple rigid receptor conformations, and collect the best score for each molecule. 
So we used 5 X-ray structures of SIRT3 available in the Protein Data Bank; four accounts for 
conformational variations in the active site (PDB codes 3GLS, 3GLT, 3GLR, 3GLU) and one (PDB 
code 4C78) was used to define a putative allosteric activation site. This second binding site is 
located on the surface of Sirt3 and connected through two helices to peptide-binding active site 
loops. In Sirt1, this site appears to comprise a residue that is essential for its activation by small 
molecules and it therefore constitutes a candidate for the long-sought allosteric activator binding 
site. We screened a large database of commercial compounds
132
 in a high-throughput docking 
screening campaign (Figure 6.2). The best scoring compounds were visually inspected and the final 
candidate selection was done taking in account the interactions of each molecule in the active sites, 
the structural diversity and specific physicochemical properties of molecules. Hit compounds were 
purchased and tested for their ability to inhibit or activate SIRT3 using fluorescence-based assay      
in the Laboratory of Dr. Diego Albani (Istituto di Ricerche Farmacologiche Mario Negri). Active 
compounds were also tested for their ability to modify acetylation pattern in mitochondria. 31 
molecules were purchased and tested using fluorescence-based assay; after removing of interfering 
compounds (>10% of interference) we identified 2 putative activators and 3 putative inhibitors. The 
best results were obtained for compound 20 and compound 24 (Table 6.1 and Figure 6.3). 
 
Figure 6.2: Molecular design workflow of new Sirtuin-3 inhibitors and activators 
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Table 6.1. Results of biological testing 
 
 
Figure 6.3. Dose-Response curves for active compounds 
6.2 Evaluation of acetylation pattern of mitochondrial proteins 
To confirm the SIRT3 activation and inhibition by the identified compounds, we evaluated the 
acetylation pattern of mitocondrial proteins. In particular, neuroblastome SH-SY5Y cells were 
treated with compound 20 and compound 24 at 10uM for 24h, and then the mitochondrial lysate 
were analyzed by western blot using a generic antibody able to recognize acetylated lysines as 
antigen, and the mithocondrial channel VDAC as loading control. Both total acetylated lysines and 
acetylation pattern of ETC Complexes 1 and 4 were analyzed. 
As reported in Figures 6.4 and 6.5, cells treated with compound 20 (inhibitor) shows an acetylation 
level significantly higher than control, while cells treated with compound 24 (activator) shows an 
acetylation level significantly lower than control. 
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Figure 6.4. Total acetylated lysines/VDAC (One way-ANOVA, Tukey‟s post-hoc test; ** p<0,01; **** p<0,0001) 
   
Figure 6.5. Acetylation pattern of ETC Complexes 1 (COX I) and Complex 4 (COX IV) vs VDAC (One way-ANOVA, 
Tukey‟s post-hoc test; ** p<0,01; **** p<0,0001) 
6.2.1 Evaluation of acetylation pattern of a specific protein target of SIRT3 
To better confirm the modulation of SIRT3 activity by active compounds, we evaluated the 
acetylation pattern of a known target of SIRT3, the mitochondrial superoxide dismutase (SOD2) 
protein. The test was conducted as above but using a specific SOD2 antibody. Before this test, we 
also confirmed, by co-immunoprecipitation, that in our model SIRT3 and SOD2 are interacting 
proteins, and that compounds 20 and 24 do not alter the expression level of SOD2 protein (data not 
shown). The results shows in Figure 6.6 confirm the alteration of acetylation pattern by both the 
activator and the inhibitor, strongly reinforcing the hypothesis of a direct interaction of these 
molecules with SIRT3. 
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Figure 6.6. Acetylated SOD2 vs non-acetylated SOD2 (One way-ANOVA, Tukey‟s post-hoc test; * p<0,05; **** 
p<0,0001) 
6.3 Evaluation of cell response to toxic stimulation 
We tested the ability of the activator molecule, compound 24, to modify the cell response to toxic 
stimuli using two different oxidative compounds. SH-SY5Y cells were treated with compound 24 at 
10uM for 24h and then with hydrogen peroxide or 6-hydroxydopamine (6-OHDA) at 75uM 
overnight. Then the cellular viability was measured using colorimetric assay. As reported in Figure 
7, cells pre-treated with compound 24 show cell viability comparable to control, confirming the 
protective role of this compound against oxidative stress induced by two different toxic stimuli. 
   
Figure 6.7. Cell response to toxic stimuli in absence or presence of activator compound 24. (Two way- ANOVA, 
Tukey‟s post-hoc test; ** p<0,01; **** p<0,0001) 
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6.4 Conclusions 
This virtual screening approach led us to the discovery of new putative modulators of SIRT3 with 
interesting in-vitro and cellular activity. The activator compound 24 is of special interest since no 
specific SIRT3 activators are reported in literature so far. 
The results, that need to be confirmed by other in vivo testing, could represent a good starting point 
for the development of new therapeutic strategies in many SIRT3-related pathologies. 
6.5 Experimental Section 
In silico techniques.  
Several crystal structures of the SIRT3 in different conformation was used as a template for virtual 
screening purposes (PDB id: 3GLS, 3GLT, 3GLR, 3GLU and 4C78). These structures were 
prepared with standard preparation procedures (protein preparation wizard) as included in the 
software package Maestro
134
. The docking software Glide
135
 was used to perform a high-throughput 
virtual screening experiment. A docking grid was obtained by centering a 25 Ǻ box in the centroid 
of the ADP-ribose ligand, as present in the template crystallographic structure of the human SIRT3. 
Although many water molecules are present in the crystal structure, none of these seems to be 
involved in stable interactions with ligand- or NAD
+
-binding, therefore all waters were removed 
from the grid.  Standard precision (SP) docking was used to perform a first round of virtual 
screening. The top 1500 molecules, sorted by Glide score, were further refined with the extra-
precision (XP) docking. Docking results were ranked based on the Glide score and the first 500 hits 
were considered for visual inspection. Compounds were visualized by taking into account several 
structural and physico-chemical rules, such as the qualitative evaluation of ligand-protein 
interactions within the active site, probability of suggested protonation and tautomeric states, 
stereochemistry complexity, compound availability, chemical diversity, drug-likeness and synthetic 
accessibility.  
Compound Sources. We screened in silico the Asinex subset of the CoCoCo databases. Selected 
molecules were purchased in milligram quantities from chemical vendor. Purity of compounds was 
>= 95%, as declared by the chemical vendor. 
Biological assays (Laboratory of Dr. Albani, Istituto Mario Negri - Milano) 
Cell Lines. SHSY5Y cell line, derived from the original line SK-N-5H (obtained by biopsy from the 
bone marrow of a patient with neuroblastoma), was used for testing. Cells were maintained at 37°C 
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in a humidified atmosphere with 95% air and 5% CO2. SHSY5Y cells grow in acceptance of 
polypropylene flasks (T75, Falcon) in DMEM medium (Invitrogen) supplemented with fetal bovine 
serum 10% (Gibco), 2 mM L-glutamine and 1% Penicillin-Streptomycin 1% (Invitrogen). 
In vitro assays. Effects on enzymatic activity were tested with a standard kit from Cayman 
Chemical. SIRT3 Direct Fluorescent Screening Assay Kit provides a convenient fluorescence-based 
method for screening SIRT3 inhibitors or activators. The procedure requires only two easy steps, 
both performed in the same microplate. In the first step, the substrate, which comprises the p53 
sequence Gln-Pro-Lys-Lys(ε-acetyl)-AMC, is incubated with human recombinant SIRT3 along 
with its cosubstrate NAD+. Deacetylation sensitizes the Substrate such that treatment with the 
Developer in the second step releases a fluorescent product. The Fluorophore can be analyzed with 
an excitation wavelength of 350-360 nm and an emission wavelength of 450-465 nm. 
Western Blotting. About 20 µg of total protein extract was subjected to gradient SDS-PAGE 
electrophoresis (5–12%) and transferred to a nitrocellulose membrane. The membrane was 
incubated overnight with a primary antibody (anti-SIRT3, Anti-SOD2, Anti-VDAC or Anti-Ac-
Lys), for 1 hour with a horseradish peroxidase-conjugated secondary antibody and ECL-detected. 
The resulting impressed film was quantified using a digital image analyser. 
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7. Discovery of new SIRT6 inhibitors 
SIRT6 is a sirtuin family member with a role in intermediary metabolism, genome stability and 
inflammation
266
. SIRT6 regulates gene expression as a transcriptional co-repressor by physically 
interacting with transcription factors, such as NF-κB152, HIF1α267, and MYC268 and by 
deacetylating histone H3 lysine 9 (H3K9) and 56 (H3K56) at target gene promoter. In line with this 
notion, SIRT6 deficiency results in an increased expression of genes controlled by these 
transcription factors, including pro-inflammatory genes through NF-κB activity, glycolytic genes 
and the glucose transporter GLUT-1 due to increased HIF1α activity, and genes involved in 
ribosome biogenesis due to de-repressed MYC-dependent transcription. Another mechanism 
through which SIRT6 may regulate cell signaling and gene transcription is through the production 
of Ca2
+
-mobilizing nucleotides, such as O-acetyl-ADP ribose (OAADPR), as a result of its catalytic 
activity
245,269
. Last, but not least, SIRT6 has also been ascribed deacylation activity, which would be 
key to its ability to promote TNF-α secretion, and mono-ADPribosyltransferase activity, which 
would be self-directed but also used to modify other proteins, such as PARP1
270,271
. 
Consistent with these molecular roles of SIRT6, SIRT6-deficient mice are viable at birth but rapidly 
succumb to hypoglicemia after weaning
272
. In particular, SIRT6-deficient animals were found to 
clear glucose from blood much faster than their wild-type littermates and to exhibit increased 
glucose uptake in the muscle and in brown adipose tissue, a phenotype that can be reversed though 
HIF1α inhibition267. In addition, defective production of TNF-α and of other pro-inflammatory 
cytokines has also been observed in cells with reduced or absent SIRT6 expression
271,273,274
.  
Overall, taking into account SIRT6 biological functions, small molecule inhibitors of this enzyme 
hold potential for applications in metabolic disorders, such as diabetes (as blood glucose-lowering 
agents), in inflammatory conditions, and in cancer (as chemosensitizers)
266
. In addition, such 
compounds would complement the already available genetic tools and represent a valuable resource 
to study SIRT6-dependent biological processes in vitro and in vivo. In this context, the recent 
availability of SIRT6 crystal structure represents an important tool for structure-based in silico 
screenings and for the general understanding of the mode of action of SIRT6 and of its chemical 
modulators
245
.  
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7.1 Structure-based in silico screening 
In this study, we took advantage of the availability of SIRT6 crystal structure and performed a high-
throughput molecular docking screen with the goal of identifying selective chemical scaffolds with 
inhibitory activity on SIRT6.  
At the time of this study, four different X-ray structures were available in public domain (PDB 
accession codes 3PKI, 3PKJ, 3K35 and 3ZG6)
229,245,271
, one in complex with 2-N-acetyl-ADP-
ribose (3PKJ) and the other in complex with ADP-ribose. When structurally compared, the four 
structures showed to be similar in terms of the overall protein conformation and shape of the active 
site. We therefore selected the 3K35 complex as the reference structure for in silico screens because 
of its higher resolution. A deeper analysis and a comparison with other sirtuin structures co-
crystallized with the natural antagonist nicotinamide (NAM) revealed a different conformation of 
the Phe62 side chain that partially occludes the so-called nicotinamide pocket (or pocket C)
230
 
impairing the binding of any ligand, including NAM itself. Because of this conformational 
constraint, and in order to maximize the chances to identify new potential scaffolds with the ability 
to bind in this position of the active site, the conformation of this side chain was modified using a 
custom procedure (see experimental section). The resulting model of SIRT6, after a standard 
protein preparation procedure, was used as template to virtually screen the Asinex compound 
dataset, as prepared in the CoCoCo database
132,133
. The first hundreds hits were visually inspected to 
prioritize compounds that reproduced, at least in part, the binding mode of known substrates, 
cofactors and inhibitors, and to comply with simple physicochemical rules such as Lipinski‟s rule-
of-five
275
. The structure of known SIRT1/SIRT2 binding compounds was also taken into account in 
order to select for compounds with high diversity and increased chances to be specific for SIRT6. 
Finally, sample availability from compound providers was also verified, leading to a final list of 20 
compounds that were purchased and experimentally tested in the laboratories of Prof. Santina 
Bruzzone (University of Genova) for biochemical assays and Prof. Alessio Nencioni (University of 
Genova) for cellular and other functional assays. A commercial kit exploiting SIRT6 NAD
+
-
dependent deacetylase activity was used to assess the effect of the selected compounds on this 
enzyme. The percentage of SIRT6 activity inhibition obtained with each compound at a 200 µM 
concentration is reported in Table 7.1. 
Among the 20 compounds tested, 4 led to a significant inhibition of SIRT6 deacetylase activity, 
ranging from 12 to 100%, thus giving a remarkable hit-rate obtained with the virtual screening 
protocol. Ten compounds resulted inactive at the concentration used in the assay, while 6 
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compounds could not be tested due to interferences with the fluorescence-based assay. None of the 
active compounds identified include substructures described as Pan Assay Interference Compounds 
(PAINS)
276
. 
We subsequently determined the IC50 values of the active compounds (Table 7.2). Consistent with 
the results of the preliminary screening, three compounds were found to inhibit SIRT6 activity in 
the low micromolar range (5, 9, and 17), while compound 16 was the less potent as it showed an 
IC50 in the millimolar range. 
Figure 7.1 reports the predicted binding modes of the four active molecules identified with the 
virtual screening. Compound 5 and compound 9 are both predicted to bind the NAM binding pocket 
(pocket C) and part of the substrate binding pocket, while compounds 16 and 17 are predicted to 
bind the adenine binding pocket (pocket A) and the ribose binding pocket (pocket B). Compound 5 
is characterized by the presence of a quinazolinedione group that is predicted to establish an 
extended hydrogen bond network with Val113 and Asp114, similar to the observed binding of the 
NAM moiety in other sirtuin complexes
277,278
, and an additional hydrogen bond with the backbone 
carbonyl of Pro60. The aromatic part of 5 quinazoline ring is predicted to form a stacking 
interaction with Phe62 and the pyridine moiety to interact with His131 and, in part, with Trp186. 
Compound 9 has a different chemical structure but a very similar pharmacophore compared to 5; in 
fact, it undergoes the same interaction network within the SIRT6 active site in which the salicylic 
moiety take place of the quinazoline ring and a furan ring replace the pyridine group. Notably, the 
predicted binding mode of 9 assumes that the salicylic group is in a protonated form. However, 
since the estimated pKa of this group is 2.73, a deprotonated form could also be hypothesized, 
which would likely prevent the formation of the hydrogen bond with Asp114 and favour the 
formation of a hydrogen bond with the amino group of Asn112 (Figure 7.2). 
Compound 16 is predicted to form a number of hydrogen bonds with different residues in the 
NAD
+
-binding active site, as observed in the ADPR-SIRT6 complexes. Namely, such interactions 
are predicted to occur with Val256, Thr55, Asn238, Ser214 and Phe62. Notably, 16 also shows a 
double hydrogen bond with Asp61 side chain which is not observed in the available ADPR-SIRT6 
complexes. The triazolyl-pyrimidine moiety of 16 fills up the adenine binding pocket and is packed 
between the hydrophobic residues Gly52 and Leu239; this functional group is able to reproduce, at 
least in part, the key structural binding features of the adenine moiety of NAD
+
, while the pyrazine-
2-carboxamide group replaces the phosphate and ribose groups of the coenzyme.  
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Compound 
ID 
Compound Structure Asinex ID 
% inhibition 
of SIRT6 
at 200 M 
1 
NH
N
H
O
O
 
BAS00130267 NI 
2 
NH
N
H
O
O
 
BAS00565226 NI 
3 
N
H
NH
NH
OO
O
S
Cl
Cl
 
BAS09175153 NI 
4 
NHNH
O
O
O
FF
F
 
BAS02804575 ND 
5 
S
NH
N
H
NH
O
OO
O
N
O
 
SYN17739303 100±4 
6 NH
S
NH
O
O
O
 
BAS07297446 NI 
7 
NH
N
H
O
O
O
OH  
BAS06501826 NI 
8 N
+
N
+
O
O
NH2
NH2
 
BAS00229902 NI 
9 NHNH
O
O
O
O
OH
OH  
BAS13555470 62±7 
10 
N
H
NH
N
N
O
ON
 
BAS00780431 ND 
11 N
SN
H
NH
N
S
O
OO
O
NH
O
Cl
 
BAS00620938 ND 
12 
N
N
N
NH
O
O
NH
O
OH
O
 
BAS02378913 NI 
13 
S
N
N
NH
N
N
O
O
O
NH
O
O
Br
 
BAS00324098 ND 
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14 
SN
+
NH
NH
O
O
OH
O
O
O
 
BAS00127176 NI 
15 N
S
N N
NH
S
O
O
O
O
 
BAS01918477 ND 
16 N
N NH
NH
N
O
N
N
 
SYN10366754 12±3 
17 N
S NH
O
O
O
NHOH
 
BAS00417531 66±6 
18 N
NNH
N
H
N
N
SS
O
 
BAS09805329 NI 
19 N
H
N
H
N
O
O
O
O
O
 
SYN13238554 ND 
20 
NH
+N
N
H
O
O
 
LEG19281134 NI 
Table 7.1 Structures and SIRT6 inhibition activities of compounds selected with in silico techniques. NI = no 
inhibitition and ND = not determined (interfering with the assay). 
Compound 17 is predicted to form hydrogen bonds with Val256, Gln240 and Arg63, while 
hydrophobic interactions are observed between its benzoate moiety and the residues Gly52 and 
Leu239. Notably, these interactions are also observed in the binding of NAD
+
. In this case, the 
adenine binding pocket is predicted to be occupied by the benzoate moiety, while the succinimide 
and imino-phenyl groups are located in the ribose binding pocket. This compound was purchased 
and tested as a racemic mixture, as available from the vendor. However, it should be mentioned that 
docking results suggest a favorable binding for the R enantiomer. 
7.2 Selectivity profiling 
In order to evaluate the selectivity of the most interesting SIRT6 inhibitors, their IC50 values were 
also determined for SIRT1 and SIRT2 by using commercially available kits. Compounds 9 and 17 
proved to be the most selective compounds towards SIRT6, their IC50 values being almost 20 times 
higher for SIRT1, and approximately 9 times higher for SIRT2 (Table 7.2). Compound 5 showed 
moderate SIRT6/SIRT1 selectivity, with an IC50 value approximately three times higher for SIRT6, 
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and almost no selectivity over SIRT2; similar results were also obtained for compound 16, which 
showed poor or no selectivity over the other two sirtuins.  
The analysis of previously solved sirtuin structures showed the presence of the so-called cofactor 
binding loop which adopts different conformations depending on the ligands bound in the active 
site
230
. SIRT6 is the only sirtuin isoform lacking this loop which is replaced by an ordered helix 
which confers a less flexible binding pocket
245
. This distinctive feature of SIRT6 entails the 
presence of relevant modifications in the active site that might be exploited to design selective 
inhibitors. Figure 7.3 shows a superposition of SIRT6, SIRT1 and SIRT2 active sites with the 
predicted binding poses of compounds 5 and 16 reported as reference. In fact, the presence of 
specific binding site residues in SIRT1 and SIRT2 determine differences in the shape and properties 
of the cavity compared to SIRT6. Specifically, the NAM binding pocket of SIRT1 and SIRT2 
(Figure 7.3 A) shows the presence of bulky and hydrophobic residues, such as Phe119/Phe297, 
Leu103/Ile279 and Ile316, which have not cognate representation in the SIRT6 binding site, thus 
reducing the volume cavity and most probably leading to steric clash with the SIRT6 inhibitors. 
Similarly, the adenine binding pocket (Figure 7.3 B) shows also remarkable differences which 
modify the binding site properties: Leu239 in SIRT6 is substituted by Lys287/Arg466, and Gly64 is 
replaced by Ser98/Ser275. Taken together with the predicted binding poses, these differences can 
justify the selectivity ratio between SIRT6 and SIRT1/SIRT2 for the two most selective 
compounds, 9 and 17. Conversely, no structural explanation for the weak selectivity of compounds 
5 and 16 can be proposed. Among other hypothesis, the lower selectivity of compound 5 could be 
explained with a higher conformational flexibility allowing this molecule to adapt more easily to the 
binding site of different sirtuins without losing key interactions. In the case of 16, its low activity 
(IC50 for SIRT6 in the millimolar range) makes it difficult to speculate about possible determinants 
of its lack of selectivity for the different sirtuins. 
 
Compound 
ID 
SIRT6  SIRT1  SIRT2  
ratio 
SIRT1/SIRT6  
ratio 
SIRT2/SIRT6  
5 106±16 314±19 114±5 2.96 1.07 
9 89±5 1578±47 751±23 17.7 8.44 
16 1339±54 1470±29 2291±69 1.10 1.71 
17 181±15 3466±208 1744±52 19.15 9.63 
Table 7.2. Determination of IC50 (μM) for compounds 5, 9, 16 and 17 on SIRT6, SIRT1 and SIRT2 and fold-
selectivity SIRT1/SIRT6 and SIRT2/SIRT6. 
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Figure 7.1. Putative binding mode of active inhibitors. Predicted binding mode of compound 5 (A), compound 9 (B), 
compound 16 (C) and compound 17 (D). Hydrogen bonds are represented as red dotted lines. 
 
88 
 
 
Figure 7.2. Alternative predicted binding modes of compound 9 in its deprotonated state. 
 
 
Figure 7.3. Superposition of binding sites of SIRT6 (cyan), SIRT1 (green), SIRT2 (orange) and the predicted binding 
mode of two reference compounds (maroon). Different residues among sirtuin structures are drawn in thick tube and 
labelled using the same colour coding. A) Superposition of the nicotinamide binding pocket and the predicted binding 
mode of compound 5. B) Superposition of the adenine binding pocket and the predicted binding mode of compound 16. 
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7.3 Biological characterization of the identified SIRT6 inhibitors 
5, 9, and 17 were selected for further biological evaluations while 16 was excluded due to its low 
potency and specificity. In particular, experiments were performed to determine whether 5, 9, and 
17 are active in intact cells and whether they achieve the biological effects that are predicted to 
occur as a result of SIRT6 inhibition. The acetylation status of H3K9, a known target of SIRT6 
deacetylase activity
279
 was used as the initial reading frame to monitor the activity of the SIRT6 
inhibitors in human cells (BxPC-3, pancreatic adenocarcinoma). Figure 7.4A shows a time course 
experiment in which H3K9 acetylation in response to 9 (100 μM) was monitored over time, while 
the quantification of similar experiments performed with 5 and 17, in addition to 9, is shown in 
Figure 7.4B. The results demonstrate that all of the three identified SIRT6 inhibitors increased 
H3K9 acetylation, suggesting that they all are cell permeable and active in cultured cells. Notably, 
in response to all compounds, H3K9 acetylation appeared to peak at 18h of exposure and to decline 
afterward, suggesting that complex mechanisms may intervene in regulating H3K9 acetylation in 
response to sustained SIRT6 inhibition. 
Subsequently, we focused on the ability of the identified SIRT6 inhibitors to increase glucose 
uptake in cultured cells and to reduce TNF-α secretion, two effects that have both been detected in 
SIRT6-deficient cells
174,266,267,269,273
. Indeed, 5, 9 and 17 effectively increased the uptake of 
radioactive glucose in BxPC-3 cells (Table 7.3). 
By comparison, specific down-regulation of SIRT6 expression by RNA interference determined an 
approximately 3-fold increase in glucose uptake. A similar enhancement in glucose uptake was also 
observed with 5, 9 and 17 in L6 rat myoblasts (Table 7.3). To gain insight into the mechanism 
through which SIRT6 inhibition increases glucose uptake in cultured cells, we monitored the levels 
of the glucose transporter GLUT-1 in BxPC-3 cells given previous evidence that SIRT6 represses 
GLUT-1 expression by opposing HIF1α-dependent transcription and that SIRT6 deletion leads to 
increased GLUT-1 levels
267
. A strong increase in GLUT-1 expression in response to both 5 and 9 
was detected in total cell lysates by Western blotting (Figure 7.5 A, B). Similar results were 
obtained with 17 which, in time course experiments, demonstrated to substantially increase GLUT-
1 expression in BxPC-3 cells starting from 6h of exposure (Figure 7.5 C). Finally, upregulated 
GLUT-1 expression at the cell surface in cell treated with 5 or 9 could be documented by flow 
cytometry (Figure 7.5 D, E).  
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Finally, we also evaluated whether 5, 9 and 17 would prevent TNF-α secretion by cultured BxPC-3 
cells stimulated with phorbol myristate acetate (PMA), as predicted based on the reported role of 
SIRT6 in TNF-α production271,273,274 and on previous data from our own laboratories on the effect 
of SIRT6 silencing in this cell line
269
. Indeed, all of the three SIRT6 inhibitors effectively reduced 
PMA-induced TNF-α secretion (Table 7.3). Overall, these results indicate that the SIRT6 inhibitors 
identified in this study have the potential to recreate the biological effects that are commonly 
observed in response to SIRT6 ablation or silencing.  
 
 
Figure 7.4. Compounds 5, 9, and 17 increase H3K9 acetylation in cultured cells. 4 x105 BxPC3 cells were plated in 6-
well plates and allowed to adhere for 24h. Thereafter, cells were stimulated with 100 μM 5 (B), 9 (A, B), or 17 (B) or 
the respective amounts of vehicle DMSO for the indicated time amounts. Finally, cells were used for protein lysate 
generation and total H3 and acetylated H3K9 levels were detected by immunoblotting. In B, the levels of acetylated 
H3K9 were quantified, normalized to total H3 levels, and expressed as percentage increase vs. vehicle-treated cells. 
 
Compound 
ID 
Glucose Uptake TNF-α release 
BXPC3 cells (rel to NT) L6 cells (rel to NT) 
% Inhibition 
on BXPC3 cells 
5 1.30±0.21 1.98±0.23 73±10 
9 1.11±0.08 1.20±0.12 50±16 
17 3.09±0.49 1.55±0.19 53±13 
Table 7.3. Evaluation of biological effects of the identified SIRT6 inhibitors. 
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Despite the emerging pathophysiological role of SIRT6 in human disease and its potential as a 
therapeutic target
266
, few SIRT6 modulators have been identified so far. Yasuda et al.
280
 identified 
the fenugreek seed extract as able to inhibit SIRT6 deacetylase activity, but, aside for quercetin and 
vitexin that are known promiscuous sirtuin modulators3, the specific component responsible for this 
biological activity was not clarified. A set of five small molecules that exert a partial inhibitory 
activity on SIRT6 (approximately by 25% at 100 M) was reported by Schliker et al.
240
. However, 
these compounds were classified as semi-specific and were not further investigated. More recently, 
a series of peptides and pseudopeptides was reported as SIRT6 inhibitors, with the most potent 
compound exhibiting an IC50 in the micromolar range, but showing no selectivity for SIRT6 versus 
SIRT1 and SIRT2
281
. Our study represents an important advancement in this research area since it 
reports for the first time a number of active, structurally diverse, non-peptide, selective SIRT6 
inhibitors. The most active compounds (5, 9 and 17) are able to inhibit SIRT6 deacetylase activity 
in the micromolar range, as expected for not yet optimized compounds and consistently with the 
typical results of an in silico screening
282
. The SIRT6/SIRT1 selectivity ratio for two of these 
compounds (9 and 17) is also remarkable, showing a SIRT6 activity respectively 17 and 19 fold 
higher than SIRT1 activity (Table 7.2). Since no previous knowledge on specific SIRT6 inhibitors 
was available, our selection was based on the conformations of the reaction cofactor, of the 
substrate, and/or of product of this enzyme. As a consequence, many of the compounds selected 
from the virtual screening are characterized by the presence of small saturated nitrogen rings, such 
as uracil or hydantoin groups. These are able to form a hydrogen bond network in the active site 
similar to the one formed by the natural product/inhibitor NAM, but in some cases unable to 
reproduce the aromatic interactions (see for example compounds 1-3). All of these compounds, with 
the exception of compound 5, showed no activity on SIRT6, demonstrating that this chemical 
feature alone is not sufficient to improve potency on SIRT6. On the contrary, quinazoline or 
salycilate derivatives (compounds 5 and 9) both reproduce NAM interactions, but also show extra 
features, such as a partial filling of the substrate and cofactor binding pockets, and lead to a marked 
SIRT6 inhibition. The other two active compounds, 16 and 17, are both predicted by docking 
software to bind mainly the adenine binding pocket, suggesting a possible binding competition with 
NAD. However, these molecules also show chemical features that are similar to NAM, such as the 
pyrazine-2-carboxamido group in compound 16 and the succinimidobenzoate group in compound 
17. Therefore their ability to bind the NAM binding pocket should be also considered. Certainly, 
complementing in silico data with information that could be obtained with crystallographic 
complexes and/or extensive structure-activity relationship studies, will contribute to better explain 
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the fine mechanism underlying SIRT6 inhibition by these small molecules. From a biological point 
of view, it is worth to emphasize that compound 5, 9, and 17 were all able to reduce TNF-α 
secretion as would be expected based on the current knowledge on the role of SIRT6 in TNF-α 
production
269,271,273,274
. Thus, it is conceivable that such compounds could find potential application 
in the treatment of inflammatory conditions in which TNF-α secretion plays an important 
pathophysiological role, such as arthritis or Crohn disease. In addition, a strong increase in GLUT-1 
expression that was accompanied by a consistent increase in glucose uptake was also observed in 
cultured cells treated with these compounds. This data is in line with the observation of high 
GLUT-1 levels in the muscle and of increased tissue glucose uptake and consequent hypoglycemia 
in SIRT6-/- mice
267,283
. These properties make the identified SIRT6 inhibitors, or derivatives of 
them, particularly appealing for their possible applications as blood glucose-lowering drugs. In 
particular, their ability to upregulate GLUT-1, which is not reliant on insulin for its expression
284
, 
could make them suitable for treating patients with insulin-resistant diabetes. 
7.4 Conclusions 
SIRT6 is emerging as a possible therapeutic target for a wide range of conditions, including 
diabetes, immune-mediated disorders and cancer
230,266
. Nevertheless, no selective small-molecule 
SIRT6 inhibitor has been identified to date. In this study, we made use of in silico design 
approaches to identify novel and selective scaffolds that would bind and inhibit SIRT6 selectively. 
We report several drug-like compounds that show in vitro activities in the low micromolar range of 
concentration and have some degree of selectivity for SIRT6 versus other sirtuins. A structural 
analysis of the ligand binding modes suggests that the selectivity and potency of the identified 
chemical scaffolds are susceptible to be further improved. In conclusion, since the identified SIRT6 
inhibitors show a favorable drug-likeness profile and their biological annotation has already 
revealed strong activity in cell line models, these compounds can be considered as highly promising 
leads for the development of future SIRT6-based therapeutics. 
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Figure 7.5. Compounds 5, 9, and 17 increase GLUT-1 expression in cultured cells. A, B, 4 x105 BxPC-3 cells were 
plated in 6-well plates and allowed to adhere for 24h before being stimulated for 24h with 5 or 9 at the indicated 
concentrations. Thereafter, cells were used for protein lysate generation and subsequent detection of GLUT-1 and γ-
tubulin by immunoblotting. C, BxPC-3 cells were plated as above and then stimulated for the indicated time amounts 
with 17 (200 μM). Subsequently, cells were used for protein lysate preparation and GLUT-1 and γ-tubulin were 
revealed by immunoblotting. D, E, BxPC-3 cells were plated and treated with 100 μM 5 or 9 as in A, B. After 24h of 
exposure to the compounds, cells were detached and GLUT-1 expression at the cell surface was detected by flow 
cytometry. 
7.5 Experimental section 
In silico techniques.  
The crystal structure of the SIRT6 in complex with ADP-ribose was used as a template for virtual 
screening purposes (PDB id: 3K35). This structure was prepared with standard preparation 
procedures (protein preparation wizard) as included in the software package Maestro
134
. In order to 
allow searching ligands that are able to target the NAM pocket, we corrected the partially occluded 
structure of the human SIRT6 by aligning it to the structure of the Archeoglobus fulgidus SIR2, 
which is co-crystallized with NAM (PDB id: 1YC2). The NAM molecule was merged in the 
template of human SIRT6 and the Phe62 residue was minimized to allow the binding of NAM in 
the C pocket. The final conformation of the Phe62 side chain was incorporated in the final template 
that was used for the docking grid generation. The docking software Glide
135
 was used to perform a 
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high-throughput virtual screening experiment. A docking grid was obtained by centering a 25 Ǻ box 
in the centroid of the ADP-ribose ligand, as present in the template crystallographic structure of the 
human SIRT6. Although many water molecules are present in the crystal structure, none of these 
seems to be involved in stable interactions with ligand- or NAD
+
-binding, therefore all waters were 
removed from the grid.  Standard precision (SP) docking was used to perform a first round of 
virtual screening. The top 1500 molecules, sorted by Glide score, were further refined with the 
extra-precision (XP) docking. Docking results were ranked based on the Glide score and the first 
500 hits were considered for visual inspection. Compounds were visualized by taking into account 
several structural and physico-chemical rules, such as the qualitative evaluation of ligand-protein 
interactions within the active site, probability of suggested protonation and tautomeric states, 
stereochemistry complexity, compound availability, chemical diversity, drug-likeness and synthetic 
accessibility. Finally, the active compounds were filtered for Pan Assay Interference Compounds 
(PAINS) using FAF-Drugs2
285,286
. 
Compound Sources. We screened in silico the Asinex subset of the CoCoCo databases. Selected 
molecules were purchased in milligram quantities from chemical vendor and ID are reported in 
Table 7.1. Purity of compounds was >= 95%, as declared by the chemical vendor. 
Biological Assays (biochemical assays: Prof. Santina Bruzzone, University of Genova. Cellular 
and other functional assays: Prof. Alessio Nencioni, University of Genova) 
Cell lines. BxPC-3 cell line (human pancreatic ductal adenocarcinoma) was purchased from ATCC 
(LGC Standards S.r.l., Milan, Italy) and maintained in RPMI1640 medium supplemented with 10 % 
FBS, 50 IU/ml penicillin and 50 μg/ml streptomycin (Lonza Milano S.r.l., Treviglio, Italy). BxPC-3 
cells were transduced with the empty plasmid pRETROSUPER (pRS), or with a validated RNA-
interference construct (sh2 SIRT6)
269
, and cultured as above. Rat L6 myoblasts were obtained from 
Prof. Beguinot (University of Napoli Federico II, Naples, Italy) and maintained in DMEM with 
10% FBS, 100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were maintained in a humidified 
5% CO2 atmosphere at 37°C.  
In vitro assays and IC50 determination. The identified molecules were tested as sirtuin inhibitors 
using commercial kits for SIRT6, SIRT1 and SIRT2 (Cayman, Ann Arbor, MI), following 
manufacturer‟s instructions. IC50 values were determined using the same commercial kit assays. All 
compounds were solubilized at 50 mM concentration in DMSO. The concentrations of the 
compounds for IC50 determination were in the range from 8 μM to 5 mM. IC50 were determined 
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from the logarithmic non linear regression curves in GraphPad Prism (GraphPad Software, La Jolla, 
CA). Three independent IC50 measurements were performed for each compound. 
Immunoblotting. BxPC-3 cells (pancreatic ductal adenocarcinoma) were incubated for the indicated 
amounts of time with the specified compounds or with the corresponding amount of vehicle DMSO 
(the final concentration of DMSO that was added to the medium to test the effects of a compound at 
100 μM concentration ranged between 2‰ and 6‰, depending on the compound). Thereafter, cells 
were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40 and protease 
inhibitor cocktail). Thirty μg of proteins were loaded on a 15% polyacrilamide gel and separated by 
SDS-PAGE. Proteins were subsequently transferred to polyvinyl difluoride (PVDF) membranes and 
the expression of total or modified proteins were detected using the following primary antibodies: 
anti-acetylated H3K9 (rabbit polyclonal, H9286, Sigma Aldrich), anti-histone H3 (rabbit 
polyclonal, 9715, Cell Signaling Technology), anti-GLUT-1 (mouse monoclonal, SPM498, 
Abcam). Following incubation with the appropriate secondary antibodies and ECL detection (GE 
Healthcare, Milano, Italy), band intensity was quantified with the ChemiDoc imaging system (Bio-
Rad, Milan, Italy). H3K9 acetylation was normalized to total H3 levels and expressed as percentage 
of H3K9 acetylation vs. vehicle-treated cells.  
Flow cytometric GLUT-1 detection. For flow cytometric detection of GLUT-1 expression at the cell 
surface, adherent cells were trypsinized and washed in cold PBS. 5 x 105 cells were subsequently 
fixed for 10 min in 100% methanol at -20°C. Thereafter, cells were washed in cold PBS, 
resuspended in 100 μl cold culture medium and incubated with or without 2.5 μl anti-GLUT-1 
antibody (SPM498, Abcam) for 30 min at 4°C. Subsequently, cells were washed in cold PBS and 
incubated in 100 μl cold culture medium with 10 μl anti-mouse IgG2a (a kind gift of Dr. Alessandro 
Poggi, IRCCS AOU San Martino IST, National Cancer Institute, Genoa, Italy) for 30 min at 4°C. 
Finally, cells were washed twice with cold PBS and analysed using a FACS Calibur (Becton 
Dickinson) by acquiring 10.000 events/sample.  
TNF-α ELISA. BxPC-3 cells (3 × 105 cells/well) were seeded in 6-well plates and allowed to adhere 
for 24 h. Thereafter, cells were incubated overnight with SIRT6 inhibitors (100 μM) or vehicle. 
Thereafter, to induce cytokine secretion, cells were stimulated for 24 h with PMA. Finally, 
supernatants were collected and assayed for TNF-α using commercially available DuoSet® ELISA 
kits (R&D Systems, Minneapolis, MN). 
Glucose uptake assay with [14C]-2-deoxy-d- in BxPC-3 and L6 cells. BxPC-3, pRS and sh2 SIRT6 
BxPC-3 and L6 cells (6x105/well), seeded in 12-well plates, were treated in triplicate for 18 h with 
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or without the different compounds (200 μM, final concentration), in complete medium. The cells 
were then washed twice with 1 ml of PBS buffer and glucose transport was measured by the 
addition of 0.5 mM d-glucose/[14C]-2-deoxy-d-glucose (0.5 μCi/well) in 0.4 ml KRH buffer (129 
mM NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4, 1 mM CaCl2, 1.2 mM MgSO4, 10 
mM Hepes, 0.5% bovine serum albumin) for 5 min at 37°C. Glucose uptake was stopped by 
immediately removing the labeling mix and washing the cells 3 times with ice-cold PBS. Cells were 
then lysed with 0.1% sodium dodecyl sulfate (SDS), and each lysate was used for scintillation 
counting in a Beta-Counter LS 6500 (Beckman-Coulter, Krefeld, Germany). Unspecific uptake in 
the presence of 20 μM cytochalasin B and 200 μM phloretin was subtracted from each experimental 
value. 
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8. Optimization of SIRT6 inhibitors - Quinazolinedione 
derivatives 
We have identified a series of novel and selective SIRT6 inhibitors with a favorable drug-likeness 
profile and strong activity in cell line models. Nevertheless, selectivity and potency of the identified 
chemical scaffolds are susceptible of further improvement (see chapter 6). In particular, a 
quinazolinedione derivative (Figure 8.1) was found to inhibit SIRT6 activity in the low micromolar 
range, but showed moderate SIRT6/SIRT1 selectivity (the IC50 value for SIRT6 was approximately 
three times lower compared to the IC50 for SIRT1), and close to no selectivity over SIRT2. The goal 
of the present study was to obtain a better understanding of the structure-activity relationship (SAR) 
of this promising hit compound identified in our previous work, to improve its potency and 
selectivity as a SIRT6 inhibitor and to assess the value of 1 and its analogs as chemosensitizers. 
 
Figure 8.1. Chemical structure and activity data of the reference compound. The colored boxes indicate the parts of the 
molecule that were considered to identify interesting analogues. 
8.1 Selection of analog candidates for biological testing 
Using the chemical structure of compound 1 as a reference, and taking into account its predicted 
binding mode into the SIRT6 active site, as described in our previous study, we screened a 
collection of commercial compounds (the CoCoCo database)
132,133
 to identify analogues that could 
be easily purchased and tested, with the final goal to shed more light on the structure-activity 
relationship of this compound series. These derivatives were selected from the database using 
different substructure searches aimed to explore modifications on each fragment of the reference 
structure. Three main fragments were identified in the reference compound, the pyridine-3-
yloxyphenyl moiety, a sulfonamide linker, and the quinazolinedione group (Figure 8.1, boxes 1, 2 
and 3, respectively), and available modification of each fragment were independently searched for 
in the CoCoCo database. The starting list of approximately 450 analog compounds was then filtered 
by removing duplicates and by checking sample availability from compound providers, leading to a 
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final list of 88 compounds. The putative binding mode and the calculated binding score of these 
candidate molecules into the SIRT6 active site were predicted using molecular docking (see 
experimental section). Out of the thirteen representative compounds that were finally selected, 
seven presented variations of the pyridine-3-yloxyphenyl moiety (compounds 2-8 in Table 8.1), five 
presented variations of the quinazolinedione group (compounds 10-14 in Table 8.2), and one 
compound was chosen as it presented a variation of the sulfonamide linker (compound 9 in Table 
8.1). To obtain independent assessments of the effect of these compounds on SIRT6 activity, two 
commercially available assays were utilized to determine the IC50s of the identified thirteen 
compounds (Table 8.1, 8.2), namely a fluorescence-based and a luminescence-based assay, both of 
which are able to detect SIRT6 deacetylase activity. Assays were performed in the laboratory of 
Prof. Santina Bruzzone (University of Genova). Overall, an excellent agreement between the IC50 
values was obtained with the two methods and the use of the luminescence-based assay was of 
special value for those compounds that, having an intrinsic fluorescence, could not be assayed with 
the fluorescence-based kit.  
Among the seven derivatives with the modified pyridine-3-yl-oxyphenyl moiety, five showed an 
improved activity on SIRT6 compared to 1, while two compounds showed a striking decrease of 
activity. The substitution of the oxyphenyl group with more hydrophobic substituents, such as 
benzyl (compound 8), ethylphenyl (compound 3) or even methylindole (compound 4) seemed to 
improve the compounds‟ inhibitory activity, while the replacement of the same group with a polar 
non-aromatic ring such as a pyrrolidine (compound 7) strongly reduced the inhibitory activity. The 
change in the substitution position from 3-yl to 4-yl (compounds 3) appeared to be almost 
irrelevant, with the exception of the introduction of a metamethylindole (compound 6), which 
caused a complete loss of activity. The substitution of sulfonamide linker with a sulfonate was 
tolerated (compound 9), indicating that the presence of a donor function is not essential to 
determine inhibitory activity. The methylation of the quinazolinedione group was also found not to 
be detrimental for the inhibitory activity, as demonstrated by compound 8. Finally, the replacement 
of the quinazolinedione group was found to be detrimental for SIRT6 inhibition in all cases with the 
exception of compound 10, whose activity was comparable to the reference compound. The results 
obtained in these SAR studies are only partially explained by the predicted binding mode of the 
tested molecules. In fact, compound 2 and compound 6 both show a predicted binding mode that is 
similar to the reference compound 1 (Figure 8.2A and 8.2B); both are predicted to bind the 
nicotinamide (NAM) binding pocket, also known as pocket C, and part of the substrate binding 
pocket. Both compounds maintain the extended hydrogen bond network with Val113, Asp114, and 
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Pro60, as well as the stacking interaction with Phe62, formed by the quinazolinedione group. The 
imidazole ring replaces the pyridine moiety of compound 1 forming interactions with His131 and 
with Trp186. Compound 6 also shows an additional hydrogen bond with the backbone carbonyl of 
Asp185. While the increase in activity reported for compound 2 compared to reference compound 1 
can be explained by the better fit of methyl-imidazole moiety compared to oxy-piridinyl group in 
the hydrophobic region comprised among His131 and Trp186, the remarkable drop in activity 
reported for compound 6 is apparently not attributable to its predicted binding mode since the 
substitution of the phenyl and of the o-oxy-piridinyl moieties with a benzyl and a m-
methylimidazole, respectively, seems to be perfectly tolerated, if not even preferred. Similarly, 
compound 7 is predicted to bind SIRT6 in a similar way compared to other active compounds in 
this series, also forming an additional hydrogen bond with Leu184 (Figure 8.2C), but shows a ten-
fold reduction in terms of potency of SIRT6 inhibition compared to the reference compound, which 
wouldn‟t be explained by this predicted binding mode. The binding pose of compound 8 represents 
a particular paradigm in our binding hypothesis since it presents a double methylation of 
quinazolinedione group and therefore lacks two hydrogen-bond donor features that are considered 
to be key interactions in the proposed binding mode. In line with this model, the docking pose of 8 
reveals an unfavorable binding in which the NAM pocket is occupied by the pyridine ring and the 
quinazolinedione group is directed towards the substrate binding pocket (Figure 8.2D). Despite 
these predictions, this molecule falls in the same activity range of the reference compound, 
indicating that other mechanisms or alternative/additional bindings may occur, underlying 8‟s 
ability to bind and inhibit SIRT6. Efforts aimed at identifying a more reliable binding model, such 
as the binding in adenine pocket or the presence of additional pockets, were unfortunately not useful 
to explain this behavior (data not shown). 
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Comp ID R1 R2 R3 X 
SIRT6 IC50 
(μM) 
Fluorescence 
Assay 
SIRT6 IC50 (μM) 
Luminescence 
Assay 
1 -H -H 
 
NH 106±16 136±12 
2 -H -H 
 
NH 60±4 ND 
3 -H -H 
 
NH 37±2 55±4 
4 -H -H 
 
NH ND 82±4 
5 -H -H 
 
NH 137±7 137±8 
6 -H -H 
 
NH ND 2872±546 
7 -H -H 
 
NH ND 517±77 
8 -CH3 -CH3 
 
NH 49±4 38±3 
9 -H -H 
 
O ND 127±14 
Table 8.1. Structures and SIRT6 inhibition activities of compounds with modified pyridine-3-yloxyphenyl fragment or 
with modified linker. ND = not determined (interfering with the assay). 
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Compound ID R 
SIRT6 IC50 
(μM) 
Fluorescence 
Assay 
SIRT6 IC50 
(μM) 
Luminescence 
Assay 
10 
 
77±14 102±10 
11 
 
270±47 275±7 
12 
 
441±23 ND 
13 
 
297±15 242±23 
14 
 
ND 300±9 
Table 8.2. Structures and SIRT6 inhibition activities of compounds with modified quinazolinedione fragment. ND = 
not determined (interfering with the assay). 
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Figure 8.2. Putative binding mode of SIRT6 inhibitors derived from 1. Predicted binding mode of compound 2 (A), 
compound 6 (B), compound 7 (C) and compound 8 (D). Hydrogen bonds are represented as red dotted lines. 
8.2 Selectivity profiling 
In order to evaluate the selectivity of the most interesting SIRT6 inhibitors of this series, their IC50 
values for SIRT1 and SIRT2 were also determined using commercially available kits and compared 
to the results obtained with the reference compound 1. 
Compound 2 showed a SIRT6/SIRT1 selectivity ratio that was comparable to reference compound 
1, and a slightly better selectivity SIRT6 over SIRT2. Conversely, compounds 3 and 8 proved to be 
the most SIRT6/SIRT1 selective, their IC50 values being respectively almost 12 times and more 
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than 100 times higher for SIRT1, respectively, while showing a moderate SIRT6/SIRT2 selectivity. 
A distinctive feature of SIRT6 is the lack of the so-called cofactor binding loop, a structural element 
identified in previously solved sirtuin structures and which can adopt different conformations 
depending on the ligands bound in the active site
230
. In SIRT6, this element is replaced by an 
ordered helix that reduces the flexibility of the active site itself
245
, making its structure unique 
among sirtuins, which, in turn can be exploited for designing selective inhibitors, as demonstrated 
in our previous study
259
. This feature is likely to play a main role in explaining the selectivity of the 
reported compounds even if the predicted binding poses are still not sufficiently accurate to provide 
a conclusive structural explanation for each binding mode. For instance, the remarkable 
SIRT6/SIRT1 selectivity of compound 8 should be ascribed to the double methylation of 
quinazolinedione fragment that is well tolerated in SIRT6 and in SIRT2 but clearly not permitted in 
SIRT1, suggesting the occurrence of different binding modes in each sirtuin isoform. 
Compound ID SIRT6  SIRT1  SIRT2  ratio SIRT1/SIRT6  ratio SIRT2/SIRT6  
1 106±16 314±19 114±5 2.96 1.07 
2 60±4 238±12 159±4 3.97 2.65 
3 37±2 424±26 85±3 11.46 2.30 
8 49±4 6521±130 242±16 133.08 4.94 
Table 8.3. Determination of IC50 (μM) on SIRT6, SIRT1 and SIRT2 for compounds 1, 2, 3 and 8 and of the selectivity 
ratios SIRT1 IC50/SIRT6 IC50 and SIRT2 IC50/SIRT6 IC50 for the same compounds 
8.3 Mechanism for SIRT6 inhibition by quinazolinediones 
In order to better clarify the mechanism underlying SIRT6 inhibition by the reference compound 1 
and by the compound 3, which is the analog with the lowest IC50, we evaluated the NAD
+
 saturation 
curves in enzymatic reactions utilizing recombinant SIRT6. We also explored the inhibition 
mechanism of compound 1 and 3 by varying the concentration of the substrate peptide, which 
contains an acetylated Lysine as a substrate for SIRT6 activity. As shown in Fig. 8.3A, Vmax was 
not altered by the presence of compound 1, indicating a competitive inhibition by this compound 
with respect to the coenzyme. The same holds true for compound 3 (Fig. 3B), which also appeared 
to competitively inhibit SIRT6 deacetylase activity. Similar results were obtained by varying the 
concentration of substrate peptide (Fig. 8.3C and 8.3D) since both compounds inhibited SIRT6 
through competition with the peptide substrate. The results of these competition experiments are 
consistent with SIRT6 inhibition by compounds 1 and 3 occurring through their binding in the 
nicotinamide pocket and in the substrate pocket, in agreement with our previous hypothesis for 
compound 1
259
. 
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Figure 8.3. Mechanism of SIRT6 deacetylase activity inhibition by compounds 1 and 3. NAD
+
 (A and B) or peptide (C 
and D) saturation curves were generated incubating recombinant SIRT6 in the presence or absence of 50 μM compound 
1 or 3, and varying the concentrations of NAD+ or of the peptide, respectively. Inset in panels C and D, magnification of 
line intersections. SIRT6 activity was determined using the chemiluminescent assay kit.   
8.4 Biological evaluation of quinazolinedione SIRT6 inhibitors 
Having identified analogs that, as compared to the reference compound 1, exhibited improved 
potency and specificity (compounds 2, 3, and 8), we set out to determine whether they would also 
be active in mammalian cells, recreating the biological effects that are predicted to occur as a 
consequence of SIRT6 inhibition. In particular we aimed at confirming an increase in histone 3 
lysine 9 (H3K9) acetylation, an increase in cellular glucose uptake, and a reduction in TNF-α 
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production
266
. These assays were performed in the laboratory of Prof. Alessio Nencioni (Univ. 
Genova). 
An increase in H3K9 acetylation in BxPC-3 cells (pancreatic ductal adenocarcinoma) could be 
observed with all of the three compounds, the strongest effect being achieved with compound 3. A 
representative time course experiment evaluating acetylated H3K9 levels in cells treated with 3 is 
shown in Figure 4. Notably, similar to what observed with 1, H3K9 acetylation peaked at 18 h of 
exposure and started decreasing afterward, suggesting the existence of feedback mechanisms 
regulating H3K9 acetylation in cells in response to sustained SIRT6 inhibition. Compounds 3 and 8 
significantly increased the uptake of radiolabeled glucose in both BxPC-3 and L6 myoblasts (Table 
8.4) and a similar enhancement in glucose uptake was also observed in L6 myoblasts by evaluating 
the uptake of a fluorescent glucose analog, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-
deoxy-D-glucose (2-NBDG), whereas no stimulation of glucose uptake by compound 2 could be 
detected. Compound 3 could not be tested with 2-NBDG, due to interference with the method (see 
Experimental Section). A strong inhibition of TNF-α production by 2 and 3 could be documented in 
BxPC-3 cells stimulated with PMA. Compounds 1, 3 and 8 inhibited TNF-α production in human 
peripheral blood mononuclear cells (PBMC) stimulated with phytohemagglutinin (PHA) or with 
allogeneic antigen-presenting cells (in mixed leukocyte reaction, MLR) (Table 8.4). 2 only reduced 
TNF-α production by PBMC stimulated in MLR while its effect on PHA-stimulated TNF-α release 
did not reach statistical significance (p=0.07), possibly because of the high inter-donor variability.  
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Figure 8.4. Compound 3 increases H3K9 acetylation in cultured cells. A, B. 2 x 105 BxPC-3 cells/well were seeded 
in 6-well plates, allowed to adhere overnight and subsequently stimulated with 3 for the indicated amounts of time. 
Thereafter, cells were used for cell lysate preparation and acetylated H3K9, total H3 and β-actin were detected by 
immunoblotting. Band intensities were quantified and acetylated H3K9 signals were normalized to those of the 
corresponding total H3 bands and, finally, to the corresponding intensities that were obtained with vehicle DMSO. A, 
one representative experiment out of three is presented. B, results are presented as means ± SD of three separate 
experiments. 
 
Compound 
ID 
H3K9 
acetylation 
(normalized 
to control) 
Radiolabelled 
glucose 
uptake in 
BxPC-3 cells 
(normalized 
to control) 
Radiolabelled 
glucose 
uptake in L6 
cells 
(normalized 
to control) 
2-NBDG 
uptake in 
L6 cells 
(normalized 
to control) 
% 
inhibition 
of TNF-α 
production 
in BxPC-3 
cells 
% 
inhibition 
of TNF-α 
production 
in human 
PBMC 
(PHA) 
% 
inhibition 
of TNF-α 
production 
in human 
PBMC 
(MLR) 
1 2.2±0.5* 1.3±0.2* 2.0±0.3* 2.4±0.5* 73±10 52±37* 47±26* 
2 1.5±0.2* 0.6±0.3 0.8±0.2 0.7±0.4 25±8 31±31
n.s. 21±16* 
3 1.4±0.2* 1.2±0.2* 2.8±0.4* I 72±18 44±28* 27±17* 
8 1.6±0.3* 1.9±0.3* 4.0±0.4* 3.1±0.5* ND 39±27* 30±19* 
Table 8.4. Biological evaluationa of quinazolinedione SIRT6 inhibitors. I = interfering with the assay; ND = not 
determined.  *, p<0.05 compared to control, vehicle-treated cells; n.s., not statistically significant. 
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8.5 Quinazolinedione inhibitors sensitize cancer cells to 
chemotherapeutics 
SIRT6 deficient cells exhibit increased sensitivity to chemotherapeutics and to γ-irradiation272,287–
289
.
 
 Thus, we decided to evaluate whether SIRT6 inhibitors would sensitize pancreatic cancer cells 
to a commonly administered chemotherapeutic, such as gemcitabine. To obtain the proof-of-
concept that reduced SIRT6 activity could indeed be effective to this aim, we first exposed BxPC-3 
cells in which SIRT6 had been silenced by RNA interference
269
 to titrated concentrations of the 
chemotherapeutic. As predicted, in SIRT6-silent BxPC-3, gemcitabine caused a more pronounced 
reduction in cell viability as compared to the control BxPC-3 (Figure 8.6A). Drawing from these 
experiments, we assessed the effect of 2 and 3 on the anticancer activity of gemcitabine in plain 
BxPC-3 cells. The two SIRT6 inhibitors were tested at concentrations that were close to their IC50 
(30 and 60 μM) and, while essentially not affecting BxPC-3 cell growth as single agents, they 
caused a striking enhancement of gemcitabine activity when used in combination with this 
chemotherapeutic (Figure 8.5). 
Within the DNA damage response, SIRT6 was shown to specifically cooperate with PARP1 in 
ensuring double strand break repair
270
. Thus, we reasoned that SIRT6 inhibitors could possibly 
achieve a potentiation of the activity of PARP inhibitors, such as olaparib, in cancer cells. The 
BRCA2-deficient pancreatic cancer cell line Capan-1 was chosen for these experiments since 
BRCA1/2 deficient tumors represent an important clinical indication for PARP inhibitors in 
oncology
290
. The proof-of-concept that SIRT6 inhibitors could indeed be effective to this end was 
first obtained by silencing SIRT6 in Capan-1 cells (Figure 8.6B) since SIRT6-silent Capan-1 did 
exhibit an increased sensitivity to olaparib as compared to the control cells, particularly for 
concentrations ranging between 0.5 and 4 μM (Figure 8.6C). Drawing from these findings, we used 
confocal microscopy and flow cytometry to monitor DNA damage, as detected by γH2AX staining, 
in Capan-1 treated with olaparib, SIRT6 inhibitors, and their combination. Both types of studies 
readily demonstrated that, even though single-agent olaparib, 1 or 3, did induce some degree of 
DNA damage, the combination of olaparib with a SIRT6 inhibitor led to a much more pronounced 
γH2AX expression (Figure 8.7A-C). These findings were paralleled by results of viability assays in 
which 1 and 3 were found to effectively increase olaparib‟s anticancer activity in Capan-1 cells 
(Figure 8.7C-D). A cooperative inhibition of Capan-1 cell viability was also obtained by combining 
SIRT6 inhibitors with NU1025, an unrelated PARP inhibitor (data not shown). 
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Figure 8.5. SIRT6 inhibitors sensitize pancreatic cancer cells to gemcitabine. A, B, 5 x 103 BxPC-3 cells/well were 
plated in 96-well plates, allowed to adhere overnight and subsequently incubated with 2 or 3 at the indicated 
concentrations or with vehicle DMSO (vehicle) for 2 h. Thereafter, cells were treated with or without the indicated 
concentrations of gemcitabine. 72 h later, cell viability was quantified utilizing CellTiter96 Aqueous1. Results are 
means ± SD of three separate experiments. The lower inset of each panel presents the CIs that were calculated for each 
concentration of gemcitabine in combination with 2 or 3 at the indicated concentration.  
 
Figure 8.6. SIRT6 silencing sensitizes cancer cells to gemcitabine and to olaparib. 5 x 103 BxPC-3 that were either engineered to 
express an anti-SIRT6 shRNA (SIRT6 shRNA) or a control vector (vector) were plated in 96-well plates and allowed to adhere 
overnight. Thereafter, cells were treated with or without the indicated concentrations of gemcitabine. 72 h later, cell viability was 
quantified utilizing CellTiter96 Aqueous1. B, Capan-1 cells were transduced with a vector (pRS) expressing an anti-SIRT6 shRNA 
(SIRT6 shRNA) or with a control vector (pRS, vector). Successfully infected cells were selected with puromycin and used for protein 
lysate generation. SIRT6 levels were detected by immunoblotting while a non-specific immune band (n.s.i.b.) was used as a loading 
control. C, 103 Capan-1 cells that were either engineered to express an anti-SIRT6 shRNA (SIRT6 shRNA) or a control vector 
(vector) were plated in 96-well plates and allowed to adhere overnight. Thereafter, cells were treated with or without the indicated 
concentrations of olaparib. 7 days later, cell viability was quantified utilizing CellTiter96 Aqueous1. A, C, Results are means ± SD of 
three separate experiments. B, One representative experiment out of three is presented. *:p<0.05; n.s.: not statistically significant.  
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Figure 8.7. SIRT6 inhibitors cooperate with olaparib to induce DNA damage and cytotoxicity in BRCA2-
deficient Capan-1 cells. A. γH2AX levels, nuclei staining (Qnuclear), and their overlap were detected by confocal 
microscopy in Capan-1 cells treated with vehicle DMSO, 1, olaparib, or the combination 1 + olaparib. B, γH2AX levels 
in Capan-1 cells treated with vehicle DMSO, 1, olaparib, or the combination 1 + olaparib were detected by flow 
cytometry. C, Mean fluorescence intensities (MFI) of γH2AX staining in Capan-1 cells treated with vehicle DMSO, 1 
(100 μM), 3 (100 μM), olaparib (8 μM), or the combinations were normalized to the MFI measured in cells treated with 
vehicle DMSO and expressed as percentage variation vs. vehicle. D, E, 103 Capan-1 cells/well were plated in 96-well 
plates, allowed to adhere overnight and subsequently incubated in the presence of the concentrations of 1 or 3 indicated 
on the x axis or of vehicle DMSO. Olaparib was administered (or not) according to a 1:1 titration starting from 8 μM, 
the latter concentration being the one that was combined to the highest concentration of 1 or 3. Viability was detected 7 
days later using CellTiter96 Aqueous1. Cooperative indexes (CI) for each drug combination are indicated within each 
panel. A, B, One representative experiment out of three is presented. C-E, results are means ± SD of three separate 
experiments. 
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8.6 Conclusions 
Here we reported on the identification of new derivatives of a quinazolinedione SIRT6 inhibitor (1) 
with improved potency as compared to this reference compound. Three compounds have been 
identified (2, 3, 8) which exhibit an IC50 for SIRT6 of 60, 37 and 49 μM, respectively, versus 106 
μM of compound 1. Although further efforts are clearly still required to increase the potency of 
these sirtuin inhibitors, it should be noticed that these improvements were paralleled by concomitant 
progresses in terms of isoform selectivity. Indeed, weakly selective compounds such as 1 
(SIRT2/SIRT6 IC50 ratio of 1.07) could result in major disadvantage when specific SIRT6 
inhibition was to be sought for clinical uses. With the newly identified SIRT6 inhibitors a 
significant improvement in terms of selectivity profile has been achieved since compounds 2, 3, and 
8 exhibit a SIRT2/SIRT6 IC50 ratio ranging between 2.3 (for 3) and 4.9 (for 8). Notably, the 
SIRT1/SIRT6 IC50 ratio has also be improved, since, starting from the 2.9 value of 1, we were able 
to increase it to 3.9, 11.4, and 133 with compound 2, 3, and 8, respectively. 
A qualitative SAR was performed and allowed us to highlight some structural changes that appear 
to critically affect the activity of 1 and its derivatives, although a complete understanding of the 
SAR for this compound series is still unclear An obvious explanation for the inability of our SAR 
studies to explain the activity of all of the analogs of 1 that were evaluated could be the ability of 
some of these compounds to exert their biological effects through different binding modes, even 
when small structural changes apply. Nevertheless, the competition experiments on the most active 
compounds clearly indicated the active site of the enzyme as the putative binding site, excluding the 
presence of allosteric inhibition. For a conclusive assessment of the fine mechanisms underlying 
SIRT6 inhibition by the identified compounds, particularly by those whose inhibitory activity 
would not be predicted based on the in silico model such as 8, in silico data should be 
complemented with specific, corroborating experiments, such as site-directed mutagenesis or X-ray 
crystallography.  
Extensive biological evaluations were undertaken to assess the ability of the newly identified SIRT6 
inhibitors to produce the effects that would be expected as a consequence of SIRT6 inhibition. As 
previously described for 1, 2, 3, and 8 all proved to be active in cultured cells as shown by increased 
acetylation of H3K9, a well-known target of SIRT6 deacetylase activity
279
. 3 and 8 successfully 
recreated the effects of SIRT6 knock-down and of treatment with 1 in that they increased glucose 
uptake in cultured cells
259,267
. In addition, similar to 1, 2, 3, and 8 all reduced TNF-α production by 
BxPC-3 cells, as well as by cultured human PBMC that were either stimulated with the mitogen 
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PHA or in mixed leukocyte reaction. Therefore, these findings are all consistent with the effects that 
SIRT6 inhibition is predicted to cause in cells and suggest possible applications of the identified 
compounds (or of derivative of them) as blood sugar lowering agents or as anti-inflammatories. 
A specific focus of this study was to assess whether the identified SIRT6 inhibitors would be 
effective as enhancers of the activity of chemotherapeutics (i.e. gemcitabine) and of PARP 
inhibitors, as would be predicted based on the well-known roles of SIRT6 in DNA repair and on its 
emerging roles in carcinogenesis
269,288,291–293
. 2 and 3 proved to be extremely active at potentiating 
the anti-proliferative activity of gemcitabine in BxPC-3 pancreatic cancer cells, while for 1 and 3 a 
striking potentiation of olaparib‟s activity could also be documented. These experiments represent 
the first proof-of-concept that small-molecule SIRT6 inhibitors can be used to sensitize tumor cells 
to commonly used anticancer agents and mandate further evaluations of these agents in in vivo 
tumor models and in combination with other cancer therapeutics. 
8.7 Experimental section 
In silico tecniques.  
Structure database management and substructure searches were conducted using Instant JChem 
from Chemaxon (ver. 5.11.5, 2012, http://www.chemaxon.com). The crystal structure of the SIRT6 
in complex with ADP-ribose was used as a template for virtual screening purposes (PDB id: 3K35). 
This structure was prepared with standard preparation procedures (protein preparation wizard) as 
included in the software package Maestro (Version 9.3, Schrödinger, LLC, New York, NY, 2012). 
In order to allow searching ligands that are able to target the nicotinamide binding pocket, we 
corrected the partially occluded structure of the human SIRT6 using a special procedure previously 
reported
259
. The docking software Glide (Version 5.8, Schrödinger, LLC, New York, NY, 2012) 
was used to perform a high-throughput virtual screening experiment. A docking grid was obtained 
by centering a 25 A box in the centroid of the ADP-ribose ligand, as present in the template 
crystallographic structure of the human SIRT6. Although many water molecules are present in the 
crystal structure, none of these seems to be involved in stable interactions with ligand- or NAD
+
-
binding, therefore all waters were removed from the grid. Extra Precision (XP) docking was used to 
obtain a binding pose for each ligand. 
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Biological Assays (biochemical assays: Prof. Santina Bruzzone, University of Genova. Cellular 
and other functional assays: Prof. Alessio Nencioni, University of Genova) 
Cell Lines. BxPC-3 and Capan-1 cells line were purchased from ATCC (LGC Standards S.r.l., 
Milan, Italy) and maintained in RPMI1640 medium supplemented with 10% FBS, 50 IU/mL, 
penicillin and 50 μg/mL streptomycin (Lonza Milano S.r.l., Treviglio, Italy). Rat L6 myoblasts, 
obtained from Prof. Beguinot (University of Napoli Federico II, Naples, Italy), were cultured as 
previously described
19
. Cells were maintained in a humidified 5% CO2 atm at 37°C.  
In Vitro Assays and IC50 Determination. The compounds were tested as sirtuin inhibitors with 
commercial kits: for SIRT6, SIRT1, and SIRT2, fluorescence-based assay kits (Cayman, Ann 
Arbor, MI) were used, following manufacturer‟s instructions; for SIRT6, a luminescence-based 
assay kit was used (Enzo Life Sciences, Vinci-Biochem, Vinci, Italy). For the luminescence-based 
kit, SIRT6 was recombinantly produced (see below). IC50 values were determined using these 
commercial kit assays. All compounds were solubilized at 50 mM concentration in DMSO (except 
for compounds 2, 8 and 13 that were solubilized at 16 mM concentration in DMSO). The 
concentrations of the compounds for IC50 determination were in the range from 4 μM to 1 mM. 
IC50s were determined from the logarithmic nonlinear regression curves in GraphPad Prism 
(GraphPad Software, La Jolla, CA). Three independent IC50 measurements were performed for each 
compound.  
Determination of inhibition mechanism. NAD
+
 saturation curves were generated with recombinant 
SIRT6, in the presence or absence of compounds 1 or 3 (50 μM, final concentration) with 
increasing concentrations of NAD
+
 (ranging from 200 μM to 5 mM) and a constant peptide 
concentration (100 μM), or with increasing concentrations of  peptide (ranging from 10 to 100 μM) 
and a constant NAD concentration (2 mM). SIRT6 activity was determined using the commercially 
available, chemiluminescent assay kit (Enzo Life Sciences). 
Production of recombinant SIRT6. Human recombinant SIRT6 production was carried out as 
described by others
20
, with a slight modification: SIRT6 purification was obtained with a His 
GraviTrap Talon® (GE Healthcare, Uppsala, Sweden). 
Immunoblotting. Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
NP40, and protease inhibitor cocktail). Thirty microgram amounts of proteins were loaded on a 
15% polyacrilamide gel and separated by SDS-PAGE. Proteins were subsequently transferred to 
polyvinyl difluoride (PVDF) membranes, and the expression of total or modified proteins was 
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detected using the following primary antibodies: anti-acetylated H3K9 (rabbit polyclonal, H9286, 
Sigma-Aldrich), anti-histone H3 (rabbit polyclonal, 9715, Cell Signaling Technology), anti-SIRT6 
(S4197, Sigma-Aldrich), or anti-β-actin-HRP (sc-47778, Santa Cruz Biotechnology). Following 
incubation with the appropriate secondary antibodies and ECL detection (GE Healthcare, Milano, 
Italy), band intensity was quantified with the ChemiDoc imaging system (Bio-Rad, Milano, Italy). 
H3K9 acetylation was normalized to total H3 levels and expressed as percentage of H3K9 
acetylation vs. vehicle-treated cells. 
Glucose Uptake Assay with [
14
C]-2-Deoxy-D-glucose or with d-glucose analog 2-NBDG. Glucose 
uptake was evaluated as previously described
14
 in BxPC3 and L6 cells incubated for 18 h in the 
presence or absence of the different compounds (100 μM, final concentration).  In addition, glucose 
uptake in L6 cells was evaluated with a fluorescent d-glucose analog, 2-NBDG.  L6 cells 
(2x10
6
/well) were seeded in 96-well plates, treated in triplicate for 18 h with or without the different 
compounds (200 μM, final concentration), in complete medium. The cells were then washed twice 
with 0.2 ml of KRH buffer (129 mM NaCl, 5 mM NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4, 1 mM 
CaCl2, 1.2 mM MgSO4, 10 mM Hepes, 0.5% bovine serum albumin) and glucose transport was 
measured by the addition of 200 μM 2-NBDG in 50 μl KRH buffer for 10 min at 37°C. Glucose 
uptake was stopped by removing the buffer and washing the cells twice  with KRH buffer; 100 μl of 
the same buffer were then added and fluorescence was evaluated with a fluorescence plate reader 
(Fluostar Optima, BMG Labtechnologies GmbH, Offenburg, Germany; excitation 485 nm, 
emission 520 nm). Unspecific uptake in the presence of 20 μM cytochalasin B and 200 μM 
phloretin was subtracted from each experimental value. In addition, autofluorescence of cells 
incubated or not with the different compounds was evaluated: compound 2 proved to increase cell 
autofluorescence by itself. 
TNF-α  ELISA. TNF-α levels in cell supernatants were measured by a commercially available 
ELISA kit (TNF-α DuoSet, R&D Systems) according to the manufacturer‟s instructions. 
PBMC isolation and stimulation. Peripheral blood mononuclear cells (PBMC) were isolated from 
buffy coats of healthy blood donors (n=4) by density gradient centrifugation using Ficoll-Paque 
PLUS (density 1·077 g/ml; GE Healthcare,Uppsala, Sweden). PBMCs were cultured in round-
bottomed 96-well plates (Nunc, Roskilde, Denmark) in RPMI-1640 medium supplemented with 
10% fetal calf serum, glutamine and penicillin-streptomycin (Biochrom, Berlin, Germany) in a 
humidified atmosphere with 5% CO2 at 37°C. 5×104 effector PBMC were either stimulated with 10 
μg/ml PHA for 3 days or with 5×104 γ-irradiated (40 Gy) allogeneic PBMC (mixed leukocyte 
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reaction, MLR) for 7 days. Thereafter, supernatants were harvested and TNF-α concentration was 
detected by commercially available ELISA. Cultures were set up in the presence of either 200 μM 
1, or 100 μM 2, 3, or 8, or of vehicle DMSO (CTR). Cell viability, as measured by FACS-
assessment of propidium iodide exclusion, was on average 84%, 71%, 81%, 85%, 82% for CTR, 1, 
2, 3, and  8, respectively, in PHA-stimulated cells, and 71%, 57%, 70%, 73%, 74% for CTR, 1, 2, 3, 
and  8, respectively, in cells stimulated in MLR. 
Viability assays. 5x10
3
 cells/well were plated in 96 well plates. Following stimulation with the 
indicated stimuli, viability was detected at the indicated time points using CellTiter96 Aqueous1 
(Promega) according to the manufacturer‟s instructions. The cooperative index (CI) was calculated 
as the sum of the specific cell deaths induced by the single agents divided by the specific cell death 
in response to the combination. CI values <1, = 1 and >1 indicate a synergistic, additive or infra-
additive effect respectively. 
Retroviral transduction. Empty pRETROSUPER (pRS) was from Dr. Thijn Brummelkamp 
(Netherlands Cancer Institute, Amsterdam, The Netherlands), while pRS SIRT6 sh2 was a kind gift 
from Dr. Katrin F. Chua (Department of Medicine, Stanford University School of Medicine, 
Stanford, CA). 1.5 × 10
6
 Phoenix cells were plated in 4 ml of medium in 6-cm dishes and allowed 
to adhere for 24 h. Thereafter, cells were transfected with 4 μg of plasmid DNA using TransIT-293 
(Mirus Bio, Madison, WI) according to the manufacturer's instructions. Viral supernatants were 
harvested after 36, 48, and 60 h and used to infect Capan-1 cells (5 × 10
5
) in 10-cm dishes in the 
presence of 5 μg/ml protamine sulfate. Successfully infected cells were selected using 1.5 μg/ml 
puromycin. 
Confocal microscopy. 3x10
4 
Capan-1 cells were plated on glass coverslips (Thermo Scientific™ 
Nunc Lab-Tek II Chamber Slide System) and allowed to adhere overnight. Thereafter, cells were 
incubated for 24 h with 100 μM 1 or vehicle DMSO. Subsequently, cells were treated with or 
without 8 μM olaparib. 24 h later, cells were then fixed with 4% paraformaldehyde, washed, 
saturated and incubated with anti a FITC-conjugated anti-γH2AX primary antibody (Ser139, 
JBW301, Millipore) over night at 4°C. Nuclei were counterstained with Qnuclear™ Deep Red Stain 
(Life Technologies, Monza, Italy). After that, glass coverslip were mounted using Prolong Gold 
antifade reagent (Life Technologies Ltd, Paisley, UK). The images were collected using a three-
channel TCS SP2 laser-scanning confocal microscope (Leica Microsystems, Wetzlar, Germany). 
Flow cytometric γH2AX detection. 105 Capan-1 cells/well were plated in 6-well plates, allowed to 
adhere overnight and subsequently treated with 100 μM 1 or 3, or with vehicle DMSO for 24h. 
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Thereafter, cells were stimulated with or without 8 μM olaparib for additional 24 h. Finally, cells 
were trypsinized and γH2AX levels were detected with the FITC-conjugated anti-γH2AX primary 
antibody according to the instructions of the manufacturer. The mean fluorescence intensity of each 
sample was normalized to the MFI of cells treated with vehicle DMSO and expressed as % 
variation versus vehicle.  
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9. Optimization of SIRT6 inhibitors – Salicylate derivatives 
Using the same methodology reported for optimization of quinazolinedione derivatives, we tried to 
identify analogues of another scaffold identified as active in our previous study, with the same final 
goal to shed more light on the structure-activity relationship of this compound series. These 
derivatives were selected from a database of commercially available compounds (CoCoCo 
Database) using different substructure searches aimed to explore modifications on each fragment of 
the reference structure. A final list of 26 derivatives of reference compound were purchased from 
vendors and tested in vitro using a commercial kit exploiting SIRT6 NAD
+
-dependent deacetylase 
activity. The percentage of SIRT6 activity inhibition obtained with each compound at a 200 µM 
concentration is reported in Table 8.1. 
Among the 26 compounds tested, 17 led to a significant inhibition of SIRT6 deacetylase activity 
(>10%), ranging from 17 to 100%, thus giving a remarkable hit-rate obtained with the virtual 
screening protocol. Five compounds resulted inactive at the concentration used in the assay, while 4 
compounds could not be tested due to interferences with the fluorescence-based assay. None of the 
active compounds identified include substructures described as Pan Assay Interference Compounds 
(PAINS)
276
. We subsequently determined the IC50 values of the most active compounds (Table 7.2). 
Consistent with the results of the preliminary screening, five compounds were found to inhibit 
SIRT6 activity in the low micromolar range (3, 5, 9, 11 and 13); compounds 11 and 13 showed a 
remarkable increment of activity, resulting approx. four times more active than reference compound 
1. In order to evaluate the selectivity of the most interesting inhibitors, their IC50 values were also 
determined for SIRT1 and SIRT2 by using commercially available kits. Compounds 5, 11 and 13 
proved to be fairly selective compounds towards SIRT6, their IC50 values being more than 20 times 
higher for SIRT1 and for SIRT2 (Table 8.1). 
Biological characterization of identified inhibitors is currently ongoing and will be completed in 
due course. 
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Compound ID 
% 
Inhibition 
(200µM) 
KIT 
SIRT6 
SIRT6 
IC50 
(µM) 
SIRT1 
IC50 
(µM) 
SIRT2 
IC50 
(µM) 
1 62 89 1578 751 
2 54    
3 89 122   
4 50    
5 100 34 783 453 
6 44    
7 62    
8 70    
9 100 86   
10 17    
11 100 22 599 482 
12 ND    
13 100 20 424 333 
14 NI    
15 ND    
16 NI    
17 17    
18 ND    
19 5    
20 NI    
21 39    
22 NI    
23 54    
24 68    
25 18    
26 4    
27 ND    
Table 8.1. Structures and SIRT6, SIRT1 and SIRT2 inhibition activities of compounds selected with in silico 
techniques. NI = no inhibitition and ND = not determined (interfering with the assay). 
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10. Interleukin 6 inhibitors 
10.1 Biologic Functions of IL-6 
Human IL-6 consists of 184 amino acids with two potential N-glycosylation sites and four cysteine 
residues; the core protein is about 20 kDa, and glycosylation accounts for the 21- to 26-kDa size of 
natural IL-6. In response to infections or tissue injuries caused by burns and traumas, IL-6 is 
promptly synthesized and activates an acute immune response (Figure 9.1). IL-6 induces the 
differentiation of activated B cells into immunoglobulin-producing plasma cells and acts as a 
growth factor for hybridoma and myeloma cells. In addition to B cells, IL-6 also affects T cells by 
inducing the specific differentiation of naive CD4
+
 T cells into effector T-cell subsets; in 
combination with TGF-β, IL-6 preferentially induces the differentiation of naive CD4+ T cells into 
Th17 cells, but inhibits the TGF-β–induced development of regulatory T cells (T-reg). The IL-6–
induced dominance of Th17 cells over T-reg cells may account for the disruption of the immune 
tolerance that is involved in the development of autoimmune and inflammatory diseases. IL-6 
stimulates hepatocytes to produce acute-phase proteins, such as C-reactive protein (CRP), serum 
amyloid A (SAA), fibrinogen, hepcidin, and a1-antichymotrypsin, and it reduces the production of 
fibronectin, albumin, and transferrin
294
. IL-6 exerts other effects that are detected frequently 
inchronic inflammatory diseases. Bone marrow stromal cells produce IL-6 that stimulates the 
receptor activator of NF-kB ligand (RANKL), which is essential for the differentiation and 
activation of osteoclasts, leading to bone resorption and osteoporosis. IL-6 also induces the 
production of VEGFs, resulting in angiogenesis and increased vascular permeability, which are 
pathologic features of cancers and of inflammatory lesions in the synovial tissues of rheumatoid 
arthritis. Moreover, it has been reported that IL-6 promotes keratinocyte proliferation and the 
synthesis of collagen in dermal fibroblasts and their differentiation into myofibroblasts, which may 
account for skin fibrosis in patients with systemic sclerosis. Mesangial cell proliferation and matrix 
overproduction are characteristic features of glomerular diseases, and IL-6 has been found in matrix 
deposits and may be involved in mesangial cell proliferation. Finally, IL-6 has been shown to 
interact with and affect various cells and organ systems, including the vascular endothelial cells, the 
endocrine system of the hypothalamic–pituitary–adrenal axis, and the neuropsychologic system. 
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Figure 9.1. Pleiotropic activity of IL-6. Reproduced from Tanaka et al.295 
10.2 IL-6 Signaling Pathway 
The IL-6 receptor (IL-6R) exists in two forms, which are the membrane-bound and soluble forms. 
Signaling through membrane-bound IL-6R is called the classical or the cis-signaling pathway. The 
transmembrane IL-6R is an 80 kDa protein that contains the IL-6 binding site and a very short 
cytoplasmic domain. Its expression is restricted mainly to leukocytes and hepatocytes. After binding 
to IL-6, the complex IL-6/IL-6R recruits another transmembrane glycoprotein gp130, the signaling 
subunit of the functional IL-6R complex. In contrast to IL-6R, gp130 is ubiquitously expressed and 
is also the signaling subunit of other cytokine members in the IL-6 family. Through IL-6R and 
gp130, IL-6 signaling activates tyrosine kinases JAK1, JAK2, and TYK2, which leads to the 
phosphorylation of signal transducers and activators of transcriptions 1 and 3 (STAT1 and STAT3). 
The modulation and termination of this JAK/STAT3 pathway are regulated by the suppressor of 
cytokine signaling (SOCS) feedback inhibition and protein inhibitor of activated STAT (PIAS) 
proteins. In addition to the JAK–STAT3 pathway, IL-6 activates RAS–MAPK, and PI3K–AKT 
signaling pathways which also contribute to anti-apoptotic and tumorigenic function. 
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The presence of soluble IL-6R (sIL-6R) also allows IL-6 to function through a pathway known as 
trans-signaling
296
. The soluble IL-6R, is mainly produced by hepatocytes, neutrophils, 
macrophages, and some CD4
+
 T cells and forms a complex with IL-6 and interacts with cell surface 
gp130. The fully assembled, activated IL-6 receptor complex is a hexameric structure containing 
two of each IL-6, sIL-6R (or membrane- bound IL-6R), and gp130 molecules, and this complex 
activates signaling pathway in a broader range of cell types
297
. Both classical and trans-signaling are 
mediated by gp130, and both activate the identical intracellular pathway even if trans-signaling is 
considered as a potential danger signal because it enhances IL-6 responsiveness and inflammatory 
events. In normal cells, IL-6 production can be regulated by different signals including IL-1, tumor 
necrosis factor (TNF), interferons (IFNs), DNA viruses, RNA viruses, and bacterial endotoxin
298
. 
During acute inflammation, monocytes and macrophages are the main producers of IL-6 after 
activation of Toll-like receptors via a MyD88-dependent pathway, whereas T cells appear to be the 
major source of IL-6 during chronic inflammation. 
10.3 IL-6 in aging and aging-related diseases 
Inflammation is a physiological process that repairs tissues in response to endogenous or exogenous 
aggressions. Nevertheless, a chronic state of inflammation may have detrimental consequences. 
Aging is associated with increased levels of circulating cytokines and proinflammatory markers. 
Aged-related changes in the immune system, known as immunosenescence, and increased secretion 
of cytokines by adipose tissue, represent the major causes of chronic inflammation. This 
phenomenon is known as "inflamm-aging"
299
. IL-6 is called "a cytokine for gerontologists"
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because age is associated with its increased production, although changes in IL-6 levels reflected 
the inflammatory processes associated with aging, and not aging itself. The plasma levels of IL-6 
are low or undetectable in most young people and start to increase in healthy people at about 50–60 
years of age; this increase appears to be unexpectedly present in both persons who enjoyed 
successful aging and those who suffered pathological aging. This increase continues with age, until 
the extreme limit of human life, and high levels of IL-6 are found in a high percentage of 
centenarians in good shape. In sharp contrast, high levels of IL-6 have been referred to as the most 
powerful predictors of morbidity and mortality in the elderly
301,302
. 
Indeed, the increase in IL-6 with age is the consequence of the successful adaptation to a number of 
stresses, including infections, which unceasingly occur throughout life. This process occurs 
continuously, and in centenarians inflamm-aging eventually reaches levels very close to the 
threshold of morbidity and mortality, which indeed occur within months or a few years. Thus, the 
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beneficial effect of the defense system network (innate immunity, stress, and inflammation), 
devoted to the neutralization of dangerous/harmful agents early in life and in adulthood, turns out to 
be detrimental late in life, in a period largely not foreseen by evolution
299
. 
IL-6 dysregulation is involved in age-related diseases such as cancer, lymphoma, cardiovascular 
disease, osteoporosis, Alzheimer's disease, diabetes, and atherosclerosis
303
. 
10.4 IL-6 and cancer 
IL-6 is one of the most ubiquitously deregulated cytokines in cancer, with over-expression of IL-6 
observed in virtually every tumor that has been studied. Several investigators have reported an 
aberrant IL-6 pathway activation in a variety of human cancer cell lines and solid tumors, including 
epithelial tumors of ovary, breast and prostate as well as multiple myelomas, leukemias and 
lymphomas
304
. Preclinical and translational findings indicate that IL-6 plays an important role in 
diverse malignancies and provides a biologic rationale for targeted therapeutic investigations. 
10.5 Pharmacological approaches to blockade of IL-6 signaling 
In conventional therapy, a number of agents that inhibit the expression of IL-6 and its signaling are 
effective in treating IL-6-mediated disorders
305
. Corticosteroids may inhibit IL-6 production at the 
transcription level, and are routinely used in the treatment of chronic inflammatory and autoimmune 
diseases such as rheumatoid arthritis and lupus erythematosus. Nonsteroidal anti-inflammatory 
drugs (NSAIDs) are known immunoregulators, and may inhibit the expression of IL-6 and its 
activity while increasing the production of TNF-α, IFN-γ, IL-12, and IL-2. Based on the large 
number of studies conducted on biological activities of IL-6 and its pathological roles, targeted 
therapeutic strategies using IL-6 blockade by antibody drugs are in development for inflammatory 
and autoimmune diseases. Tocilizumab binds to the IL-6 binding site of membrane-bound human 
IL-6R and sIL-6R and neutralizes IL-6-mediated activities. The inhibition of the IL-6 pathway by 
tocilizumab is a clinical breakthrough in the treatment of rheumatoid arthritis and has been 
approved for RA in more than 90 countries worldwide.  
Several small molecule compounds inhibiting IL-6 and its downstream targets have been developed 
and evaluated in preclinical and clinical studies of various human cancers, such as Atiprimod, a 
JAK2/JAK3 inhibitor, or Ruxolitinib, a JAK1/2 inhibitor; however, since STAT3 is not IL-6 
specific as it is activated by all other cytokine signaling associated with gp130 and JAK1/2, these 
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drugs are not specific to inhibits IL-6 mediated effects. At the time of this study, no small molecule 
modulators of IL-6/IL-6R interaction have been reported in literature. 
10.6 Drug repurposing 
One approach to speeding up drug discovery is to find new uses for existing approved drugs. This is 
termed „drug repositioning‟ or „drug repurposing‟, and traditionally has occurred by serendipity306. 
Recently, repurposing of known drugs for new biological targets acquired popularity as a new 
medicinal chemistry paradigm. Indeed, finding new biological applications/therapies of existing 
drugs entails several advantages in respect to de novo design. The benefits of repositioning include 
the availability of chemical materials and previously generated data that can be used and presented 
to regulatory authorities and, as a result, the potential for a significantly more time- and cost-
effective research and development effort than typically experienced when bringing a new drug to 
market. In silico methods, including target- and ligand-based strategies, are excellent complements 
to experimental techniques, and should be used alongside in vitro methods to drug repurposing, if 
for no other reason than to speed up the process of drug discovery at little additional cost. 
10.7 Screening for IL6 – IL6 receptor interaction modulators 
10.7.1 Screening of hexameric assembly IL-6/IL-6R/gp130 ligands 
As a first approach we tried to identify small molecules able to bind potential interaction sites on 
the surface of the ternary complex formed by IL-6, IL-6R and gp130. The basic idea underlying this 
strategy is that the binding of an high affinity ligand may in fact lead to a destabilization of the 
complex of IL-6 with its receptor, and/or interfere with the binding of the ternary complex to 
effector proteins, and thus induce a reduced activation of the signaling pathway, and consequently 
of the biological effects of IL-6. 
At the time of this study, only an X-ray structure of the complex between human IL-6, the 
extracellular binding domains of human IL-6 receptor, and the extracellular activation and binding 
domains of gp130 was available in public domain (PDB accession code 1P9M). The ternary 
complex forms a hexamer containing two IL-6, two IL- 6R, and two gp130 that assemble 
sequentially and cooperatively. The hexamer is held together by 10 two-fold–related protein-protein 
interfaces, five of which are unique to each half of the hexamer, namely (according to Boulanger et 
al
297
) sites I, sites IIa and IIb, sites IIIa and IIIb. 
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The binding site I is localized between IL-6 and IL-6R and form the initial IL-6/IL-6R binary 
complex. IL-6R provides the majority of contact surface with IL-6, contributing more that 70% of 
the total buried surface area; of the 18 contact residues contributed by the IL-6R, PHE229 and 
PHE279 dominate the binding interface, and dock into two cavities on the IL-6 surface. Mutational 
data have identified Phe229 as a “hotspot” residue at the interface307. IL-6 also contributes several 
charge interactions within the site I interface surrounding the PHE229 residues, such as ARG179 
and LYS171. The site II is separated into two spatially distinct interfaces: site IIa is located between 
the IL-6 A and C helical faces and the boundary between the D2 and D3 domains of gp130, and site 
IIb is located between the IL-6R D3 domain and the gp130 D3 domain. In site IIa, PHE169 
contributes the largest fraction of the total buried surface area; this residue was originally identified 
as conserved in gp130, and as crucial for all cytokine interactions from mutational studies
308,309
.  
Site IIIa is a broad and discontinuous interface between IL-6 and gp130 where the tip of the IL-6 
four-helix bundle (A/B loop and N- terminal region of D helix) abuts into the bottom sheet of the 
D1 domain of gp130. In site IIIb the tip of the gp130 D1 domain forms a large interaction surface 
with the side of the D2 domain of IL-6R. The critical residue in the site IIIa interface is TRP157 of 
IL-6 which has been defined by mutagenesis as being the critical aromatic site III signature 
residue
310,311
.  
The available model of the asymmetric unit (ternary complex IL-6/IL-6R/gp130) was obtained from 
PDB database and prepared using a standard protein preparation procedure (see experimental 
section); the 3D coordinates of the complete hexameric assembly, not available direct on PDB 
database, was obtained from PDBePISA service
312
 and prepared with the same procedure. 
A systematic search using the software Sitemap was conducted on both the asymmetric unit and the 
hexameric assembly; the latter allowed finding potential active sites located also in the interfaces 
between the different asymmetric units. 
From this search, we identified three putative sites (Figure 9.2): 
 Site A: A long "tunnel" formed by the small cavity located at the intersection between the 
three subunit (Site I, Site IIIa, Site IIIb) and the cavity at the intersection of IL6-R and 
gp130 (Site IIb); although they are quite close, this two cavity could be considered two 
different sites (A1 and A2) 
 Site B: A cavity between IL-6 and gp130, mainly on the surface of Site IIIa; adjacent to Site 
A, with small portion shared among the two sites 
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 Site C: A cavity at the interface between IL-6 and gp130, on the surface of Site IIa. 
The active sites identified by sitemap was located near the interaction interfaces between the three 
subunits, and no other putative active sites seemed to be present on the external surface of the 
complex; the active site A was of special interest because located at the intersection of all the three 
subunits and included several interaction interfaces in its cavity. Due to its remarkable volume this 
site was split in two different sites to simplify the virtual screening procedure. 
All the putative sites identified were used as template to virtually screen the Prestwick Chemical 
Library, as prepared in the CoCoCo database
132,133
. This library contains 1200 small molecules that 
are 100% FDA approved drugs; the choice of this subset limits the chemical diversity compared to 
the whole CoCoCo database, which include more than 7M molecules, but entails the advantages of 
drug repurposing strategy (see above). The first hundred hits of each putative site were visually 
inspected to prioritize more interesting compounds; since no knowledge about active ligands was 
available, and physicochemical rules such as Lipinski‟s rule-of-five275 was not relevant since the 
screening is limited only to approved drugs, the selection was based on the quality of docking poses 
and on known pharmacological activities and side effects of screened drugs.  
Unfortunately, this screening strategy was unsuccessful; the first positions of the docking output 
list, in which compounds are ranked based on estimated free energy of binding, are largely 
dominated by glycosidic compounds, which are highly hydrophilic and highly flexible molecules, 
such as aminoglycosides (neomycine, paromomycine), flavanone glycosides (hesperidin), and 
acarbose. This is probably due to the large number of charged residues which characterize the 
protein-protein interaction patches; the abundance of this kind of residues stabilize the binding 
between the three subunits, but also makes the hypothetical binding sites highly hydrophilic, and 
the scoring functions of docking software probably overestimate this contribution to the ligand 
binding affinity. At the same time, important hydrophobic pockets, which are certainly present on 
interaction surfaces, are not accessible by the potential ligands as they are in close contacts with the 
matching interaction surface on the nearby subunit. As a result, the docking software rewards only 
high hydrophilic molecules, adversely affecting the quality of screening results. 
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Figure 9.2. Putative binding sites identified on hexameric assembly of IL-6/IL-6R/gp130. Different subunits are 
represented using ribbons and labeled using different color: red for IL-6, orange for IL-6R, and green and gray for 
gp130 (2 symmetric subunits are observable). Putative sites are represented using colored surfaces: orange for Site A, 
purple for Site B and green for Site C. 
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10.7.2 Screening of Protein-Protein Interface inhibitors 
Having regard to these unsatisfactory results, we tried a different screening strategy aimed to find 
potential inhibitors of ternary complex formation. The goal of this screening is to find some 
molecules able to bind the single interaction patches and therefore block the protein-protein 
interaction between the subunits. However, since the interaction patches are small and quite flat, 
and no defined cavity seems to be present, docking couldn't be the right method to use since it 
requires the presence of a putative active site to work properly. For this reason, we used a mixed 
structure-based and ligand-based approach based both on fragment docking search and on 
pharmacophore search. We implemented a method reported by Loving et al.
313
 which use energetic 
analysis of structure-based fragment docking to elucidate key features for molecular recognition. 
This method requires three steps: i) docking of a focused library of diverse fragments, curated from 
the literature, as a set of probe molecules to find interaction sites; ii) mapping the energy terms 
computed by the docking scoring function onto individual ligand atoms to determine the most 
favorable pharmacophoric features for a given pose and generation of an energy-optimized 
pharmacophore; iii) pharmacophoric screening of ligand database. This approach combines 
strengths of both ligand- and structure-based methods; namely, energetic contributions to binding 
can be accurately computed from the structure-based docking, while the pharmacophore-based 
screening is fast and allows a great deal of control. Furthermore, there is no need for knowledge of 
known active compounds, as required in standard ligand-based methods. 
The initial screening was conducted on site A as main target, since the interaction between IL-6 and 
IL-6R is the first interaction involved in the formation of the ternary complex, and it is needed for 
the interaction with gp130 (neither IL-6 nor IL-6R has affinity for gp130 alone)
297
, thus blocking of 
this interaction should impair the complex formation. The screening was based on the surface of IL-
6 as reference, and centered using the position of phe299, residue known as one of the most 
important interaction residues from mutagenesis study (see above). 
A 7-features pharmacophore was generated, including 1 aromatic ring, 2 hydrogen bond acceptor, 3 
hydrogen bond donors and 1 negative charge (Figure 9.3A). A second pharmacophore was 
generated manually using as reference a selection of important residues of IL-6R that are likely to 
be responsible for binding to IL-6, considering both the three-dimensional structure and the 
mutagenesis data reported by Kalai et al.
307
. The selected IL6-R residues were: phe229, tyr230, 
arg231, glu277, glu278, and phe279. A 5-features hypothesis was generated, including 3 aromatic 
rings and 2 negative charges; the features was selected among all the available features considering 
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only the interactions clearly identified in the 3D structure and reported as important in the 
mutagenesis data (Figure 9.3B). A last 5-features hypothesis was generated by adding to the above 
hypothesis a negative charge feature that match the arg182 residue in IL-6 (Figure 9.3C). This 
residue show a high positive electrostatic potential due to the positive charge, and its side chain 
points toward the IL-6 surface, but no interactions with IL-6R residues are present; therefore we 
manually added an hypothetical negative feature able to account for the presence this IL-6 surface 
property. The excluded volume based on IL-6 receptor was added to all hypotheses, in order to 
simulate the surface of IL-6 interaction patch. All the generated hypothesis was used to search the 
multiconformer version of Prestwick database with the following restrictions: 
 Pharmacophore 1 (fragment-based): hit molecules must match the aromatic ring and the 
negative charge features near phe279, and 1 feature among the remaining (total required 
matches: 3) 
 Pharmacophore 2 (based IL6-R residues): hit molecules must match one of the two negative 
features and two out of the three aromatic features (total required matches: 3) 
 Pharmacophore 3: (Pharmacophore 2 modified): hit molecules must match one of the three 
negative features and two out of the three aromatic features (total required matches: 3) 
The hit molecules from each search was collected in a single list, and then subjected to energy 
minimization in the context of the IL-6 protein (see experimental section), in order to evaluate the 
stability of the ligand-protein interactions found by the pharmacophore search. 
The final list of compound to buy was selected using the following parameters, in order of 
importance: 
1. Quality of interactions between putative ligand and IL-6 surface 
2. Stability of the complex after energy minimization 
3. Minimum strain of binding conformation (flexible molecules were preferred against rigid 
molecules) 
4. Molecular diversity 
The final list of selected compound is reported in Table 9.1. The selected compounds exert their 
biological effect in physiological pathways not directly related to cytokine pathways. Interestingly, 
some of them are used in therapy as anti-inflammatory drugs, and methotrexate in particular is used 
in IL-6 related autoimmune disease including rheumatoid arthritis, although its exact mechanism of 
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action remains uncertain. The putative binding pose of zafirlukast, one of the most interesting 
compounds found in our screening, is reported in Figure 9.4. 
10.8 Conclusion and perspective 
It is challenging to design small molecules to disrupt multiple binding “hot spots” on the interface 
of protein−protein interaction. The approach to combine fragment docking and pharmacophore 
searches with drug repositioning could potentially help to design novel inhibitors targeting this kind 
of interactions. 
During this study we analyzed the characteristics and properties of the surfaces of interaction 
between IL-6 and its receptor, and coded into a short series of pharmacophores that could be used to 
identify ligands capable of interacting specifically with the target protein. In the near future the 
selected compounds will be tested in vitro to measure the direct binding with IL-6 and the ability to 
reduce the pro-inflammatory effects of IL-6. 
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Figure 9.3. Pharmacophore used in virtual screening. Interaction patch of IL-6 with IL-6R is represented as a 
molecular surface colored according to electrostatic potential (blue = positive, red = negative, white = neutral). 
Pharmacophoric features are represented using colored balls (red for negative charges, blue for hydrogen bond donors 
and orange for hydrogen bond acceptors) and circles (aromatic rings). A) Pharmacophore 1, based on fragment-based 
docking; small molecular fragments are represented in orange. B) Pharmacophore 2, manually generated based on most 
important IL-6R residues, represented in gray. C) Pharmacophore 3, modified version of pharmacophore 2. 
A 
B 
C 
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Prestwick ID Chemical name Pharmacological activity 
Prestw-859 Fluvastatin sodium salt HMG-CoA reduttase inhibitor 
Prestw-503 Cetirizine dihydrochloride H1 receptor antagonist 
Prestw-819 Moxalactam disodium salt antibiotic (b-lactamic) 
Prestw-658 Suxibuzone NSAID 
Prestw-1129 Benazepril HCl ACE inhibitor 
Prestw-1364 Zafirlukast Leukotriene receptor antagonist 
Prestw-135 Methotrexate DHFR inhibitor 
Table 9.1. Interesting compounds identified using virtual screening.  
 
 
Figure 9.4. Putative binding mode of zafirlukast. Interaction patch of IL-6 with IL-6R is represented as a molecular 
surface colored according to electrostatic potential (blue = positive, red = negative, white = neutral). 
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10.9 Experimental section 
In silico techniques.  
The crystal structure of the IL-6/IL-6R/gp130 ternary complex was used as a template for virtual 
screening purposes (PDB id: 1P9M). This structure was prepared with standard preparation 
procedures (protein preparation wizard) as included in the software package Maestro
134
. 
The docking grid was created using the IL-6 structure (chain B in structure) and centered using 
phe299 of IL-6R and a 12Ǻ cube; this grid was large enough to include all the interaction surface of 
IL-6. The Schrodinger fragment library (available from www.schrodinger.com) was docked into the 
generated grid using the modified parameters reported in Loving et al
306
. Briefly, we increased the 
number of poses per ligand for the initial docking stage to 50,000, used a wider scoring window of 
500.0 kcal/mol for keeping initial poses, and kept the best 1,000 poses per ligand for energy 
minimization. The keyword roughmin was added to the maxkeep line of the Glide input file, 
instructing Glide to bypass the sorting by the rough score and to minimize all maxkeep (50,000) 
poses on the Glide grid. This allows for a much larger number of poses to be scored with the more 
accurate scoring function in Glide. We also subjected the top 100 poses per fragment to post- 
docking minimization and requested the top 100 poses to be returned. The results of fragment 
docking were used to generate an e-pharmacophore using a ad-hoc script in Maestro; the fragments 
clustering was applied and a maximum of 7 features was required. The script extracts the energetic 
descriptors of the Glide XP score and assigns them to pharmacophore features. The resulting energy 
pharmacophore (e-Pharmacophore) hypotheses can be used directly in a Phase search or can be 
manually modified based on visualization and the energetics. The hit molecules from 
pharmacophoric search was collected in a single list, and then subjected to energy minimization in 
the context of the IL-6 protein; in particular, each molecule was minimized using the Embrace 
interface in Macromodel (version 9.9, Schrödinger, LLC, New York), keeping the receptor atoms 
frozen and with the ligand free to move, with a max of 5000 steps of minimization. Other options 
set as default. 
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11. Concluding remarks and future perspectives 
This thesis describes the discovery of new compounds able to modulate activity of relevant targets 
involved in cancer and aging-related pathologies using a rational design approach. We 
demonstrated that in silico techniques, mainly virtual screening methods, can efficiently 
complement standard screening technologies, and maximize the number of hit molecules found. 
In summary, we identified new moderately active and selective non-peptidic compounds able to 
inhibit the activity of both standard and immunoproteasome, as well as novel and selective scaffolds 
that would bind and inhibit SIRT6 selectively and can be used to sensitize tumor cells to commonly 
used anticancer agents such gemcitabine and olaparib. Moreover, our virtual screening approach led 
us also to the discovery of new putative modulators of SIRT3 with interesting in-vitro and cellular 
activity; the activator compound 24 is of special interest since no specific SIRT3 activators are 
reported in literature so far. Although the selectivity and potency of the identified chemical 
scaffolds are susceptible to be further improved, these compounds can be considered as highly 
promising leads for the development of future therapeutics. 
In addition, two theoretical studies provided i) a simple tool to estimate the selectivity of a small 
molecule ligand between two or more sirtuin isoforms and ii) a deep analysis of the characteristics 
and properties of the surfaces of interaction between IL-6 and its receptor, encoded into a short 
series of pharmacophores that could be used to identify ligands capable of interacting specifically 
with the target protein. 
For the future, the following issues would be of interest to investigate: 
 In vitro testing of selected IL-6 putative inhibitors, to measure the direct binding with IL-6 
and the ability to reduce the pro-inflammatory effects of IL-6 
 Design and chemical synthesis of active compounds derivatives, with improved biological 
activity and better pharmacokinetic and pharmacodynamic profiles.  
 In vivo proof-of-concept studies to measure the effect of the identified inhibitors/modulators 
in animal models of neurodegeneration (for SIRT3 activators) or type 2 diabetes (for SIRT6 
inhbitors). 
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